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The hardship of cancer is continuously increasing and is rapidly spreading 
globally. At present, almost one-third of newly discovered potential therapeutics 
have poor pharmacokinetics and biopharmaceutical properties. 
Chemotherapeutic agents known to be the most effective treatment, lack 
tumour specificity and suffers from poor solubility. The lack of specificity results 
in severe side effects in off-target tissues, whereas poor soluble drugs exhibit 
short half-life in the bloodstream and high overall clearance rate. Amphiphilic 
block copolymers based on hydrophobic dendrons have shown to be a 
promising strategy to enhance the solubility of hydrophobic drugs, prolong 
circulation time, minimise non-specific uptake, and allow for specific tumour-
targeting through the EPR effect. Herein, we have proposed the development of 
a new safe and more specific non-viral vector system based on peptide 
dendronised polymeric micelles to enhance the delivery of hydrophobic drugs 
into liver cancer cells. G3(PLLA and OGPLLL) arginine dendron of third 
generation bearing eight peripheral hydrophobic or cationic groups (PBF and 
BOC or guanidine groups) were synthesised in high yield, identified and tested 
for purity using NMR, MS and TLC. A series of three amphiphilic system 
characterised by different hydrophilic pullulan derivatives segments were then 
synthesised using Huisgen azide-alkyne 1,3-dipolar cycloaddition between 
pullulan (P), lactosylated pullulan (P(Lac)) and pullulan bearing disulphide 
linkage (PSS) with the G3 dendron to lead amphiphilic block copolymers P-
PLLA, P(Lac)-PLLA and PSS-PLLA, respectively. Hydrophilic pullulan and 
lactobionic acid were selected for amphiphilic modification, aiming at specific 
asialoglycoprotein receptors recognition onto hepatocytes cells in the liver. 
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Macromolecular structures of amphiphilic P-PLLA, P(Lac)-PLLA and PSS-PLLA 
were able to self-assemble spontaneously into spherical nanoarchitectures of 
sizes less than 90nm with low polydispersity in the aqueous media, which was 
confirmed by CAC, DLS and TEM. Furthermore, the polyaromatic anticancer 
drug Doxorubicin (Dox) was selectively encapsulated in the hydrophobic core 
through multiple interactions with the dendron, including π-π interactions, 
hydrogen bonding and hydrophobic interactions. Such multiple interactions had 
the merits of enhanced drug loading capacity (>16%), excellent stability against 
dilution, and excellent sustained release property. Results showed that a high 
number of hydrophobic segments within a micellar core enhance higher loading 
efficiency of hydrophobic drugs, whereas, an increase of surface hydrophilicity 
or an increase in the length of the hydrophobic segment, both have an effect in 
reducing the micellar size and CAC value. The disulfide-containing PSS-PLLA 
micelles were able to co-encapsulate both hydrophobic drugs Dox and 
Curcumin (Cur) which could simultaneously be co-released in high rate from the 
carrier (>80wt% in 60hours) in response to the high redox potential 
environment. Most importantly, the release of Dox from the carrier at pH 5 
enhanced the release of curcumin, whereas curcumin, in turn, would improve 
the efficiency of Dox anticancer activity by overcoming Dox MDR. Such a 
delivery system provides a promising approach for combination therapy in 
cancer. The cell viability assay presented that the blank micelles had excellent 
biocompatibility both in the normal and tumour cells. Moreover, loaded drugs 
nanoparticles could be effectively internalised into the hepatoma carcinoma 
cells, and Dox-Cur-PSS-PLLA dramatically inhibited cell proliferation. Also, 
cationic dendron conjugated pullulan (P-OGPLLL) could efficiently condense 
DNA with excellent hemocompatibility and high gene transfection in Hela and 
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Hek293T cells. Thus, this work offers an effective strategy of designing a non-
viral system and the P-PLLA, P(Lac)-PLLA, PSS-PLLA and P-OGPLLL 
nanocarriers serve as a reliable drug/gene delivery nanoplatform to enable the 
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CHAPTER 1. INTRODUCTION 
Cancer is one of the most significant disease that affects the world population. 
GLOBOCAN estimates that in 2012, there were 14.1 million new cancer cases, 
8.2 million cancer deaths and 32.6 million people living with cancer within five 
years of diagnosis (IARC.FR-Globocan, 2017). An increase to 19.3 million new 
cancer cases per year by 2025 has been predicted. According to WHO, the 
most commonly diagnosed cancers worldwide are those of the lung (1.8 million, 
13.0% of the total), breast (1.7 million, 11.9%) and colorectum (1.4 million, 
9.7%) whereas the most common causes of cancer death were cancers of the 
lung (1.6 million, 19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 
million, 8.8%) (IARC.FR-WHO, 2017).  
1.1. Causes and formation of Cancer 
The cause of cancer is a series of successive mutation in genes changing the 
function of a cell. Chemical compounds can easily cause a gene mutation; also, 
smoking contains some carcinogenic chemicals that can lead to lung cancer 
(Aizawa et al., 2016, Poon et al., 2014; Antwi et al., 2015). Viruses, bacteria and 
radiation are other carcinogenesis factors (Parkin, 2006). In 2011, Hanahan and 
Weinberg reported the six biological capabilities that enable tumour growth and 
metastatic dissemination. These include sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis 
(Hanahan and Weinberg, 2011). Cancer cells proliferate abnormally resulting 
into a tumour which can either remain confined to its site of origin (a benign 
tumour) or invade surrounding healthy tissue and metastasise throughout the 
body via the circulatory or lymphatic systems forming a malignant tumour (the 
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one referred adequately as cancer). Cancers can be divided in 3 categories: 
carcinomas consisting of 90% of cancers (malignancies of epithelial cells), 
sarcomas (tumors of connective tissue such as muscle, bone cartilage and 
fibrous tissue), and leukemias or lymphomas consisting of 8% of cancers 
(arising from blood-forming cells and cells of the immune system) (Cooper and 
Hausman, 2000). 
1.2. Cancer therapy  
Cancer treatment mainly consists of surgery, radiotherapy and systemic therapy 
(hormonal therapy, targeted therapy and chemotherapy). The procedures are 
sometimes combined for an effective cure (Mokhtari et al., 2017). They all work 
in different ways by either killing the tumour cells directly or stopping their 
increase or by stimulating factors inside the body that can kill cells or reduce 
proliferation. Here, we briefly present the main advanced types of treatment 
used in cancer therapy.  
1.2.1. Surgery  
Surgery has been used as a treatment for cancer since 3000 B.C (Wyld, 
Audisio and Poston, 2015). After the invention of anaesthesia, surgeons, 
Bilroth, Handley and Halsted became famous because of their first contributions 
to the science of cancer surgery (Kapur, 2014). In the 1970s, advances in 
technology such as the development of sonography, computed tomography (CT 
scans), magnetic resonance imaging (MRI scans) and positron emission 
tomography (PET scans) have improved surgery techniques (Sudhakar, 2009). 
Moreover, the introduction of cryosurgery in the 18th century consisting of 
freezing cells and killing cancer cells has shown to be less invasive with lower 
morbidity compared to surgical resection (Yiu et al., 2007).  
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1.2.2. Radiotherapy (RT) 
X-rays were discovered in 1895 by Wilhelm Conrad Röntgen from Germany 
(Panchbhai, 2015). The year 2011 was designated as the year of radiation 
therapy in the UK after a century of advances in the field. It has been reported 
that 50% of all cancer patients will receive radiotherapy which contributes to 
around 40% towards curative treatment (Delaney et al., 2005; Begg, Stewart 
and Vens, 2011; Barnett et al., 2009; Baskar et al., 2012). Radiotherapy 
consists of a physical agent (ionising radiation) which destroy cancer cells by 
forming electrically charged particles or by depositing high energy that can 
damage the genetic material in the cells of tissue it passes through, therefore 
resulting in cell death (Jackson and Bartek, 2009). Ionising radiation rapidly 
induces water radiolysis products inside cells mitochondria, which trigger ROS 
production such as hydroxyl radicals which then causes DNA damages (Azzam, 
Jay-Gerin and Pain, 2012). 
1.2.3. Photodynamic therapy (PDT) 
PDT has only been developed in the last century and is being clinically tested 
for the treatment of the head, neck, brain, lung, pancreas intraperitoneal cavity, 
breast, prostate and skin (Dolmans, Fukumura, and Jain, 2003). The therapy 
consists of the administration of photosensitizers (PSs) followed by illumination 
on the tumour with a localised energy source to activate the specific PSs which 
produce cytotoxic singlet oxygen that results in damage to cell membrane 
structure and destroys biological tissues (Huang et al., 2012). Examples of 
photosensitizers used in PDT include haematoporphyrin derivative (Myers et 
al., 1989), Photofrin (Gollnick and Brackett, 2009), phthalocyanines (Rosenthal, 
1991), benzoporphyrins, purpurins and chlorines (Kadish, Smith and Guilard, 
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2010). PDT has shown extreme valuable approach for cancer treatment since it 
can directly kill tumour cells, damage tumour vasculature, inhibit angiogenesis 
by disrupting the supply of oxygen and nutrients to the tumour cells, thus 
inhibiting tumour growth and also, activate the body’s immune response against 
tumours (Castano, Mroz and Hamblin, 2006; Gollnick and Brackett, 2009; 
Bhuvaneswari et al., 2009).  
1.2.4. Ultrasonic therapy 
Low power ultrasound has been applied since the 1950s for physical therapy. 
By the 1970s, this technique was used for physiotherapy, Parkinson’s disease 
and cancer (Wells, 1977; Kremkau, 1979; Miller et al., 2012). The therapy 
consists of the exposure to heat, mechanical effects and acoustic cavitation. 
Studies have shown that low-intensity ultrasound could suppress cell 
proliferation and clone formation, improve the impact of anti-cancer chemicals 
and deactivate cells via indirect mechanisms (Lejbkowicz and Salzberg, 1997; 
Yu, 2004). Similarly, to PDT, sonodynamic therapy (SDT) is a technique that 
can activate some chemicals known as sonosensitizers to generate free 
radicals such as hydrogen, hydrogen peroxidase, singlet oxygen and 
superoxide ions that are produced by the breakdown of water molecules 
(Kardos and Luche, 2001; Yu, 2004). FDA has approved a number of devices 
for therapeutic applications by ultrasound based on their thermal use (physical 
therapy, hyperthermia and high intensity focussed ultrasound: HIFU) and non-
thermal use (extracorporeal shock wave lithotripsy, intracorporeal lithotripsy and 
lower power kilohertz frequency ultrasound devices) (Miller et al., 2012).   
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1.2.5. Chemotherapy  
Chemotherapy was first introduced in the 1940s (Brighton, 2005), it was noticed 
that during the first and second World War, soldiers exposed to mustard gas 
presented low levels of leucocytes, from this in 1943, Gilman developed the first 
chemotherapy agent (nitrogen mustard) to treat lymphomas (Smith, 2017).  
In the following years, more classes of drugs were designed for different tumour 
treatment. The drugs exert their effects on cancer cells by interfering with the 
processes involved in cell division in many ways. They cause cell apoptosis by 
either directly interfering with DNA or by targeting the proteins involved in cell 
division (Caley and jones, 2012). The table-1 shows the classification of 
chemotherapy drugs and their mode of action with corresponding examples of 
drugs reported by Caley and jones in 2012.  
Table 1-1. Biochemical classification of chemotherapy drugs (Caley and jones, 
2012) 
Drug class Mechanism of action Examples 
Alkylating agents Impair cell function by forming covalent bonds on 
essential molecules in proteins, DNA and RNA. 
Classified by their chemical structure and mechanism 





Anti-metabolites Structural analogues of naturally occurring metabolites 
involved in DNA and RNA synthesis. They either 
substitute for a metabolite that is usually incorporated 









Intercalate DNA at specific sequences, creating free 
radicals which cause strand breakage. Anthracyclines 
are products of the fungus Streptomyces, also have a 
mechanism of action of topoisomerase I and II, 






Topoisomerases are enzymes that control the 3-D 
structure of DNA. Topoisomerase I and Topoisomerase 








Vinca alkaloids bind to tubulin and prevent the 
formation of the microtubule, which is essential during 
mitosis, but also for cell shape, intracellular transport 
and axonal function. Taxoids prevents the disassembly 







1.2.6. Gene therapy  
Gene therapy was first proposed in the 1960s, it can be used to express a gene 
that induces apoptosis (examples include TNF-related apoptosis-inducing 
ligand: TRAIL (Griffith et al., 2009); Melanoma differentiation-associated gene-
7: mda-7 or Interleukin-24: IL-24 (Fisher, 2005)), to increase the efficiency of 
conventional drug or radiation therapy, to replace a defective or missing tumour 
suppressor gene by a functional healthy copy of the same gene (examples 
include p53 (Matlashewski et al., 1984), retinoblastoma gene Rb (Wiman, 
1993), p16INK/CDKN2, PTEN, E1A, Fhit, Fus1 and BiKDD (Shanker et al., 
2011)) and to block the expression of oncogene by using an antisense 
(RNA/DNA) approach, also, to enhance the immunogenicity of tumour 
(Friedmann, 1992).   
1.2.7. Immunotherapy  
Immunotherapy is currently the treatment of choice for several illnesses 
including allergies (Larenas-Linnemann et al., 2017), autoimmune (Di Sabatino 
et al., 2018), infectious diseases (Naran et al., 2018) and macular degeneration 
(Kosmidou et al., 2018). It incorporates the use of antibodies, cytokines and 
dendritic cells and presents much more specificity, higher efficacity, directed 
therapy, less toxicity, lower secondary effects and better tolerance. The 
objective of this technique is to help the immune system to recognise and attack 
cancer cells. There has been many FDA approved product and monoclonal 
antibodies for the treatment of metastatic melanoma. Example includes 
Ipilimumab for colorectal cancer and kidney cancer, Pembrolizumab for 
urothelial cancer, Nivolumab for lung cancer and Kidney cancer, Trastuzumab 
for breast cancer and gastric cancer, Rituximab for non-Hodgkin lymphoma and 
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chronic lymphocytic leukaemia  and Cetuximab for bowel cancer) (Sharma and 
Allison, 2015; Farkona, Diamandis and Blasutig, 2016; Meiliana, Dewi and 
Wijaya, 2016). 
1.3. The drawback of existing therapy  
All the existing therapies have shown to kill cancer cells successfully, but at the 
same time, affect other healthy cells lacking tumour targeting and thus resulting 
in severe side effects in off-target tissues and organs. Also, the development of 
therapy-resistance has contributed to the failure of some treatments.            
Despite the new advancements, treatment by surgery can be very risky and 
inconvenient for patients. During operation, there could be risks of cutting 
through lymphatics or manipulation of a tumour can occur, resulting in tumour 
spread (Saltzstein, Levin and Sharp, 1957). Moreover, after surgery, there are 
chances of patients death due to recurrences. For example, it has been 
reported that 30-50% of non-small cell lung cancer (NSCLC) patients develop 
recurrence and die (Al-Kattan, 1997; Uramoto and Tanaka, 2014).  Also, severe 
trauma scars and injury of soft tissues during surgery (breast cancer, for 
example) can cause acute and chronic pain (Fassoulaki et al., 2005). 
  Radiotherapy is limited due to its unacceptable normal tissue toxicity, radiation 
sensitivity, and resistance in tumour lesions. For example, the technique has 
shown complications and mortality among elderly patients over 75 years with 
rectal cancer (Maas et al., 2013). Also, radiotherapy faces challenges in tumour 
repair since malignant cells can repair radiation-induced DNA damage leading 
the tumour to become insensitive to radiotherapy owing to intrinsic resistance, 
or recur after treatment because of acquired resistance (Wang et al., 2010; 
Morrison et al., 2011). Radiotherapy, therefore, still needs improvement.  
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   For the photodynamic therapy, the PSs are activated by visible light at the 
wavelength range of 630-690nm. However, light can only penetrate in tissue by 
2-4mm depth, therefore long wavelength light sources are needed, this, can 
come as a tradeoff with excitation losses due to poor overlap with absorption 
spectra (Kalka, Merk and Mukhtar, 2000; Prasad, 2003; Ran et al., 2011; Xu, 
Gao and Wei, 2016). Xu and his colleagues reported in 2016, the side effects of 
the different categories of PSs used in photodynamic therapy including first, 
second and third generation PSs. The first-generation PSs have been reported 
that they induce cutaneous phototoxicity and increased risk of sunburns and 
may be less effective. An example is that of photofrin which has showed 
phototoxicity effects to 20-40% patients after treatment and also have shown to 
be less useful to tumours larger than 10 mm in diameter with a fall in response 
rate from 98% to 43% (Dougherty, Cooper and Mang, 1990; Furuse et al., 
1993). The other generation of PSs has also been reported to present severe 
drawbacks in the fact that they can be overactive even in dim light (60-watt 
bulb) and can lead to severe skin photosensitivity (Allison et al., 2004). Although 
there have been regulatory-approved PSs, PDT is limited due to its inability to 
deliver adequate light doses to the target, unavailability of suitable PSs, high 
toxicity, slow pharmacokinetics and high skin photosensitivity (Allison, 2014).  
  Ultrasounds also present adverse effects since it can suppress the mitosis of 
cancer cells but at the same time could trigger the proliferation of malignant 
tissues, thus favouring cancer metastasis (Yu, 2004). The ultrasonic therapy 
uses irradiation that can create damage to the biological milieu, for example, it 
has been reported that ultrasound-induced shear forces, can disrupt cellular 
membranes and activate gas in the body and inertial cavitation which can result 
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in cell lysis (Miller, Miller and Brayman, 1996). Side effects can also occur from 
ultrasound as when affecting tumour cells, healthy cells morphology can also be 
affected either by DNA strand breakage, chromosome breakage, sister 
chromatid aberrations, cell transformation, calcium uptake or by mutations 
(Liebeskind et al., 1979; Miller, Reese and Frazier, 1989; Macintosh and Davey, 
1970; Mortimer and Dyson, 1988; Kaufman, 1985; Miller, Miller and Brayman, 
1996; Rosenthal, 2004).  
Treatment by immunotherapy also faces various challenges. Although 
immunotherapy helps the immune system attack tumour cells, it has, at the 
same time, been reported to promote tumour development or growth. For 
example, CD4+T cells are known to be protective in a murine model of human 
papillomavirus (HPV)-induced cervical carcinoma whereas in (HPV)-induced 
skin carcinogenesis, both CD4+T and B cells enhance tumor growth (Daniel et 
al., 2005; De Visser, Korets and Coussens, 2005; Daniel et al., 2003). Tumours 
and their microenvironment can become so used to the therapy that they can 
potentially grow in the inflamed environment becoming immune-resistant. 
Moreover, tumour cells tend to have this ingenious capability of entirely 
transforming the immune system. The cells can achieve this by either producing 
substances such as cytokines and chemokines, which deactivates dendritic 
cells. This can happen by either displaying losses of tumour antigens (losses of 
HLA class I, for example, can result in NK cell lysis) or by inducing lymphocyte 
cell death through the triggering of Fas pathway (Bottino, Moretta and Moretta, 
2006; Rescigno, Avogadri and Curigliano, 2007; Zitvogel, Tesniere and 
Kroemer, 2006).  
     Gene therapy and Chemotherapy are the other most dangerous treatments 
that cause severe side effects as they do not discriminate between tumour and 
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healthy cells. Moreover, traditional chemotherapeutic agents do not achieve 
satisfactory therapeutic results due to their low solubility, poor stability, rapid 
metabolism, non-targeted body distribution and multi-drug-resistance. Also, 
both therapies face various challenges before reaching their targets. In the 
systemic circulation, naked DNA has been used successfully either by direct 
injection or DNA vaccines (Cohen et al., 2018). However naked DNA can be 
degraded rapidly by nucleases, and monocular-phagocyte system, a specially 
when DNA is injected directly into tissue drains, the lymphatic system and 
endonucleases in the extracellular space can degrade naked DNA within 30 
minutes (Schmidt-Wolf and Schmidt-Wolf, 2003). Similarly, before reaching the 
tumour site, chemotherapeutic drugs can be cleared by the immune system, 
which then reduces the amount necessary to achieve tumour cell killing.  
   To improve the therapeutic potential of cancer immunotherapy, PDT, SDT, 
gene therapy and most importantly cancer chemotherapy, new approaches 
have been developed for better long-term prognosis, improved targeted therapy 
with reduced side effects, improved drug solubility and to overcome therapy 
resistance. These approaches are illustrated in the following part of the 
introduction. 
1.4. New approaches to improve cancer therapies: delivery 
systems 
 The new approach is based on the fact that drugs, DNA, sonosensitizers, 
photosensitizers, antibodies, cytokines or other single cancer therapeutic 
agents can be encapsulated in a safe (protect from blood/renal clearance) 
carrier (vehicle or cargo) that can deliver them specifically to the target tumour 
depending on the route of administration. Two or more therapeutic agents can 
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also be incorporated at the same time in one carrier, forming a combinational 
therapy. The whole idea of being able to deliver therapeutic agents came from 
the mechanism of how viruses carry their gene into cells. There are two types of 
carriers: biological and non-biological carriers (viral and non-viral). The 
approach here is to incorporate a therapeutic agent into a vector or a chemically 
synthesised carrier, then introduce the vector into the body, and the cells are 
expected to uptake the carrier similarly as viruses. 
1.4.1. Viral delivery system.  
Biological carrier involves the use of viral vectors derived from natural viruses 
that can deliver genetic materials into host cells. Viruses are known to be able 
to efficiently gain access to host cells and exploit the cellular machinery to 
facilitate their replication (Thomas, Ehrhardt and Kay, 2003).  
In the early 1990s, a retrovirus-vector was the first successful therapeutic 
application used to deliver the gene encoding adenosine deaminase (ADA) into 
T-cells of two children suffering from severe combined immunodeficiency 
(SCID) (Blaese et al., 1995; Bordignon et al., 1995; Herzog and Srivastava, 
2010). More viruses such as adenovirus (AdV), lentivirus (LV), herpes simplex 
virus (HSV), adeno-associated virus (AAV), baculoviral and pox virus have been 
modified in the laboratory to eliminate their toxicity and maintain their high gene 
transfer capability (Kay, Glorioso and Naldini, 2001; Thomas, Ehrhardt and Kay, 
2003; El-Aneed, 2004). Although many viral vectors have been developed for 
gene delivery, their use has been limited due to their immunogenic response, 
insertional mutagenesis and cytotoxicity (Nayak and Herzog, 2009). In the 
recent years, a decline in the use of retroviral vectors and adenoviruses has 
been observed (Thomas, Ehrhardt and Kay, 2003). For example, the case of a 
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clinical trial patient who died four days after receiving adenoviral therapy for the 
treatment of ornithine transcarbamylase deficiency (Marshall, 1999). 
Researchers have, therefore focussed on non-viral systems as an alternative to 
viral vectors. There have been over 1500 approved clinical trials using viral and 
non-viral systems since 1990 for various cell types and diseases (Herzog and 
Srivastava, 2010). 
1.4.2. Non-Viral Delivery System  
   Over the past few decades, many drug and gene delivery systems have been 
developed in different structures and sizes (nm or µm); made of polymers 
(polymeric carriers, micelles or dendrimers), lipids (liposomes), solid lipid 
carriers, gold carriers, nanotubes and magnetic carriers (Cho et al., 2008). The 
use of nanotechnology for the non-viral delivery system and its extreme 
advantage over the other types of a delivery system is illustrated here.  
1.4.2.1. Nanotechnology  
Nanotechnology is defined as the branch of technology that creates functional 
material, devices and systems through control of matter at dimensions between 
1 and 100nm where unique phenomena enable novel properties (physical, 
chemical, biological, mechanical, electrical) and novel application (Hulla, Sahu 
and Hayes, 2015; www.nano.gov). Nanotechnology is the most recently arrived 
therapeutic alternative for controlled drug delivery, combining imaging and 
treatment, applying hyperthermia and providing directed target therapy (Arruebo 
et al., 2011). As delivery systems, various nanoparticles (NPs) have been 
formulated to improve chemotherapeutic agents delivery in several ways: by 
controlling their release and distribution, by enhancing drug absorption, by 
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protecting their degradation, by delivering agents specifically in tumours via the 
enhanced permeation and retention (EPR) effect (Talekar et al., 2011; Hillaireau 
and Couvreur, 2009; Fumagalli et al., 2016), by increasing drug concentration in 
tumour tissues (loading efficiency), by improving drug solubility (Fang et al., 
2015) and by overcoming drug resistance. In addition to that, nanoparticles 
present optimal size and surface characteristics to increase their circulation time 
in the bloodstream (Fumagalli et al., 2016). Moreover, non-viral systems can be 
easily produced on a large scale at a reduced cost (McCrudden and McCarthy, 
2013). Although nanoparticles have shown increased benefits, some obstacles 
exist in their implementation for therapeutic purposes.  
In the following part, the biological and chemical fundamental concept in the 
design of targeted drug delivery systems will be reviewed.                                  
Generally, a nanocarrier must be designed in a way that it overcomes all 
biological strategies (Figure 1-4) in vitro and in vivo environments which may 
limit their efficacies. This is dependent on the carrier physical and chemical 
properties such as structure, shape, size, surface charge and composition as 
well as the site of the target to be delivered. The overall carrier should be 
biodegradable, stable, nonimmunogenic, easy to fabricate, cost-effective, and 
able to release the chemotherapeutic agents only at the target site.  
Delivery systems including NPs, can be administrated intravenously, 
intramuscularly, ocularly, and by nasal airways. Figure 1-1. shows the 




It is reported that intravenously delivered therapies have the potential to target 
almost all tissues in the body, therefore, we will be focussing more on 
systematic delivery systems (McCrudden and McCarthy, 2013; Miyata, 
Nishiyama and Kataoka, 2012). In fact, oral administration can easily degrade 
carriers in the digestive tract (Varde and Pack, 2004).  
                                          
Figure 1-1. Routes of administration: summary of the routes of exposure 
commonly used for nanomaterial administration, including their main 
advantages (green) and challenges (red) (Bourquin et al., 2018). 
 
1.4.2.2. Importance of size, surface charge and composition of 
carriers to overcome extracellular barriers in the bloodstream 
When administrated intravenously or intramuscularly, the agents get straight 
access to the bloodstream; the first clearance chances are that nucleases can 
easily destroy therapeutic agents whereas nasally or ocularly-administrated 
15 
 
carriers may not face nucleases clearance (Bitko et al., 2004; Dawson et al., 
2004; McCrudden and McCarthy, 2013). The body can excrete unwanted 
materials from the body through renal (urine) and hepatic (bile or faeces) 
pathways. Since the blood consists of proteins and low molecular weight 
solutes (plasma), non-viral agents with overall positive charge may interact with 
negatively charged proteins resulting in non-specific binding forming 
aggregation or dissociation of non-viral carriers. Aggregation of the 
nanoparticles for examples can cause embolisation of microvessels (Miyata, 
Nithe shiyama and Kataoka, 2012). Conventional non-stealth polymeric carriers 
can quickly bind with the opsonin protein present in blood serum, allowing their 
visibility to macrophages of the mononuclear phagocytic system (MPS) resulting 
in their elimination within seconds. Phagocytic cells such as monocytes, 
macrophages, dendritic cells and neutrophils all form a network or a reticulum in 
different organs contributing to a system known as the reticuloendothelial 
system (RES). It is reported that when using non-degradable polymers, they 
undergo readily phagocytic attack which accumulates the carriers into organs 
such as liver by Kupfer cells and spleen by spleen macrophages which can lead 
to severe toxicity and side effects (OwensIII and Peppas,2006). Also, larger 
particles of 500-5000nm have shown to be cleared faster than smaller sizes by 
the RES (Harashima, Ochi and Kiwada, 1994; Bourquin et al., 2018).                 
For this reason, carriers need to have a so-called ‘Stealth’ property, which 
overcomes the challenges of nucleases attack, proteins interaction and 
opsonisation so that their stability in circulation is increased. To reduce 
opsonisation effect, for example, researchers have discovered that grafting 
shielding groups (non-ionic surfactant or neutral or negatively charged 
hydrophilic polymer such as polysaccharides, polyacrylamide, poly (vinyl 
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alcohol), poly(N-vinyl-2-pyrrolidone) and PEG) which can block the electrostatic 
and hydrophobic interactions in carriers surfaces can be helpful (Hidalgo-
Alvarez, 2009). Also, nanoparticles of less than 100nm have been reported to 
have reduced hepatic filtration (Alexis et al., 2008). Renal excretion can also be 
done by glomerular filtration in kidneys, which can be influenced by the carrier 
size, charge and shape. It is reported that the filtration-size threshold of 
glomerular capillary walls is typically 6~8 nm for spherical particles (Yu and 
Zheng, 2015). 
Furthermore, molecules with a molecular weight of around 5000 to 100,000 
Daltons can easily be removed from the body by the renal system before 
reaching their target (OwensIII and Peppas,2006; Ostroff and Ernesto, 2016) 
whereas negatively charged nanoparticles and liposomes have shown faster 
uptake by the RES than that of neutral particles (Li and Huang, 2008). It is still 
important that delivery systems be appropriately designed to evade these 
clearance mechanisms enabling the systems to stay longer in the circulation.   
1.4.2.3. Targeted delivery system accumulation in tumours 
Once carriers bypass extracellular barrier, they then need to reach tumours 
without affecting healthy cells. Targeted delivery systems are the best approach 
for this; it consists of targeting specific sites or characteristics that only tumours 
environment present. Carriers can be designed to target tumours in 3 different 
ways: passive targeting, active targeting and physical targeting.  
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1.4.2.3.1. Passive targeting: pathophysiology and anatomy of 
tumour vasculature enhancing the enhanced permeation and 
retention (EPR) effect  
The tumour microenvironment is characterised by abnormal vasculature, 
inefficient lymphatic network and disorganised endothelial cells compared with 
healthy tissues. Within the tumour microenvironment persists a neovasculature 
supplying an increased amount of nutrients and oxygen; this permits the cancer 
cells to proliferate rapidly near the vessels (Armulik, Genové and Betsholtz, 
2011; Nakamura et al., 2016). As a tumour grows, new vessels that engulf 
existing blood vessels are recruited and reach 2-3mm, where angiogenesis is 
induced (Iyer et al., 2006). Normal capillaries are lined by tightly sealed 
endothelium supported by stellate-shaped pericytes which are further 
enveloped in a thin layer of basement membrane (BM) whereas the blood 
vessels in a tumour are irregular in shape and have incomplete endothelial 
lining permitting relative larger pores of 0.1-3 µm in diameter leading to higher 
vascular permeability and hydraulic conductivity (Nakamura et al., 2016). In 
addition to the space within epithelial cells in tumour vasculature, both pericytes 
and BM are loosely associated with endothelial cells and occasionally penetrate 
deep in the tumour parenchyma (Nakamura et al., 2016). The tumour 
anatomical defectiveness along with the disorganised epithelial cells with large 
fenestrations results in the extensive leakage of blood plasma components, 
such as macromolecules, nanoparticles and lipidic particles, into the tumour 
tissue (Iyer et al., 2006). Moreover, due to the poor lymphatic drainage, carriers 
that reach the tumour environment are less prone to immune clearance which 
means that carriers can retain in a tumour for an extended period (Danquah, 
Zhang and Mahato, 2011; Nakamura et al., 2016, Iyer et al., 2006). This 
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phenomenon of how delivery systems accumulate the tumours by passing 
across the fenestrated capillary endothelium and then get introduced into the 
interstitial space through tumour vasculature leakage is known as the enhanced 
permeability and retention (EPR) (Kobayashi, Watanabe and Choyke, 2014). In 
another term, it is the consequence of increased vasculature permeability and 
decreased lymphatic functions of a tumour (Sun et al., 2017, Hillaireau and 
Couvreur, 2009; Miyata, Nishiyama and Kataoka, 2012). Polymeric 
macromolecules larger than 40KDa including poly (styrene-co-maleic acid half-
butylate) linked neocarzinostatin (SMANCS), the first macromolecular 
anticancer drug approved for use in clinical trials in 1993 have shown to be very 
highly accumulated in tumours via the EPR effect compared to healthy tissue 
(Maeda and Konno 1997; Fang, Nakamura and Maeda, 2011). Low-molecular-
weight drugs do not apply the EPR effect due to their rapid diffusion into the 
circulating blood, followed by renal clearance (Iyer et al., 2006). Also, it has 
been reported that carriers of less than 200nm accumulate effectively into 
tumours (Miyata, Nishiyama and Kataoka, 2012). Since passive targeting of 
delivery systems is a progressive step, stability and solubility of the carriers in 
the plasma becomes essential to achieve the minimum time required in 
circulation for the EPR effect to occur (6h) (Matsumura and Maeda, 1986; 
McCrudden and McCarthy, 2013). The use of ionic or neutral particles would be 
ideal for increasing their plasma half-life. Also, the use of polymers to make 
drugs macromolecules would facilitate not only their EPR effect but would 
permit their diffusion across matrix gel (fibrin gel or stromal tissues) which 
surround tumour tissues (Fang, Nakamura and Maeda, 2011). 
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Figure 1-2. Schematic representation of nanoparticles accumulation within 
tumour by passive targeting (pelissari et al., 2018). 
 
Although EPR facilitates the tumour targeting of carriers passively, more 
challenges can still limit their effect on tumour cells. The increased vessel 
permeability, hyperfusion, the poor lymphatic drainage, the hyperplasia around 
blood vessels and increased production of extracellular matrix components 
elevate the interstitial fluid pressure in tumours (from 0mmHg to 10-40mmHg) 
(Nakamura et al., 2016). This, in turn, creates hypoxic and acidic intratumoral 
conditions and at same time may prevent the penetration of carriers deep within 
the tumor therefore contributing to tumor progression, metastasis and therapy 
resistance (Jain, 1987; Carmeliet and Jain, 2000;  Jain, 2005; Jacobetz et al., 
2012;  Nakamura et al., 2016). Also, other organs may present different tumour 
features, for example, the brain possesses the blood-brain barrier (BBB) which 
control tightly the movement of particles (more detailed will be explained in 
chapter 4).  
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1.4.2.3.2. Active targeting  
Once carriers reach the tumour interstitium via the EPR effect, they need to find 
their way to enter the cell. For this reason, active targeting via receptor-
mediated internalisation can be employed. The lipid bilayer of cells consists of 
proteins and saccharides of different shapes and sizes known as receptors 
which can be distributed evenly across the cell surface or localised within 
microdomains. These receptors can convey changes in the presence of 
external environments such as the presence of nutrients, toxins, attractants or 
foreign invaders (Kiessling, Gestwicki and Strong, 2000). Cancer cells 
overexpress specific antigens or surface receptors which can be targeted 
(Attarwala, 2010). Receptor targeting can be done by adding targeting moieties 
such as ligands or antibodies into the backbone of polymers. There have been 
some targeted cancer treatments that are FDA approved using antibodies 
(Gasser and Waaga-Gasser, 2016). However, the use of peptides as targeting 
moieties have been reported to be beneficial over antibodies because of the 
difficulties of conjugating antibodies into carriers and their high molecular weight 
of 160000 can affect their circulation time whereas peptides are smaller, simple, 
more stable and easier to produce (Aina et al., 2002; Yu et al., 2016). Since the 
1980s, there has been 239 FDA approved therapeutic proteins and peptides in 
which 60 peptide drugs are already in the market (Fosgerau and Hoffmann, 
2015; Usmani et al., 2017). Tumors have a developed lumen structure and 
secrete a variety of proangiogenic factors such as vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), basic fibroblast growth 
factor (bFGF), interleukin-8 (IL-8), angiogenin, angiotropin, platelet-derived 
endothelial cell growth factor (PD-ECGF), transforming growth factor-α (TGF-α), 
TGF-β, epidermal growth factor (EGF), and tumour necrosis factor-α (TNF-α)) 
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(Folkman, 1996; Byrne, Betancourt and Brannon-Peppas, 2008). Targeting 
angiogenesis being the central phenomenon that influences tumour growth can 
also be achieved via Vascular endothelial growth factor VEGF receptors 
targeting in angiogenic endothelial cells. The tripeptide arginine-glycine-aspartic 
acid (RGD) was the first and most widely used peptide to target angiogenesis 
by binding specifically to the overexpressed integrins αVβ3 and αVβ5 (Yu et al., 
2016). Targeting to specific cells of specific organs is also achieved by small 
ligand targeting molecules which are more beneficial than peptides as they do 
not exhibit immunogenicity. Examples include folic acid, a low molecular weight 
vitamin that selectively binds to folate receptors highly expressed by many 
primary and metastatic including breast and ovarian, endometrial, lung, kidney, 
breast, colon and nasopharyngeal cancers (Yoo and Park, 2004; Li et al., 
2016). 
Another example is the use of galactose residues for the targeting of the 
asialoglycoprotein receptor (ASGPr) in liver cancer (see chapter 4 and 5). 
Polymers such as Pullulan and Hyaluronic acid can also target overexpressed 
receptors such as ASGPr in liver and CD44 in leukaemia, breast, intestinal and 
colon cancers, respectively (Basakran,2015). However, receptors 
overexpressed in tumour cells are also present in healthy cells, which can affect 
the targeting of carriers into tumour cells only. Also, due to the tumour 
environment with a high level of proteases, transmembrane proteins expressed 
on cell surfaces can be cleaved or can be present in a variety of isoforms thus 




Figure 1-3. Schematic representation of nanoparticles accumulation within a 
tumour by active targeting (pelissari et al., 2018). 
 
Furthermore, Yu et al. in 2010 report the potential of active targeting to 
suppress multidrug resistance (MDR) via bypassing of P-glycoprotein- mediated 
drug efflux (Gottesman, Fojo and Bates, 2002; Gu et al., 2007; Peer et al., 
2007). Usually, the passive and active targeting are combined to increase the 
delivery efficiency on tumour cells, once the carrier has reached the tumour 
cells, they are often taken inside cells by a phenomenon known as endocytosis.  
1.4.2.4. Intracellular barriers and the internalisation of carriers 
(vectors) by endocytosis: the chemotherapeutic agent release 
point  
 
One of the major obstacles that non-viral carriers face is the loading capacity 
and the release rate of therapeutic agents encapsulated at the right time and in 
the right site of action. Carriers should be able to load sufficient amount of 
therapeutic agents to achieve a therapeutic effect, and they should be released 
at an optimal rate to the right site of action (3-10% per day) (Fang, Nakamura 
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and Maeda, 2011). The too slow or too rapid release rate can also affect the 
effectivity of the delivery system. A too slow release will result in an inefficient 
concentration of active drugs whereas rapid release will lead to a high 
concentration of free drug in circulation which will result to undesired systemic 
toxicity (Fang, Nakamura and Maeda, 2011). Most therapeutic agents undergo 
their mode of action to the tumour site; therefore it is essential for carriers to be 
able to release the agents to the main tumor site and achieve higher drug 
concentration in the vicinity of the tumor (Ratain and Plunkett, 2003).  
1.4.2.4.1. The cytosolic entrance of carriers 
In 2010, Ziello and his colleagues explained the mechanism of how materials 
are undertaken by cells. The cell membrane is permeable to materials less than 
1KDa and can internalise them in a variety of different ways (Bareford and 
Swaan, 2007). The primary pathway that most viruses use to enter the cell is 
the endocytic route (Thorley, McKeating and Rappoport, 2010). 
Macromolecules present in the surrounding medium of cells can be taken up by 
cells, the material is internalised by an area of the plasma membrane which 
then engulfs the material inside the cell to form a vesicle containing the ingested 
material. The other pathway is by receptor-mediated endocytosis where the 
macromolecule present in surrounding of the cells interact with specific cell 
surface receptors present in the clathrin-coated pits (specific regions of the cell 
plasma membrane) which then internalise the material (~200nm) to form 
clathrin-coated vesicles (CCV) (Wang, Upponi and Torchilin, 2012). 
Endocytosis is also reported to be achieved via the caveolae present in the 
plasma membrane (for particles of~300nm) (Wang, Upponi and Torchilin, 
2012). After macromolecules internalisation, endocytosis vesicles may fuse to 
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form acidic early, late endosomes and lysosomes (Anderson, 1998; Aniento, 
1993; Ziello, 2010; Wang, Upponi and Torchilin, 2012).   
1.4.2.4.2. Physical targeting  
Apart this accumulation of materials by the endosomal system, materials 
contained in early endosomes (can be taken as quickly as in 5-10minutes) can 
be recycled and exocytosed or trafficked to other organelles such as Golgi and 
mitochondria (Steinman, 1983; Bareford and Swaan, 2007). Therapeutic agents 
should be released safely once they reach intracellular compartments to be able 
to achieve their role. It is therefore crucial that carriers escape the endosomes 
or avoid degradation through lysosomes trafficking. It is known that 
macromolecules (hydrophobic or charged) that undergo endocytosis depending 
on clathrin are destined for lysosome degradation whereas independent clathrin 
pathway leads to endosomal accumulation only (Bareford and Swaan, 2007). 
a. pH-responsive drug release 
The early endosomes possess some vacuolar ATPase which pumps in H+ ions 
making an overall acidic environment in early endosomes to pH 6.0-6.5, late 
endosome to pH 5.5 and the lysosomes to pH nearly 4.5 (Bareford and Swaan, 
2007; Li et al., 2018). Current strategies take benefits of this pH condition to 
escape endosomes by tailoring modified carriers such as pH-sensitive 
polyplexes, cell-penetrating peptides, and photosensitive molecules. pH-
sensitive materials are either designed by incorporating a pH-responsive 
linkage within the material or by using building blocks which are pH-responsive. 
An example of this, is molecules (such as Doxorubicin) that switch from 
uncharged to charge and hydrophobic to hydrophilic when they are below their 
pKa (Kongkatigumjorn et al., 2018).  
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b. Release via endosomes lysis  
When polymeric materials are used, the polymers absorb protons in the 
endosome (proton sponge effect) which lead to chloride ions influx resulting in 
an increased osmotic pressure of water flow into the endosome and therefore 
leading to endosome rupture. Very recently, Rangasamy and his colleagues 
have also reported in 2018 a new way to facilitate endosomes rupture that can 
permit the release of biologics using a K+/H+ ionophore (Rangasamy et al., 
2018). Another strategy is that of materials such as fusogenic lipid DOPE and 
Haemagglutinin that interact with the membrane either by electrostatic 
interaction or by fusion in the lipid bilayer. The sub-physiological pH of the 
endosomes can cause the materials to undergo conformational changes from 
lipid bilayer which then can disrupt the endosomal membrane (Wiley and 
Skehel, 1987; Varkouhi et al., 2011; Wang, Upponi and Torchilin, 2012; 
McCrudden and McCarthy, 2013). Moreover, cationic amphiphilic peptides 
(AMPs) can also bind to lipid bilayers, which can lead to internal stress resulting 
in pores formation in the lipid membrane (Jenssen, Hamill and Hancock, 2006). 
Also, photosensitizers such as TPPS4, TPPS2a, AIPcS2a and dendrimer-based 
photosensitiser are able to induce the formation of singlet oxygen in the 
presence of light which have the capability to destroy endo/lysosome 
membrane (Prasmickaite, Høgset and Berg, 2001; Nishiyama et al., 2006; 
Varkouhi et al., 2011).  
c. Redox-responsive drug release  
The primary reducing agent to cause redox response is the most abundant thiol 
species known as Glutathione (GSH) present in the cytoplasm (Espinosa-Diez 
et al., 2015). The extracellular concentration of GSH is two µM, whereas a 
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higher concentration of 1-10 mM is seen in the intracellular compartment of the 
cell. Delivery systems can be designed in a way that they contain disulphide 
leakage which can be broken under high concentration of GSH inside the 
cytoplasm and most importantly is to note the advantage of using the redox-
responsive delivery system to overcome drug resistance (Bar-Zeev, Livney and 
Assaraf, 2017). For example, Ma and colleagues in 2015 have demonstrated 
that the use of redox-responsive polyphosphoester-based micellar has the 
potential to overcome MDR and can successfully deliver the anticancer drug 
dox against drug-resistant breast cancer cells. Further details are explained in 
chapter 6. 
Figure 1-4. Summary of the extra- and intracellular barriers faced by non-viral 
gene therapies following systematic delivery (McCrudden and McCarthy, 2013; 
Miyata, Nishiyama and Kataoka, 2012). 
 
d. External stimuli-responsive drug release  
Release of therapeutic agents from carriers can also be released by the 
influence of external stimuli such as temperature, electromagnetic, ultrasound, 
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electric field or applied mechanical force (Zhang et al., 2016; Ge et al., 2011; 
Comes Franchini et al., 2010; Bar-Zeev, Livney and Assaraf, 2017). Carriers 
can be designed in a way that they are stable at 37 ̊C (normal physiological 
temperature) and at a higher temperature (40-42 C̊ which is the tumour 
temperature), the carrier undergoes a change resulting in drug release. A good 
example is that of ThermoDox, a temperature-sensitive doxorubicin-pegylated 
liposome developed for liver cancer, which has reached phase III trials (Pillai, 
2014). In the condition of hyperthermia or radiofrequency ablation, the lipid 
components in the liposomes undergo a gel to liquid transition which facilitates 
the release of the drug (Pillai, 2014; Mura, Nicolas and Couvreur, 2013). 
Strategies using a magnetic field to release the drug from magnetic responsive 
carriers has also been developed. Superparamagnetic iron oxide nanoparticles 
(SIONPs) are the most famous nanoparticles used to achieve magnetic 
targeting. In 2009, Qin and colleagues developed SPEL ferrogel consisting of a 
pluronic F17 copolymer, SIONPS and hydrophobic drug in which under 
magnetic fields, iron oxide nanoparticles makes the systems attract each other 
and then get squeezed provoking drug release. Recently, a new study has also 
shown that ultrasound could destruct or degrade microparticles made of poly 
(lactic-co-glycolic acid) (PLGA) loaded and non-loaded with doxorubicin and 
therefore influencing controlled drug release of Dox (Jang et al., 2018). 
1.4.2.5. The nuclear entrance of therapeutic agents 
The final obstacle is crossing the nucleus for chemotherapeutic agents whose 
final target is inside the nucleus. Passive diffusion thought the nucleus 
membrane could only happen for materials less than 50 kDa (~10 nm) whereas 
the nucleus penetration of macromolecules greater than 50 kDa can be 
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facilitated using nuclear localisation (NLS) peptides or DNA targeting 
sequences (DTS) (Barua and Mitragotri, 2014). The material around the 
nucleus periphery can also access entrance to the nucleus during mitotic 
division where the nuclear membrane’s barrier is disrupted or via nuclear pore 
complex (NPC) (Khalil, 2006; McCrudden and McCarthy, 2013; Munsell, Ross 
and Sullivan, 2016). Non-NLS design strategies for effective nucleus entrance 
has also been developed. Sugar residues (for example lactose and mannose) 
are incorporated in carriers to induce nuclear localisation by interacting with 
sugar-binding proteins (lectins) as a shuttle between cytoplasm and nucleus 
(Munsell, Ross and Sullivan, 2016).  
1.4.2.6. Tumour Resistance  
Although successful delivery can be achieved using nanocarriers, treatment 
resistance still exists. The biggest challenge is the multi-drug resistance (MDR) 
to almost all anti-cancer agents due to the efflux of drugs by the p-glycoprotein. 
MDR is most commonly associated with the overexpression of prosurvival, anti-
apoptotic protein and ATP-binding cassette (ABC) transporters genes 
(Mansoori et al., 2017). These transporters actively transport various drugs 
outside the cell through the plasma membrane, therefore, reducing the number 
of drugs inside cells (Figure 1-5.) (Bar-Zeev, Livney and Assaraf, 2017). 
Examples for chemotherapeutic drugs that face resistance are Doxorubicin, 
Cisplatin, Daunorubicin, Colchicine, Vincristine, Vinblastine, Vinolvinorelbine, 
teniposide, irinotecan, topotecan, methotrexate and paclitaxel (Joshi, 
Vishwakarma and Bharate, 2017). 
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Various types of chemosensitizers have been developed to overcome MDR. 
These are compounds that include natural compounds derived from plants and 
marine compounds which specifically block MDR efflux transporters.  
 Figure 1-5. Mechanisms of anticancer drug resistance mediated 
by transmembrane transporters of the ATP-binding cassette (ABC) superfamily: 
p-gp, BCRP and MRP1 enhanced ATP energy-dependent efflux of various 
hydrophobic anticancer drugs (Bar-Zeev, Livney and Assaraf, 2017). 
 
 
Table-2 (tabulated by Bar-Zeev and colleagues in 2017) shows the 
chemotherapeutics drugs that are associated with the resistant transporters and 
the correspondent chemosensitizers. As seen from the table, almost all-
important ABC multidrug resistance-associated proteins involve the resistance 
of the lead compound of anthracycline: Doxorubicin. Doxorubicin being the most 
effective chemotherapeutic drug against various cancers, presents various 
cardiotoxicity effect but also presents continuous problems with MDR (Geisberg 
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and Sawyer, 2010). For this reason, many researchers focus on developing 
new strategies for improving Doxorubicin safety in cancer patients. 
Table 1-2. The three main ATP-binding cassette (ABC) efflux transporters, 
their chemotherapeutic drug substrates and chemosensitizers (Bar-Zeev, 





























































1.5. The anthracycline background: Doxorubicin (Dox)  
Anthracyclines are the most widely used anticancer drugs from all the FDA 
approved drugs. The first two anthracyclines Doxorubicin and Daunorubicin 
were developed in the 1960s and originally isolated from the fungus 
Streptomyces peucetius (Rivankar,2014). In the 1950s, the bright red pigment 
isolated from the fungus was found to have good activity against mouse 
tumours and named daunorubicin (Rivankar,2014). However, by 1967s, the 
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compound was already determined to produce fatal cardiac toxicity (Shakir, 
2009). It was then that some genetic modification to the fungus led to the 
production of Dox, which also presents severe toxicity (Rivankar,2014). So 
much effort has been put in place to develop anthracyclines analogues (~2000 
compounds) to overcome the severe side effects of first-generation 
anthracyclines such as acute toxicity, cardiomyopathy and congestive heart 
failure. However new analogues of which only a few have been clinically 
approved (epirubicin, aclarubicin, pirarubicin, mitoxantrone, idarubicin and 
valrubicin) have also failed to reduce these side effects, and none present 
stronger antitumor efficacy than the original two anthracyclines (Minotti et al., 
2004; Kumar et al., 2014; Carvalho et al., 2009). 
1.5.1. Doxorubicin structure 
The antibiotic Doxorubicin is known in different names as adriamycin or 
hydroxydaunorubicin (Pérez-Arnaiz, Busto and García, 2014). Its structure 
consists of an aglyconic and daunosamine sugar moieties. The aglycone 
consists of a tetracyclic ring with adjacent quinone-hydroquinone groups in rings 
(the quinone and hydroquinone groups on adjacent rings permits the gain and 
loss of an electron by reaction mediated by cytochrome P450 reductase, NADH 
dehydrogenase, and xanthine oxidase), a methoxy substituent and a short side 
chain with a carbonyl group. The daunosamine sugar is attached via a 
glycosidic bond to one of the rings and consists of a 3-amino-2,3,6- trideoxyL-
fucosyl moiety (Carvalho et al., 2009; Minotti et al., 2004). 
For laboratory use, the drug is commercially available in salt form as 
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; Dox.HCl; 
C27H29NO11 ·HCl; 579.98g/mol) giving it solubility in water, slightly in methanol 
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and practically insoluble in organic solvents including chloroform and ether 
(Arcamone et al., 1972, Kanwal et al., 2018).  
                                                       
Figure 1-6. Chemical structure of Doxorubicin. 
1.5.2. Antitumor activity of doxorubicin  
Dox having a low molecular weight enter cancer cells via passive diffusion and 
then binds to the 20s proteasomal subunit in the cytoplasm to form a Dox-
Proteasome complex which transports the drug into the nucleus via nuclear 
pores (Kiyomiya, Matsuo and Kurebe, 2001). The process is facilitated by the 
use of ATP. The drug then dissociates from the proteasome and binds to DNA 
to carry out its mode of action (Kiyomiya, Matsuo and Kurebe, 2001; Minotti et 
al., 2004). Anthracyclines including Dox have been reported to have the 
following mode of actions: intercalation between base pairs in DNA helix leading 
to inhibited replication and synthesis of proteins; generation of free radicals 
(superoxide anion (O2·
-) and hydrogen peroxide (H2O2)) resulting in cytotoxicity 
to cell membrane lipid peroxidation; DNA binding and alkylation;  DNA cross-
linking; interference with DNA unwinding or DNA strand separation and helicase 
activity; direct membrane effects; initiation of DNA damage via inhibition of 
topoisomerase II; and induction of apoptosis in response to topoisomerase II 
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inhibition (activation of p53-DNA binding) (Gewirtz, 1999; Minotti et al., 2004; 
Rivankar,2014). 
Dox tend to interact with the cell compartment by electron transfer, which leads 
to the formation of toxic semiquinone radical intermediates that can react with 
oxygen to form reactive oxygen species (ROS). Moreover, Dox is among the 
most active chemotherapeutic agents and has become one of the leading ‘first 
line’ anticancer drugs. It is used for the treatment of a wide range of cancers 
including breast, lung, ovarian, neuroblastoma, acute lymphoblastic leukaemia, 
bile duct, prostate, uterus, ovary, oesophagus, stomach, childhood solid 
tumours, osteosarcomas, Kaposi’s sarcoma, soft tissue sarcomas, acute 
myeloblastic and Wilms tumor (Kumar et al., 2014; Rivankar,2014). The drug is 
administrated intravenously (dose range of 10-50 mg/m2) as it can not be 
absorbed by the gastrointestinal tract since it is hugely irritating to tissues. After 
administration, Dox is very quickly distributed into the extravascular 
compartments and has a half-life of 12-18 hours (Kumar et al., 2014). It is 
reported that the binding of Dox to plasma protein is about 75% and does not 
cross the blood-brain barrier (Kumar et al., 2014). The drug is then metabolised 
in the liver into 13-OH-doxorubicinol by the enzyme aldo-ketoreductase and 
eliminated by metabolic conversion to a variety of aglycones and other inactive 
products which are then excreted through biliary and faecal excretion (Kumar et 
al., 2014). 
1.5.3. Doxorubicin side effects  
Doxorubicin having a low molecular weight quickly diffuse into all tissues in the 
body (heart, brain, liver and kidneys) thereby frequently causing toxicity leading 
to dose-related side effects. There are many common side effects associated 
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with Dox including acute nausea, stomatitis, gastrointestinal disturbances, 
alopecia, baldness, neurologic disturbances (hallucinations, vertigo, dizziness), 
acute or chronic cardiotoxicity and bone marrow aplasia (Li et al., 2017). The 
effect on bone marrow is accompanied by an increased incidence of microbial 
infection, gingival bleeding, anaemia, thrombocytopenia and neutropenia. 
Moreover, many other side effects have been reported such as cellulitis, 
vesication, thrombophlebitis, lymphangitis, painful induration, phebosclerosis 
and disruption of mitochondrial functions (Dox can bind to cardiolipin) 
(Hortobagyi, 1997; Maluf and Spriggs, 2002; Tokarska-Schlattner et al., 2007; 
Jung and Reszka, 2001; Julka et al., 2008; Carvalho et al., 2009; Li et al., 
2017). 
1.6. Targeting delivery Systems for the improvement of 
Doxorubicin therapy 
Various carriers have been developed to assist the preferential distribution of 
Doxorubicin within tumours while not exposing healthy tissues to toxic levels of 
the drugs. Figure 1-7. gives an overview of the problems accounted with the 
delivery systems, whereas Figure 1-8. gives an overview of the types of organic 
delivery systems.  
1.6.1. Liposomes 
Liposomes were first discovered by Alec Bangham (Bangham, 1980; Samad, 
Sultana and Aqil, 2007). They are small vesicles of spherical shape produced 
from cholesterols, non-toxic surfactant, sphingolipids, glycolipids, long chain 
fatty acids or even membrane proteins. The use of liposomes to deliver 
compounds in the aqueous compartment started in the 1960s and developed 
for clinical potential in 1970s (Bozzuto and Molinari, 2015). Liposomes can 
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entrap both lipophilic (in the aqueous centre) and hydrophobic compounds (in 
the bilayer membrane).                                                 
Figure 1-7.  Advantages and disadvantages of the existing delivery 
system.  
 
Conventional liposomal formulations were the first type of liposome to be 
developed, although they have shown strong enhancement for drug delivery in 
cancer cells, these systems have been prone to rapid elimination due to 
36 
 
opsonisation, RES, liver and spleen elimination. An example is that of the 
negatively charged medium-size oligolamellar liposomes containing 
Doxorubicin, which is referred as to OLV-Dox (200-500nm). The overall system 
has shown to be cleared by the RES and Dox situated in the bilayer of the 
liposome is easily released upon dilution and quickly eliminated (Hua and Wu, 
2013; Sercombe et al.,2015; Gabizon et al., 1991; Amselem, Cohen and 
Barenholz, 1993; Barenholz, 2012). Another disadvantage on the use of these 
liposomes is their size being too large (400-2.5µm) which allows their 
extravasation in the extra-hepatic tissues and their uptake by RES effect 
(Maeda, Bharate and Daruwalla, 2009; Malam, Loizidou and Seifalian, 2009; 
Barenholz, 2012). 
The reduced clearance, prolonged circulation and improved pharmacokinetics 
of conventional liposomes have been achieved by the addition of PEG and by 
the production of liposomes in nanoscales. There have been over 10 PEGylated 
drugs that have been FDA approved with over 20 drugs in clinical trials 
(Swierczewska, Lee and Lee, 2015). Doxil® (80-90nm) was the first FDA-
approved PEGylated liposomal nano-Doxorubicin drug in 1995 for the treatment 
of ovarian cancer and AIDS-related Kaposi’s sarcoma. 
However, Although PEGylation in liposomes has shown prolonged circulation 
effect, there have also been shown to reduce the ability of liposome to interact 
with the intended targets (Sercombe et al., 2015).  
More liposomes-based delivery system has been clinically approved not only in 
cancer therapy but also for other diseases such as fungal infections, vaccines 






Bulbake and colleagues in 2017 have reported 28 more products undergoing 
clinical in which 6 products are under clinical trial Phase III (Arikace, Stimuvax, 
T4N5 liposomal lotion, Liprostin, ThermoDox and Lipoplatin), 9 products in 
clinical Phase II (Aroplatin, Liposomal annamycin, SPI-077, OSI-211, S-
CKD602, LE-SN38, LEP-ETU, Endotag-I and Atragen) and 13 products in 
clinical Phase I (LEM-ETU, Liposomal Grb-2, INX-0125, INX-0076, TKM-
080301, Atu027, 2B3-101, MTL-CEBPA, ATI-1123, LiPlaCis, MCC-465, SGT-
53, Alocrest). From all products, only two other Doxorubicin based liposomes 
are undergoing under clinical trials (Thermodox and MCC-465).  
1.6.2. Albumin-based carriers 
Albumin is an acidic and very soluble protein that is commercially obtained from 
egg white, bovine serum, human serum, soybeans, milk and grains (Arshady, 
1989; Elzoghby, Samy and Elgindy, 2018). Albumin has been used as a drug 
carrier since it is biodegradable, non-toxic, easily prepared and reproducible 
(Elzoghby, Samy and Elgindy, 2018). The primary structure of albumin consists 
of charged amino acids, which can easily interact with charged molecules. It 
also has some hydrophobic binding domains which can interact with 
hydrophobic drugs (example of Abraxane® consisting of albumin and 
hydrophobic drug paclitaxel). Albumin-based nanoparticles are of smaller size 
(50 to 300nm), higher half-life in blood circulation (great solubility properties), 
better-controlled release properties, multiple ligand binding sites and high 
cellular interactions compared to liposomes (Khodabandehloo, Zahednasab and 
Ashrafi Hafez, 2016; Elzoghby, Samy and Elgindy, 2018). Aldoxorubicin (clinical 
trial phase I) is a prodrug of doxorubicin that contains an acid sensitive 
hydrazine moiety, a 6-carbon spacer and a thiol binding maleimide. The prodrug 
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is administrated intravenously, and when it reaches the bloodstream, the linker 
molecule binds covalently (within 5min) to the cysteine-34 amino acid of 
endogenous albumin. The bound albumin-doxorubicin then accumulates in 
tumour via EPR effect and the drug is released in the acidic environment of the 
tumour cells (Kratz et al., 2002; Mita et al., 2014).  
1.6.3. Amphiphilic block copolymer/ Polymeric based 
nanocarriers/micelles 
  
Polymeric carriers for the delivery of Doxorubicin have been studied. These 
consist of the use of natural or synthetic polysaccharide such as poly(d,l-lactide) 
(Margarida Cardoso et al., 2016), poly(lactic acid) PLA, poly(d,l-glycolide) PLG 
(Eisenbrey et al., 2010), poly(lactide-co-glycolide), PLGA (Tewes et al., 2007), 
and poly(cyanoacrylate) PCA, Pullulan (Lu et al., 2009), Hyaluronic acid (Cho et 
al., 2012),  Heparin (She et al., 2013), alginic Acid (Cai, Ni and Zhang, 2012), 
Dextran,  chitosan(Bisht and Maitra, 2009), sodium alginate (KITAZAWA et al., 
1997) and other hydrophilic/biodegradable polymers. These polysaccharides 
have attracted the most attention because they are non-toxic, non-
immunogenic, biocompatible, biodegradable and renewable (Akhlaghi et al., 
2013; Hassani et al.,2012). Moreover, they have a wide range of molecular 
weight and a large number of reactive groups (-COOH, -NH2, -OH,…) which 
permit their modification to various amphiphilic derivatives. The polysaccharide 
is usually considered as a backbone in which either a drug can be directly 
chemically linked by a simple ester or amide bond which can then be 
hydrolysed in VIVO. Alternatively, the hydrophilic polysaccharide can be 
modified by addition of hydrophobic complexes to form micelles that can load 
hydrophobic drugs. Current hydrophobic moieties involved in creating 
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amphiphilic polysaccharides derivatives that undergo self-assembly in aqueous 
solutions include linear molecules such as long-chain fatty acids (Nichifor et al., 
2014; Pramod et al., 2012), poly(ε-caprolactone) (Chandel et al., 2016; Gu et 
al., 2014), cyclic molecules such as cholesterol (Kawasaki et al., 2016; 
Takahashi et al., 2011), bile acids (Li et al., 2012), doxorubicin (Cao et al., 
2010; Xu et al., 2015), polyacrylate family such as Poly(methyl methacrylate) 
(Dupayage et al., 2011; Dupayage et al., 2008) and poly(isobutyl cyanoacrylate) 
(Bravo-Osuna et al., 2007; Wang et al., 2011). The stability and polarity of 
amphiphilic polysaccharides-based nanostructures are closely related to the 
structural characteristics of amphiphiles, such as hydrophobicity and 
intra/intermolecular interactions (Aschenbrenner et al., 2013). The overall 
polymeric carriers can be structured in many ways as seen in Figure 1-9.  
Figure 1-9. Schematic view of diverse types of polymeric carriers. Polymeric 
micelle (a). Micelle conjugated with a targeting ligand (b). A micelle containing an 
incorporated contrast agent or chelated imaging moieties (c). Micelle modified 
for triggered drug release (d). Either the hydrophilic or hydrophobic polymer can 
be rendered thermo/pH/light/ultrasound sensitive. Optimized micelle for 
anticancer therapy, bearing targeting ligands, contrast agents or imaging 
moieties, therapeutic drugs and polymers suitable for triggered, controlled 
release (e)(Oerlemans et al., 2010). 
 
Bobo and colleagues reviewed in 2016 all the FDA approved nanomaterials. 
They reported 16 FDA approved polymeric based nanoparticles. Copaxone® 
(approved in 1996) and Neulasta® (approved in 2002) being the bestselling 
polymeric drugs in the USA are used for the treatment of multiple sclerosis and 
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chemotherapy-induced neutropenia, respectively. In 2014-2015, two new 
PEGylated drugs PLEGRIDY® and ADYNOVATE were approved for the 
treatment of relapsing multiple sclerosis and haemophilia A, respectively. 
Whereas only one FDA approved micelle (Estrasorb™) has been approved to 
date. 
Overall, polymeric carriers have shown to be more effective compared to 
liposomes for the delivery of hydrophobic drugs since their size range is much 
smaller, they can be easily modified by the addition of hydrophobic blocks which 
increases the loading efficiency of hydrophobic drugs.   
1.6.4. Dendron based nanocarriers / Dendronised polymers   
Dendrimers are new macromolecules that are classed as polymeric materials. 
They present various advantages over traditional linear polymers. The name 
comes from the word Dendron which means tree. They behave with excellent 
amplification effects, precise nanostructure, water solubility, multivalency, high 
degree of branching, and highly adaptable surface chemistry, as well as 
controllable molecular size, mainly due to the unique radiate dendritic 
structures, low polydispersity and the amplification effect, which can be 
harnessed for providing large void space within the hydrophobic inner core. 
Generally, dendrimers involving well-defined molecular structures allow 
multivalency in a turnable way upon selecting the peripheral chemical groups 
and the generation properly (Majoinen et al., 2014; Roglin et al., 2011; Rosen et 
al., 2009; Nanjwade et al., 2009). Most importantly, compared to all others 
delivery systems, dendrimers are present in the smallest range of size (1-10nm) 




                                                                   
Figure 1-10. Schematic overview of dendrons and dendrimers. 
 
Dendrimers are widely being studied as therapeutic agents for the drug, gene 
and vaccine delivery (Araújo et al., 2018). Dendrimers were first synthesised in 
the 1980s (Tomalia et al., 1985). Polyamidoamines (PANAMs) also called 
starburst dendrimers are the most widely used dendrimers (Malik, Evagorou 
and Duncan, 1999; Choudhary et al., 2017). It is known that higher generation 
dendrimers have higher loading capability due to more space available and 
surface groups to encapsulate hydrophobic drugs. Ammonia core PANAM of 
generations 3,4 and 5 are approximately the same size and shape as insulin (3 
nm), cytochrome C (4 nm), and haemoglobin (5.5 nm), respectively (Svenson 
and Tomalia, 2012). PANAM dendrimers have been investigated for oral drug 
delivery; they have demonstrated to be able to permeate across epithelial 
barriers by a combination of transcellular and paracellular routes and can 
transiently open tight junctions (Jevprasesphant et al., 2004; Noriega-Luna et 
al.; 2014). Also, PANAM dendrimers have demonstrated to increase the 
aqueous solubility of poor drugs. For example, in 2004, D'Emanuele and 
colleagues have carried a study showing that PANAM dendrimers of third 
generation can increase the solubility of propranolol and bypass P-gp-mediated 
secretory efflux, thereby increasing its absorptive drug transport. 
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Moreover, PANAM of fifth generation has demonstrated to be able to prolong 
the delivery of the poor soluble non-steroidal anti-inflammatory drug 
“Ketoprofen” with a sustained release behaviour in vitro and in vivo (Na et al., 
2006). PANAM have also been used to carry other drugs such as cisplatin, 
silver salts in which slow release was observed (Malik, Evagorou and Duncan, 
1999; Balogh et al., 2001). Many other dendrimers have been studied and 
covalently conjugated into polymers to form supramolecular amphiphilic 
dendritic block copolymers that can self-assemble into various shape (micelles) 
for gene and drug anticancer therapy.  Amphiphilic Poly (Lysine) Dendrons as 
an example have been synthesised for their use in several biomedical 
application and as carriers for drug and gene delivery. Janiszewska et al. in 
2016 found that poly (Lysine) Dendrons can inhibit the proliferation of two 
glioblastoma cell lines by mitochondrial depolarization and reactive oxygen 
species production while being nontoxic to normal cells like neurons and glia. 
The incorporation of charged amino acids such arginine and lysine in PANAM 
dendrimers have been proposed by several articles to improve their interaction 
with genes (Choi et al., 2004; Kim et al., 2006; Márquez-Miranda et al., 2015). 
However, Choi et al. in 2004 report the better transfection efficiency of PANAM-
Arginine compared to PANAM-Lysine. 
Moreover, Padilla De Jesús and colleagues in 2002 demonstrated that Dox 
covalently bound via a hydrazone linkage to a high molecular weight 3-arm poly 
(ethylene oxide)-dendrimer hybrid is rapidly released at pH<6 into several 
cancer cell lines with significantly reduced cytotoxicity of doxorubicin (80–98%).  
Although dendrons are great new carriers systems; they have still been 
reported to be toxic, similarly to other cationic macromolecules such as 
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liposomes and micelles, positively charged dendrimers are prone to destabilise 
cell membranes and cause cell lysis. PEGylation of dendrons have shown to 
reduce their cytotoxicity, for example, Bhadra and colleagues in 2013 reported 
that G4 PAMAM dendrimers with carboxymethyl PEG5000 surface chains could 
load reasonable amount of drug 5-fluorouracil with a reduced release rate and 
hemolytic toxicity compared to the non-PEGylated dendrimer. 
In comparison, anionic dendrimers possessing carboxylate surface groups 
show neither haematotoxicity nor cytotoxicity at concentrations up to 2 mg/ml 
(Malik et al., 2000). To overcome the drawback of dendrimers, new 
modifications with neutral hydroxyl, acetyl or negatively charged carboxyl 
groups are being conducted. Also, the conjugation of the amine-based dendron 
into polymers can permit their self-assembly into nanoparticles where dendrons 
are hidden in the interior, and a safe polymer is on the surface.  
1.6.5. Co-delivery system  
Sometimes single treatment is not enough to achieve a therapeutic effect on 
cancer therapy (Mokhtari et al., 2017). Combinational cancer therapy, therefore, 
comes into place in which multiple anticancer drugs are simultaneously 
administered to enhance efficacy via synergistic effects, prevent adverse side 
effects and overcome drug resistance over monotherapy. Many types of 
research have shown that the co-delivery of 2 drugs (Qi et al., 2017) or 
drug/gene (Yang et al., 2015) or drug/other chemotherapeutic agents utilising 
nanocarriers is more efficient in cancer treatment compared to single 
chemotherapy (Mokhtari et al., 2017). In 2006, Yang’s group first designed a co-
delivery system to deliver an anticancer drug and a therapeutic gene to the 
same cells simultaneously for anticancer therapy. Co-delivery systems have 
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been developed for different strategies including overcoming the membrane 
transport protein related pump resistance (siRNA against genes encoding efflux 
pump proteins has been used to sensitize cells to chemotherapeutic drugs) 
(Fowers and Kopeček,2012), inhibiting the cellular anti-apoptotic pathways that 
can be activated to increase drug resistance (the use of BCL-2 protein family 
can inhibit the release of cytochrome C from the mitochondrion, which is 
required to trigger the caspase cascade during apoptosis) (Pakunlu et al., 2004) 
and lastly for synergetic therapeutic effect where 2 agents possessing different 
curative mechanisms are used for further therapeutic enhancement (Yang et al., 
2015). However, many challenges have yet remained associated with the 
codelivery approaches including loading capacity, stability, release kinetics, 
biocompatibility and tumour targeting efficacy. Three formulations co-
encapsulating dual chemotherapeutic drugs are being investigated in clinical 
trials for combination cancer treatment. One is the liposome co-loaded with 
cytarabine and daunorubicin (CPX-351 or Vyxeos) for the treatment of acute 
myeloid leukaemia in Phase III trials (Murphy and Yee, 2017). The other is the 
liposome co-loaded with irinotecan (CPT-11) and floxuridine (CPX-1) for the 
treatment of advanced colorectal cancer in Phase II trials (Chen et al., 2012). 
The third is a combination gene therapy using lipid nanoparticle-formulated 
small interfering RNAs (siRNAs) targeting vascular endothelial growth factor 
(VEGF) and kinesin spindle protein for the treatment of advanced cancers and 
liver metastases which demonstrated enhanced efficacy in Phase I trials (Shen 





1.7. Aim and Objective  
The hardship of cancer is continuously increasing and is rapidly spreading 
globally. The anthracycline Doxorubicin is a potent chemotherapeutic drug 
which has been used to treat numerous cancers (Thorn et al., 2011). However, 
Dox present several side effects in major organs including acute cardiotoxicity 
and also develops drug resistance, which limits its dosage (Rahman, Yusuf and 
Ewer, 2007). This is a factor that makes Dox an essential subject to study and 
to improve its efficiency by developing a drug-loaded nanotechnological 
product. Doxorubicin.HCl was the first anticancer drug that was encapsulated 
into a carrier and received clinical approval against malignancies including solid 
tumours (Sercombe et al., 2015). Despite the existence of numerous studies 
focused on the encapsulation and controlled/targeted delivery of Dox by 
different nanocarriers, only a few have achieved to reduce the negative effects 
of the given devices (Malam, Loizidou and Seifalian, 2009; Vinothini et al., 
2019). We propose here, different development of safer and more specific non-
viral vector systems for the delivery of the Dox in liver cancer cells and brain 
tumour. The liver is the largest organ and plays major roles of the body function, 
therefore bears the most mutagenic phenomena which cause clinical disorders 
that have been attractive targets for liver-specific gene and drug therapy 
(Mishra et al., 2013). Hepatocytes are the principal parenchymal cells of the 
liver and mostly present errors of metabolism resulting in haemophilia and 
acquired diseases such as liver cancer and hepatitis. Therefore, targeting these 
cells with accuracy and precision without any side effects has been the goal of 
our research. Pullulan being a very  neutral, natural polysaccharide, non-toxic, 
non-immunogenic, non-carcinogenic and most importantly a ligand for ASGPr 
(Farris, 2014; Yamaoka, Tabata and Ikada, 1993; Yamaoka, Tabata and Ikada, 
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1995; kaneo, 2001) is chosen as the shielding material in which arginine 
dendrons of hydrophobic and cationic surface chemistry are conjugated. 
This work was therefore designed to meet the following objectives: 
 To successfully synthesise and characterise four different drug delivery 
systems consisting of dendrons and pullulan with or without targeting ligand 
or with and without a responsive linkage: 
- Successfully synthesise hydrophobic and cationic peptide dendrons of 
the third generation 
- Successfully modify the polymer Pullulan 
- Successfully click dendrons into polymers 
- Successfully form micelles and load Doxorubicin or curcumin 
- Successfully characterise the micelles by size and morphology 
 To examine the release studies of Doxorubicin or curcumin from each 
system 
 To test the cytotoxic effect of each system in HepG2, U251, Hek293 or 3T3 
cells  




CHAPTER 2. MATERIALS AND METHOD 
2.1. Materials  
It is important to note that this work was carried out in different universities. 
Therefore, the chemicals and instruments were ordered from different locations: 
Sichuan University and the University of Wolverhampton, whereas other 
devices were obtained from the University of Birmingham.  
2.1.1. Materials for chemical synthesis and characterisation  
2.1.1.1. Glassware and equipment for synthesis  
Beakers (100, 500, 1000 and 2000mL), a 250mL reagent bottle; 500, 1000 and 
2000mL conical flasks; microscope slides; retort stands and clamps (Beijing 
Synthware Glass Co.Ltd, A3-806, Yingte Mansion, Xibahe, Chaoyang District, 
Beijing, Beijing, 100028, China). 
150mm x 75mm crystallizing dish for the oil bath; glass desiccators with 
porcelain plates; 1000 and 2500mL vacuum filtering flasks with sidearm; 100, 
500, 1000 and 2000mL measuring cylinders and 1000 and 2000mL separatory 
funnels (Sichuan Shubo (group) co. Ltd, no.125, South Shuzhu Road, 
Chongzhou City, Sichuan Province, 611230, China). 
Rotary vacuum evaporator; high temperature drying oven; hot plate magnetic 
stirrer; lab 0.1mg analytical balance; UV viewing cabinet (Zhengzhou Nanbei 
Instrument Equipment Co. Ltd, no.72, Beihuan Road, Zhen, China). 
100, 250 and 500 mL joint 24/40 round bottom single neck reaction flask with 
glass stopcock; 24/40 septum rubber stoppers; 12-60mm pivot ring, oval and 
micro stir bar set; 10, 15, 20cm spoons and spatulas; disposable syringes; 
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tweezers and needles; TLC spotting capillary tubes; 500 and 1000 mL-50mm 
chromatography columns with reservoirs and fitted disc; 40, 53 and 73mm 
Buchner funnel high vacuum pump; recirculating water vacuum pumps (Thomas 
Scientific, 1654, High Hill Road, Swedesboro, NJ 08085, USA). 
MWCO 100-500, 1000 and 3500 Da regenerated cellulose dialysis membranes 
and clamps (Spectrum/Por, Spectrum Chromatography, 18211, Chisholm Tr 
Ste 300, Houston, TX 77060, USA). 
Reagent grade column chromatography silica gel 200-300 mesh (Yucheng 
Chemical Co. Ltd, 3f/Building 5, No.3521, Chuanzhou Highway, Pudong 
District, 201319, Shanghai, China). 
Silica quartz sand (CNPC Powder Group co. Ltd, Room 1211, No.8 Office 
building, Wanda Plaza, 58 He Xuan Road, 201803, Shanghai, China). 
High-pressure nitrogen and argon gas cylinder (Shanghai Eternal Faith Industry 
Co., Ltd, No.6598, Hutai Road Baoshan, 201908, Shanghai, China). 
Thermostatic shaking water bath (Biobase Biodustry Co., Ltd. No. 51 South 
Gongye Road, Jinan, 250101, Shandong, China).  
Freeze dryer lyophilizer (Guangzhou Aolantec Commerce And Trade Co., Ltd., 
702, Unit 2, Bldg. 5, Dingxiu Qingxi, Changping Dist., Beijing, China). 
Christ Beta 1-8 -55 °C LSCbasic & 2-8 -85 °C LSCbasic 8kg freeze dryers 
(SciQuip LTD, Newtown, Wem, Shropshire, SY4 5NU UK).                                                
NexION 2000 ICP mass spectrometer and Fourier transform infrared (3F,Tower 
6, Huidu Headquarters Garden, No.5 Xixin Avenue, High-tech West District, 
611730, Chengdu, China). 
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Fourier transform infrared (Perkin Elmer Life and Analytical Sciences, Wenlock 
Business Centre 50-52 Wharf Road, London N1 7EU, United Kingdom). 
Tecnai G2 F20 S-Twin HR (S) electron microscope with a voltage of 200kV (FEI 
Company, USA). 
Malvern: Zetasizer Nano ZSP (Malvern Panalytical, a division of Spectris 
Instrumentation & Systems Shanghai Ltd, F909, Ruida Plaza, No. 74, Lu Gu 
Road, Shijingshan District, 100040, Beijing, China). 
Advanced 400 nuclear magnetic resonance spectrometer (Bruker, 1711 Floor 
17th, Tianyin Mansion, Zhongshan Road No. 437, Tianhe District, Guangzhou 
510660, China). 
Fluorescence spectrophotometer F-7100 (Hitachi High-Technologies Co., Ltd, 
21F Hang Seng Bank Tower, 1000, Lujiazui Ring Road, Pudong New Area, 
Shanghai, China). 
Zeiss®  Evo 50 scanning electron microscope (Carl Zeiss AGCarl-Zeiss-strabe, 
22, Oberkochen, 73447, Germany). 
2.1.1.2. Chemicals for synthesis  
Propargylamine, 55.08g/mol (J&K Scientific Ltd, 5/F, Building-A, TopBox, No.69 
Bei Chen West Road, Chaoyang District Beijing, 100029, China). 
Boc-L-Arg(Pbf)-OH,526.65g/mol; Boc-L-Lys(Boc)-OH,346.42g/mol; N-(3-
dimethylaminopropyl)-N’-eth-ylcarbodiimidehydrochloride (EDC.HCI), 




379.24g/mol (GL Biochem Ltd,519 Zi Yue Road, Shanghai, 200241, Shanghai, 
China). 
Sodium azide (NaN3), 65.01g/mol;triphenylphosphine (PPh3), 262.29g/mol; 
tetrabromethane (CBr4), 331.63g/mol; 4-(Dimethylamino) pyridine (DMAP), 
122.17g/mol; copper sulphate pentahydrate (CuSO4.5H2O), 249.69g/mol; 
sodium ascorbate (SA), 198.11g/mol; pullulan (MW20,000Da), triethyllami- ne 
(TEA), 101.19g/mol; ethylenediaminetetraacetic acid disodium salt (EDTA.2Na), 
372.24g/mol and lactobionic acid, 358.30g/mol, Dicyclohexyl- carbodiimide, 
206.33g/mol (Shanghai Aladdin Bio-Chem Technology Co. Ltd, 5th Floor, 
Building 12, No 1001, North Qingzhou Road, Xuhui District, Shanghai, China). 
Trifluoroacetic acid (TFA), 114.02g/mol;N,N-diisopropylethylamine (DIEA), 
129.25g/mol; sodium chloride (NaCl), 58.4g/mol; hydrochloric acid(HCl), 3 
6.46g/mol; anhydrous magnesium sulphate (MgSO4), 120.37g/mol and sodium 
bicarbonate (NaHCO3), 84.01g/mol (AstaTech BioPharmaceuticalcorp., 488, 
West Kelin Road, Wenjiang Dist, 611130, Chengdu, China). 
Monopotassium phosphate, KH2PO4, 136.086g/mol; Sodium phosphate dibasic 
dodecahydrate (Na2HPO4·12H2O), 358.14g/mol; ninhydrin, 178.14g/mol; 3,3’-
Dithiodipropionic acid, 210.27g/mol; Pyrene, 202.25g/mol; 1H-Pyrazole-1-
carboxamidine hydrochloride, 146.58g/mol; DL-Dithiothreitol, 154.25g/mol and 
all solvents with the highest grade including ethanol, methyl sulfoxide, 
dimethylformamide, chloroform, acetone, petroleum, ethyl acetate, methanol 
(Sigma Aldrich Chemical GmbH, Sigma Aldrich Inc, 3050 Spruce Street, St 
Louis M063103, USA). 
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Curcumin, 368.39g/mol (Alfa Easer, Shore Road, Port of Heysham Industrial 
Park, Lancashire, LA3 2XY, Heysham, Lancashire, United Kingdom). 
Doxorubicin hydrochloride (Dox.HCl), 579.98g/mol (Zhejiang Hisun 
Pharmaceutical co. Ltd, no 46, Waisha Road, Jiaojiang District, 318000, 
Taizhou, China). 
Doxorubicin hydrochloride (Dox.HCl), 579.98g/mol (Alfa Easer, Shore Road, 
Port of Heysham Industrial Park, Lancashire, LA3 2XY, Heysham, Lancashire, 
United Kingdom).  
2.1.2. Materials for in vitro cell studies   
2.1.2.1. Glassware and Equipment for cells studies   
Polystyrene tubes (10, 25, 50 and 100 mL), 6-well, 24 well and 96-well flat-
bottom tissue culture plates with lids, tissue culture cell+ flasks with PE 
ventilation caps (T25, T75, T175), Filtropur V50.0.2 vacuum filter (500 mL), 
1.5mL and 0.5mL Eppendorf tubes, sterile disposable pipettes (5mL, 10mL, 
25mL) (Sarstedt Ltd., 68 Boston Rd, Leicestershire, LE4 1AW, Leicester, UK). 
Micropipettes–BiopetteTM, autoclavable pipettes (Labnet International Inc., 
USA) and PipetmanTM autoclavable pipettes (Gilson Inc., 3b Humphrys Road, 
Woodside Estate, Dunstable LU5 4TP, Luton, UK). 
Micropipette tip refill cartridges (1mL and 200μL) and nuclease-free filtered tips 
(1mL, 10μL, 40μL and 200μL) (Alpha Laboratories, 40 Parham Drive, 
Hampshire, SO50 4NU, Eastleigh, United Kingdom). 




Hausser Scientific™ Phase Contrast Hemacytometer (Fisher Scientific, Bishop 
Meadow Road, Loughborough, LE11 5RG, UK). 
Clean air laminar flow hood (Telstar, Netherlands). 
Olympus Microscope CK2-TR (Olympus, KeyMed House, Stock Road, 
Southend-on-Sea, SS2 5QH, UK). 
MSE Mistral 2000 centrifuge (DJB Labcare Ltd, 20 Howard Way, Interchange 
Business Park, Newport Pagnell, Buckinghamshire, MK16 9QS, England).  
Panasonic Direct Heat CO2 incubator (Panasonic Healthcare Co. Ltd.,1-1-1 
Sakata, Oizumi-Machi Ora-Gun, Gunma 370-0596 Japan). 
Mettler Toledo™ FiveEasy™ Plus FP20 pH/mV meters (Fisher Scientific, 
Bishop Meadow Road, Loughborough, LE11 5RG, UK). 
Zeiss LSM 880 Confocal Microscope (Carl Zeiss Ltd., 509 Coldhams Lane, 
Cambridge, Cambridgeshire, CB1 3JS, UK). 
BD FACSCalibur™ Flow Cytometer, CellQuest™ Pro, Cell wash, FACS Clean, 
FACS Rinse, BD Falcon FACS tubes (Becton Dickinson (BD), The Danby 
Building, Edmund Halley Road, Oxford Science Park, Oxford OX4 4DQ, UK). 
GloMax®-Multi Detection System (Promega GLO Reagents, 2800 Woods 
Hollow Road, Madison, WI 53711-5399, USA). 
2.1.2.2. Chemicals and reagents for cell studies  
Fetal bovine serum (FBS), F9665; Minimum Essential Medium Eagle (powder); 
M0268; Trypsin-EDTA solution, T4049; MEM non-essential amino acid solution 
(100×), M7145; antibiotic-antimycotic solution (100×), stabilised A5955; 
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Sulforhodamine B, 230162; Tris–Trizma base, T6066 – 1kg; trichloroacetic acid, 
T6399-1KG, phosphate buffered saline tablets, 79382, DAPI, D9542 (Sigma 
Aldrich Chemical GmbH, Sigma Aldrich Inc., 3050 Spruce Street, St Louis, 
M063103, USA). 
Acetic Acid Glacial, 100% pure (GPR TM BDH laboratories supplies, Poole, 
BH15 1TD, England). 
Dulbecco’s modified Eagle’s medium with high glucose (DMEM-HG) (Life 
Technologies Corporation, Gibco®, USA). 
A cell-counting kit-8 (CCK-8) (Dojindo Laboratories, Asakawa Bldg, 7F 
Shibadaimon 2-1-17 Minato-ku, 105-0012, Tokyo, Japan). 
FITC Annexin V Apoptosis Detection Kit II (Becton Dickinson (BD), The Danby 
Building, Edmund Halley Road, Oxford Science Park, Oxford OX4 4DQ, UK). 
2.1.3. Cell lines  
Human liver hepatocellular carcinoma cell line (HepG2), mouse embryonic 
fibroblast cell line (NIH3T3) (Shanghai Institute for Biological Sciences, 320 
Yueyang Road, 200031, Shanghai, China). 
Human glioblastoma cell line: U251MG and NIH3T3 (Dr Tracy Warr, BTUK 
neurooncology lab, University of Wolverhampton, UK).  
Human liver hepatocellular carcinoma cell line (HepG2), 85011430-1VL (Sigma 
Aldrich, UK).  
Human embryonic kidney cells (Hek293), (Sigma Aldrich, UK).  
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2.1.4. Buffers and solutions 
All solutions and buffers were prepared in MilliQ ultrapure water and filtered 
(0.22 mm) before use.  
 PBS buffer of pH 5, 6.8 and 7.4 
1/15M of KH2PO4 and Na2HPO4.12H2O Stock solutions: 9.07g of KH2PO4 in 1L 
water and 23.86g of Na2HPO4.12H2O in 1L water.  
Table 2-1. Preparation of pH 5, 6.8 and 7.4 PBS buffers  
 
 Ninhydrin solution: 1g of ninhydrin powder in 200ml of ethanol (stored at 
RT). 
 1L of pH 7.4 Sterile culture media solution 
Under stirring conditions in a 2000ml beaker: 
    -  9.5g of MEM powder was dissolved in 1000ml of autoclaved water giving a             
yellowish colour.  
    - 2.2.g of NaHCO3 was then added to the mixture giving a red colour. pH 
adjusted to 7.2-7.3.   
     Under sterile conditions in a clean air laminar flow hood: 




Vol [ KH2PO4] or 
[Na2HPO4.12H2O] 
1/15 M of 
KH2PO4 
1/15 M of 
Na2HPO4.12H2O 
pH 5 10  mL 990  mL 
pH 6.8 50  mL 50  mL 
pH 7.4 20  mL 80  mL 
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- In each bottle, 1% of non-essential amino acids (5mL), 1% antibiotics 
(5mL) and 10% FBS were added (50mL).  
- Stored for three months at 4 ºC.  
 Sterile PBS for tissue culture: 1 tablet of PBS dissolved in 200ml of water 
(stored at RT). 
 Cell freezing solution:  FBS+10%(v/v) DMSO (stored at 0 ºC).  
 DAPI Dilution: 5µ l dissolved in 995ul of water (stored at 0 ºC). 
 1% Acetic acid solution :10mL acetic acid in 1000mL of water.  
 0.4% SRB solution: 2g of SRB powder in 500mL of 1% acetic acid. 
 10mM Tris solution: 1.2114g of Tris powder in 1000mL of water.  
 500mL of 10% TCA: 50g TCA in 500mL water (stored at 4 ºC).  
2.2. Methods  
2.2.1. Peptide dendron detection by thin layer 
chromatography 
To monitor the course of the reaction, for successful peptide isolations and 
purification the most widely used qualitative separation technique ‘thin layer 
chromatography’ was used. This technique is a relatively cheap, highly sensitive 
and fast method that can be applied to a wide range of samples (Touchstone, 
1992). Silica gel was used as the stationary phase and suitable vapour solvents 
(~10ml of ethyl acetate/petroleum and dichloromethane/methanol) were used 
as the mobile phase whereas UV light was used to identify any spots of 
impurities observed (circled around their outline using a pencil). TLC plates 
were passed into a beaker containing ninhydrin solution and then dried with a 
strong drier which developed coloured spots. 
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The Rf value was calculated by dividing the distance travelled by the compound 
from the origin (point of compound application) by the distance travelled by the 
solvent from the origin: 
 
2.2.2. Peptides dendron purification  
2.2.2.1. Acid and basic extraction to remove impurities  
This is a method usually used after chemical synthesis to extract mostly free 
neutral acidic and basic impurities from the product. The volume of the washing 
phase is often one-tenth to one half of the volume of the organic phase, and it is 
best to repeat the wash two or three times. First, the product is dissolved into a 
solvent (50-500mg of product into 25-100mL of solvent) that is easily removed 
by a rotary evaporator (e.g. ether and chloroform), whereas solvents such as 
ethyl acetate or DCM are difficult to evaporate and often form nasty emulsions. 
The product undergoes an acid wash (12-50mL of HCl 10 %, stirred for 
1h30min) that removes the amines and a basic wash with 12-50mL of NaHCO3, 
HCl (1M) or 10% NaOH stirred for 1hr to remove unwanted acids and then 
transferred into a separatory funnel. Finally, the product undergoes a brine 
wash (12-50mL of saturated NaCl solution, stirred for 20-30min) which helps to 
disrupt emulsion and dries the organic layer by extracting the water. 
Moreover, a drying agent (MgSO4 or Na2SO4) is also added and left overnight to 
remove all traces of water which binds to water-forming clumps when they react 
(enough drying agent is added until floating-crystals forms). The drying agents 
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are removed by a standard filtration method using a Büchner funnel and 
unfluted filter paper (or a fritted funnel) under mild vacuum (Hauenschild and 
Hinderberger, 2019). The product is then concentrated by evaporating the 
solvent and dried using a vacuum pump to obtain a  solid whiteproduct.  
2.2.2.2. Column Chromatography  
For the isolation of the pure product, column chromatography was used to 
enable separation of the product from the mixture. The same stationary and 
mobile phase were used as for TLC. First, into a 2000mL beaker, silica gel 
(200-300 mesh) powder was mixed with petroleum (PE) until a tick pourable 
solution was obtained. The mixture was then transferred into a 1000mL 
chromatography column using a funnel and PE was allowed to drain out (a 
pressure vacuum was used to accelerate the process) into a beaker. More silica 
gel was added until a suitable amount of gel was present in the column. PE was 
left a very little over the gel (0.5cm) to avoid any dryness and the tap at the end 
of the column was closed. The mixture product was dissolved in DCM and then 
carefully added into the column. The rest of the PE was left to drain out taking 
along with it the product until the silica gel appeared and then the tap was 
closed again. More PE was added followed by quartz sand, and it was left again 
to drain out. The mobile phase was finally added and allowed to drain out in 
single drops. TLC was used to monitor the product.  
2.2.3. Characterisation of dendrons modified pullulan and 
conjugated products 
2.2.3.1. Mass spectrometry (MS) 
The masses of dendrons of generations 1, 2 and 3 were confirmed by mass 
spectrometry. The method is a specific analytical technique used to identify and 
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quantitate molecules based on their mass-to-charge (m/z) ratio. The mass 
spectrometer consists of an ion source, a mass analyser and an ion detector.  
                                  
Figure 2-1. Schematic of the basic components of a mass spectrometer. 
 
Each dendron products is loaded into the mass spectrometer in dried form 
(could also load in liquid or gas form). The product is evaporated and then 
leaked into the ionisation chamber where a beam of electrons bombards the 
samples which ionise the molecules (mainly positive ions are formed by the loss 
of valence electrons). A filament of the heated cathode produces the beam. The 
ions are then accelerated by an electrostatic of several hundred to thousands of 
volts before reaching the analyser. Ions separate in the mass analyser, and a 
magnetic field is applied perpendicular to the motional direction of the ions. The 
ions then move very quickly following a circular trajectory due to Lorentz 
acceleration, whose radius is determined by the mass/charge ratio of the ion 
and the strength of the magnetic field (Bagwell et al., 2017). The ions, therefore, 
hit the ion detector. A mass spectrum is obtained by a computer connected to 
the mass spectrometers with software that measures ion oscillation frequencies. 
The data analysis programs detections and produce a spectra whereby 
individual ions are presented according to their m/z values and relative 
abundance. For each dendron, databases of mass spectra were obtained, and 
the mass of each dendron molecule was confirmed based on its m/z value.  
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2.2.3.2. Fourier transform infrared spectrometry (FTIR) 
FTIR is a technique that is used to analyse the absorption or emission of a 
solid, liquid or gas in the form of infrared spectrum. The analysis of individual 
spectra provides the identity of a chemical compound in the sample and was 
used here to confirm the structure of each product synthesised. A small amount 
of the sample was placed into the diamond stage of a Genesis II ATR FTIR 
(Attenuated Total Reflection Fourier Transform IR) instrument, and the probe 
was lowered down onto the sample. An infrared light passed through the 
sample, and the bonds between molecules in the sample get excited resulting in 
vibration due to electromagnetic radiation absorption ranging between 400cm-1 
and 4000 cm -1. The changes in vibrational energy in the IR region were 
recorded to generate spectral peaks. Normally, the infrared region of the 
electromagnetic spectrum (10–14000 cm-1) is divided into three spectral sub-
regions: near- (4000–14000 cm-1), mid- (400–4000 cm-1), and far-IR (10–400 
cm-1) (Türker-Kaya and Huck, 2017).The mid-IR region is the most common 
portion of the spectrum that has been used because characteristic absorbance 
frequencies and main molecular vibrations lie within this range. The bonds are, 
therefore, determined by the radiation wavelength absorbed (Witkowski and 
Koniorczyk, 2018; Watson, 2005; Larkin, 2011; Smith, 2011). Analysis of each 
sample was undertaken without the need for further sample preparations 
(Perkin Elmer Life and Analytical Sciences, 2005) and the spectrum was 
obtained using the WinFIRST software, which controls the FTIR spectrometer.  
The spectrum of each sample was then analysed by identifying the IR band 
positions, thereby confirming their chemical structure.  
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2.2.3.3. Elemental analysis (EA) 
Elemental analysis is a simple technique that is used here to determine the 
degree of substitution of pullulan. This technique identifies and quantifies 
(typically in percentages) the elements present in a sample. The analytical 
method consists of complete and instantaneous oxidation of the sample by flash 
combustion which then converts all substances into combustion products. The 
samples experience a continuous flow of helium and are then dropped into a 
combustion reactor maintained at 900 ̊C. They are then separated and detected 
by a thermal conductivity detector which gives an output signal equivalent to the 
concentration of each elemental in the sample (Hemming, 2007; RSC.org, 
2019). Analysis of carbon, hydrogen and nitrogen of the azidated product was 
carried out and the degree of azidation was determined by elemental analysis 
using the following formula: 
                                                                                                      
Figure 2-2. The formula for determining the degree of azidation. 
2.2.3.4. Proton nuclear magnetic resonance (1H NMR) 
NMR is a powerful technique used together with FTIR to provide information 
about the molecular structure and purity of compounds. This technique was first 
used in 1946 (Webb, 2014; Becker, 1993) and its spectra have been in use 
within the field of organic chemistry since 1960. 1HNMR is the most common 
NMR used because the proton nucleus is the most sensitive and usually yields 
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sharp signals (Zangger, 2015). Hydrogen nuclei can behave like a little magnet 
and spin when an external magnetic field is applied; energy is transferred to a 
higher level at a wavelength that correlates with radio frequencies whereas 
when the nucleus relaxes back, the energy is released at the same frequency 
(Callaghan, 1993). All the dendron structures (generation 1, 2 and 3 dendrons) 
were confirmed with 1H NMR (400 MHz) using a Bruker avance 400 nuclear 
magnetic resonance spectrometer. Dried samples were dissolved in CDCl3 
before measurement. The use of NMR spectroscopy to characterise modified 
polysaccharides has also been widely used (Cheng and Neiss, 2012). All the 
clicked products and guanidilated products were confirmed using 1H NMR 
spectrum analysis (samples were first dissolved in DMSO), and the percentage 
of lactose conjugated was determined using the following formula:  
                                                       
Figure 2-3. Formula for determining the percentage of lactose conjugated into 
pullulan. 
2.2.4. Micelles formation by diafiltration 
The formation of nanoparticles and drug loading was performed according to 
the method known as diafiltration (Ma et al., 2015).  
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2.2.4.1. Preparation of blank P-PLLA, P(lac)-PLLA and PSS- 
PLLA micelles  
The blank nanoparticles of P-PLLA, P(Lac)-PLLA and PSS-PLLA were 
prepared by dissolving 5mg of each product in 1mL of DMSO and added 
dropwise into 5 mL of deionised water under vigorous stirring. The solution was 
stirred for 1hr and then transferred into a pre-swollen dialysis membrane 
(MWCO 3500 Da) and dialysed against deionised water at 4 ̊C for 12 hours. 
The outer water was replaced with fresh deionised water at 0.30, 1, 2, 3 ,5.30 
hrs. The products were then analysed or freeze dried and stored at 4 ̊C.  
2.2.4.2. Drug loading into micelles 
2.2.4.2.1. Preparation of hydrophobic doxorubicin by the 
removal of HCl 
2mg of Dox.HCl was first dissolved in 1ml of deionised water at 0 ̊C in the dark. 
Every 10 min, 50µl, 20µl, 10µl, 5 µl of 0.01M NaOH (200 µl prepared in total) 
was added to the stirring Dox.HCl solution. When 100µl was used, the sample 
was centrifuged at 2500 rpm for 20min and traces of solid Dox were observed 
with a darker reddish colour. The pellet was then collected and freeze dried to 
obtain a dry product.  
Figure 2-4. The schematic reaction of the conversion of hydrophilic doxorubicin 




2.2.4.2.2. Doxorubicin loading into P-PLLA, P(lac)-PLLA and 
PSS-PLLA micelles                                
For the preparation of drug-loaded nanoparticles, solutions of P-PLLA, P(lac)- 
PLLA and PSS-PLLA in DMSO (1.25, 0.5 and 0.25mg in 500 µL) were 
separately mixed with  0.25mg hydrophobic doxorubicin in DMSO. The resulted 
mixture was then added dropwise into 5 mL of deionised water under stirring 
and then dialysed against water for 24 hrs at 4 ̊C in the dark to remove 
unloaded drug (6 changes of water/day). MWCO 3500 Da dialysis membrane 
was used, and the resultant solution was then freeze dried. The loading content 
of Dox was calculated by fluorescence measurement (F-7000, excitation at 480 
nm) in DMSO according to the calibration curve obtained from Dox/DMSO 
solutions with different Dox concentrations (1,2,3,4,5 and 6 µg/mL). Drug 
loading content (LC) and encapsulation efficiency (EE) were calculated using 
the following equations: 
 LC (%) = (weight of loaded drug/weight of drug-loaded micelle) x 100% 
 EE (%) = (weight of loaded drug/weight of drug in feeding) x 100% 
2.2.4.2.3. Curcumin and Cur-Dox loading into PSS-PLLA 
1mg of curcumin and 5mg of PSS-PLLA were dissolved in 1mL of acetone 
under sonication. The solution was then added dropwise into 9mL of deionised 
water and stirred for 4 hrs. The nanoparticles were collected by centrifuging the 
solution at 20000rpm for 1hr and then washed with ethanol to remove the 
unloaded curcumin. The nanoparticles were then lyophilised and stored at 4 ̊C 
(Kumari et al., 2017; Sanoj Rejinold et al., 2011). The wavelength of curcumin 
was determined using a wavescan of curcumin solution in ethanol by UV 
spectrometer (highest concentration was 0.0132mg/mL, whereas the lowest 
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concentration was 0.0005mg/mL). Similarly, to Dox, the loading content of 
curcumin was calculated by fluorescence measurement (F-7000, excitation at 
438 nm) in DMSO according to the calibration curve obtained from Cur/DMSO 
solutions with different curcumin concentrations (0.4, 0.8, 1.7, 3.3, 6.6 and 13.2 
µg/mL).  
2.2.5. Nanoparticle characterisation regarding size, 
polydispersity index and morphology  
2.2.5.1. Dynamic light scattering  
The determination of nanoparticle sizes is very important when characterising 
nanoparticles. This is achieved using dynamic light scattering which is a 
technique that measures the intensity of laser light when scattered by molecules 
in solution. 1mg of P-PLLA, PSS-PLLA, P(lac)-PLLA, P-PLLL or OGPLLL were 
dissolved in 20µl of DMSO and then added dropwise under sonication into 
980µl of deionised water (1mg/mL in triplicate). The samples were then filtered 
with a 5µm filter into cuvettes and characterised using the Malvern Zetasizer 
Nano ZS instrument (the parameters were set as material: polystyrene latex; 
refractive index: 1.590; absorption 0.010; viscosity: 0.8872; temperature: 25 C̊ 
and equilibrium time: 120s). Different particles in suspension move in a random 
motion called Brownian motion and are illuminated by a laser beam which 
results in a variation of light scattering (Misono, 2019). It is the fluctuation rate of 
scattered light intensity which corresponds to the speed at which the particles 
move that is recorded. This provides information about the size of the particles. 
The results are expressed in a form of correlogram showing the scattered 
intensity as a function of time. The longer the time needed, the larger the 
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particles are, the steeper the curve, and the more monodisperse the sample is 
(Boyd, Pichaimuthu and Cuenat, 2011; Hiroi and Shibayama, 2017). 
2.2.5.2. Scanning electron microscopy (SEM) 
In early 1948, SEM was developed by Oatley (Collett, 2007). This technique 
employs a high energy electron beam which is scanned over the surface of a 
sample, and the backscattering of the electron beam is recorded (Bogner et al., 
2007). Before the introduction to the microscope, the dried nanoparticle 
samples (0.1mg) were fixed on supports and pressure sprayed to dust off any 
debris. The particles were then gold coated in a high-vacuum evaporator to 
provide electrical conduction at the surface of the sample. The micrographs of 
the samples were produced and observed with a Zeiss®  Evo 50 scanning 
electron microscope (Muscariello et al., 2005). 
2.2.5.3. Transmission electron microscopy (TEM) 
Ruska invented TEM in the 1930’s (Harris, 2018). This technique uses more 
powerful electron beams and, therefore, provides higher resolution images 
compared to SEM which is more beneficial for nanoparticle analysis 
(Utsunomiya, and Ewing, 2003) The beam of electrons is transmitted through 
the sample and interacts with the sample as they pass through to produce an 
image (Reza et al., 2015). Magnetic condenser lenses are used to manipulate 
the beam path. TEM was performed on a Tecnai G2 F20 S-TWIN electron 
microscope at an accelerating voltage of 200 kV. An aqueous solution of each 
sample (1 mg/mL) that was measured by DLS was dropped onto a lacy carbon-
coated copper grid and air-dried before morphology observation (Huseynov, 
Garibov and Mehdiyeva, 2016). 
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2.2.6. Stability studies  
2.2.6.1. CAC studies  
The critical micelle concentration was studied by fluorescence spectroscopy 
using pyrene as a hydrophobic fluorescence dye. Triplicate solutions of pyrene 
mixed with P-PLLA, P(Lac)-PLLA or PSSG3-PLLA nanoparticles of varying 
concentrations (1×10-5 to 0.1 mg/ml) were prepared, of which the concentration 
of pyrene in each sample solution was 6.0×10-7M. Fluorescence emission 
spectra of pyrene were obtained by exciting samples at 390nm and intensities 
at 337nm and 334nm were recorded. All fluorescence measurements were 
carried out at 25.0 ± 0.1◦C in the absence of light. The CAC value was 
determined by plotting a curve of the intensity ratio (I337 / I334) against the log of 
PG3 concentrations (mg/mL), where the corresponding CAC value is the 
crossover point when extrapolating the intensity ratio (I337 / I334) at low and high 
concentration regions.   
2.2.6.2. Blank and loaded nanoparticle stability studies 
To investigate the stability of nanoparticles in different media and for different 
periods, Dox or Cur loaded and blank P-PLLA, P(LAC)-PLLA and P-SS-PLLA 
nanoparticles were stored in DI water at 4 ̊C for 3 months and changes in sizes 
through DLS measurement was monitored. P(LAC)G3-Dox as required for 
publication purposes were incubated with DI water, 10% (V/V) FBS diluted with 
DI water, and DMEM containing 10% (V/V) FBS, respectively. Then the 
solutions were stored at 4 ̊C for 5-day intervals followed by a daily 
measurement with DLS. Furthermore, the dilution stability of the loaded Dox 
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nanoparticles was studied in the above solvents in 1- to 500-fold dilutions at 
room temperature. 
2.2.7. Drug release studies 
2.2.7.1. Doxorubicin release from P-PLLA, P(lac)-PLLA and 
PSS- PLLA 
In accordance with numerous empirical studies (Chen et al., 2010; Ma et al., 
2015), in vitro drug release of the drug Dox from P-PLLA or P(lac)-PLLA or 
PSS-PLLA nanoparticles at different pH was carried out using a dialysis 
method. 1mg of Dox loaded nanoparticles dispersed in 1000µl of PBS solution 
(pH 5.0, 6.8, 7.4 and 7.4 with 10mM DTT for PSS-PLLA-Dox) was placed in a 
dialysis bag (MWCO=1,000 Da) and then dialysed against 25ml of 
corresponding buffer medium which was maintained at 37.0 ± 0.5°C in a 
shaking bed at 120rpm. The experiment was performed in triplicate. At 
predetermined time intervals, 1ml of the samples was taken out from the outer 
phase, and an equal amount of fresh corresponding buffer solution was 
replaced to maintain the original volume. The amount of released doxorubicin 
was quantified with a calibration curve using fluorescence measurement (F-
7000), fluorescence was monitored at excitation 480nm and emissions were 
recorded in the interval of 500-700nm (3mm slit). The drug release experiments 
were repeated three times.  
2.2.7.2. Curcumin release from PSS-PLLA 
1mg of curcumin loaded PSS-PLLA was suspended in 10mL of PBS in triplicate 
(pH7.4 with and without 10mM DTT). The suspension was done in centrifuge 
tubes which were kept in a shaker at 37 ̊C at 120rpm. At predetermined time 
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intervals, the suspension was centrifuged at 3000rpm for 10mins to obtain the 
curcumin released from the nanoparticles. The supernatant was collected re-
dispersed in 5mL of PBS and then incubated for the next sampling, whereas the 
curcumin released present in the pellet was diluted in ethanol to be measured 
by fluorescence at excitation 438nm. Similarly, to Dox, the amount of released 
curcumin was determined by a calibration curve using a fluorescence 
measurement at 438nm (Khalil et al., 2013; Mohanty and Sahoo, 2010). 
2.2.8. Cell culture 
Purchased cells (HepG2, Hek293, U251 and NIH3T3 cells) were stored in liquid 
nitrogen until needed for the experiment. All cell culture experiments were 
carried under sterile conditions.  
2.2.8.1. Recovering cell lines from liquid nitrogen storage 
Cells were collected from liquid nitrogen storage and left to defrost for 1-2 mins 
at 37°C. The contents of the cryovial were then transferred into a vented T25 
tissue culture flask containing 5mL of MEM medium supplemented with 10% 
(v/v) fetal bovine serum and 1% of antibiotics. The cells were then incubated at 
37 ̊C and allowed to attach and recover overnight. The media was then 
replaced by new media to remove dead, unattached cells and the DMSO used 
for cell freezing.  
For each culture, media was replaced every other day and checked 
microscopically every day to ensure they are healthy (no contamination, few 
dead cells) and growing as expected.  
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2.2.8.2. Sub-culturing (splitting or passaging of adherent cells) 
2.2.8.2.1. Trypsinization of adherent cells  
When the cells reached 80% confluence (checked under a microscope), the 
media was removed, and the cells were gently washed 3 times with 2mL of PBS 
to remove the FBS which can inhibit trypsin. 1mL of trypsin was then added, the 
flask was swirled to cover all the surface and then incubated for a few minutes 
at 37 C̊ until all the cells were detached. 3mL of media was added to inactivate 
trypsin and trypsinised cells were collected into pellets by centrifugation at 
1500rpm for 5 mins and then re-suspended into 3-6mL of media.  
2.2.8.2.2. Counting cells in a haemocytometer 
After trypsinisation, 20 µL of trypsinized cells was pipetted out into 10µL of an 
isotonic solution (ISOTON® II Diluent, 20 L, Item No: 8546719, Beckman 
Coulter) and then inserted into the coulter counter for cell counting. 500μL of the 
diluted cell suspension was counted, representing the number of cells per μL of 
the original material. 
2.2.8.2.3. Seeding into tissue culture T25 and T75 vented 
flasks or 6 well and 96 well plates  
After trypsinization and calculating the number of cells needed to be added in 
T25 or T75 and 6 or 96 wells, the necessary amount of volume containing cells 
was taken from the suspension and then inserted into the flask or plates 
containing a quantity of media to make the final concentration required. The 
total volumes of media and cells were kept at 5mL for T25, 15mL for T75, 3mL 
for 6 wells and 200 µL for 96 wells plates. The flasks or plates were then 
incubated at 37°C with 5% CO2. When 80% confluent was reached, the cells 
were either treated, sub-cultured again or stored at -80 ̊ C as pellets.  
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2.2.9. Freezing cells  
After trypsinization, pellets of cells were re-suspended in freezing medium, and 
a 1mL aliquot of the suspension was transferred into labelled-cryovials. Tissue 
paper was wrapped around the cryovial and placed into a disposable labelled-
glove and frozen at -80°C. After being left overnight or for 1-3 days, the cryovials 
were then transferred into liquid nitrogen (-180°C) for long-term storage. 
2.2.10. In vitro cytotoxicity 
It is important to note that CCK8 was used in Sichuan University whereas, in 
Wolverhampton University, an alternative method was used known as SRB 
assay. 
2.2.10.1. Cell viability by cell counting kit-8 (CCK8) assay  
CCK8 is a colourimetric assay that is used for the determination of cell viability 
in cell proliferation and cytotoxicity assays. It is a better and easier method than 
MTT because it uses a tetrazolium salt known as WST-8, which produces 
water-soluble WST-8 formazan, whereas the product MTT formazan is insoluble 
in water. In this case, organic solvents are required to dissolve the MTT 
formazan product before measuring absorbance. CCK8, therefore, requires less 
procedure than MTT. Moreover, MTT can present some toxicity in the cell 
culture media and, therefore, can result in significant well-to-well error, whereas 
CCK8 is the most sensitive method compared to MTT, XTT, MTS or WST-1 and 
because WST-8 is not cell permeable, the cells used for the assay can be 
reused for other experiments. Also, CCK8 involves most of the dehydrogenases 
in a cell, whereas MTT depends only on mitochondrial hydrogenases (Mahajan 
et al, 2012; Jo et al., 2015). WST-8 is reduced to a yellowish coloured formazan 
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product by dehydrogenases (Figure 2-5.) which is easily soluble in tissue 
culture medium. The amount of the formazan dye generated in cells is directly 
proportional to the number of living cells (Dojindo Laboratories, Kumamoto, 
Japan). 
                          
Figure 2-5. Cell viability detection mechanism with CCK-8 (Dojindo Laboratories, 
Kumamoto, Japan). 
 
The cytotoxicity of the blank nanoparticles, free Dox.HCl and Dox-loaded P-
PLLA and P(Lac)-PLLA nanoparticles against HepG2, and NIH3T3 cells were 
measured using a CCK-8 assay. Briefly, the HepG2 and NIH3T3 cells were 
seeded into the 96 well plates at a density of 1 X 104 per well in 100 µL 
complete medium and incubated overnight. Then the cells were incubated with 
various concentrations of blank nanoparticles, free Dox.HCl and Dox-loaded 
nanoparticles for different intervals. Next, the culture medium was removed at 
the indicated intervals, and the cells were rinsed with PBS three times, followed 
by the addition of 100µL medium containing 10% CCK-8 into each well (light 
was avoided). Finally, the absorbance of the products was measured at 450nm 
using a microplate reader after incubating for 2hrs at 37.0 ̊C in the dark. The 
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results were expressed as the viable percentage relative to the untreated cells. 
The concentration that killed 50% of cells (IC50) was calculated using ORIGIN 
9.0 software. 
2.2.10.2. Cell viability by sulforhodamine B (SRB) assay  
A cheaper alternative method to CCK8 was used for the determination of cell 
viability in different cell lines (Hek293, NIH3T3, HepG2 and U251). This method 
was developed by Skehan et al.,1990. SBR is an anionic aminoxanthene dye 
containing two sulfonic groups that bind to basic amino acid residues of proteins 
via electrostatic interaction under mild acidic conditions and then dissociate in 
basic conditions. The amount of bound dye is, therefore, proportional to the 
number of cells mass (Orellana and Kasinski, 2016). Compared to MTT and 
CCK8, this method does not require the measurement by metabolic activity. It is 
straightforward to use with only a few steps required compared to MTT. Also, it 
can detect densities as low as 1000-2000 cells per well. Moreover, because the 
SRB-stained cell monolayers are fixed by TCA and dried, they can be stored 
indefinitely, analysed at any time and the colour extracted by SRB is endlessly 
stable. For these reasons, SRB has a high level of sensitivity and can be used 
for large-scale screening applications (Vichai and Kirtikara, 2006).  
The cytotoxicity of free Dox.HCl, free Cur, blank and loaded Dox or Cur P-
PLLA, P(lac)-PLLA and PSS-PLLA nanoparticles against Hek293, NIH3T3, 
HepG2 and U251cells using the SRB assay was carried out using the following 
method: a T-75 flask of each cell was first trypsinised, 5mL of complete media 
was added to the trypsinised cells, and the suspension was centrifuged in a 
sterile 25mL falcon tube at 1200rpm for 5 mins. Cells were counted and seeded 
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in 96 well plates at a density of 4 X 103 per well in 200µl complete media and 
allowed to grow for 24hrs. The media was then replaced with various 
concentrations of blank nanoparticles, free Dox.HCl, and Dox-loaded 
nanoparticles in media for different intervals. Treated cells were washed 3 times 
with a PBS buffer to remove any trace of drugs and then fixed with 150µl of 
10% (wt/vol) TCA for 20-30 mins at 4 ̊C. It is quiet convenient noting that 
aseptic techniques are not needed at this point. The fixed cells were washed 3 
times with deionised water and left to dry. 100 µl of 0.4% (wt/vol) SRB was then 
added to each well and left to stain for 20-30 mins at room temperature. 
Unbound die was then removed by a 3-4-time wash with deionised water (1% 
acetic acid can also be used). 80-100µl of 10mM tris base solution was finally 
added to the wells and left for 10 mins to extract the protein-bound dye. The 
plate was then taped on the side to evenly distribute the SRB throughout the 
well for accuracy. The plate was then read at 510nm using a Promega 
Glomax plate reader and the results were expressed as the viable percentage 
relative to the untreated cells. 
2.2.11. Flow cytometry  
2.2.11.1. Cellular uptake by flow cytometry  
HepG2 and U251 cells were seeded into the 6 well plates at a density of 5X105 
per well. After incubation for 24 hrs at 37.0 C̊ to achieve a confluence of 70%-
80%, the cells were treated with free Dox.HCl and Dox-loaded nanoparticles 
(Dox concentration: 5 mg/mL) for 0.5,1 and 6 hrs. The cells were then washed 
with PBS and collected after trypsinisation followed by centrifugation at 
1200rpm for 5 mins. Further washing two more times with cold PBS helped to 
remove the nanoparticles which were bound to the surface of the cells. Finally, 
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the cells were suspended in 30mL of PBS and the intensity of doxorubicin 
fluorescence in the cells was determined using FACS with a BD Accuri™ C6 
flow cytometer installed with BD Accuri™ C6 software (Version 1.0.264.21). 
2.2.11.2. Apoptosis  
Flow cytometry was used to detect the morphologic features characterising the 
apoptotic programme. The membrane phospholipid phosphatidylserine (PS) is 
generally translocated from the inner to the outer leaflet of the plasma 
membrane, thereby exposing PS to the external cellular environment (Vermes 
et al., 1995). The apoptotic cells are stained with Annexin V which has a high 
affinity for PS, and necrotic cells are stained by propidium iodide (PI) due to its 
ability to interact with the DNA of cells under stress or when dead (Chou et al., 
1987). 5X105 of HepG2 and U251 cells per well were seeded in a 6-well tissue 
culture plate and left to attend 70-80% confluency, after which they were treated 
with free Dox.HCl and Dox-loaded nanoparticles. After treatment, the cells were 
harvested by trypsinisation and washed with PBS 3 times and centrifuged at 
1200rpm for 5 mins before resuspending the pellet in a binding buffer containing 
the dyes FITC-Annexin V and PI. After 15 mins of incubation at room 
temperature, each sample was analysed using the BD Accuri™ C6 flow 
cytometer installed with the BD Accuri™ C6 software (Version 1.0.264.21).  
76 
 
                                                                        
Figure 2-6. Gating of cells undergoing apoptosis and necrosis using flow 
cytometry. The X-axis relates to the cells stained with the Annexin V FTIC, and 
the Y-axis relates to the cells stained by propidium iodide. The cytogram is 
divided into four different quadrants. Cell populations that do not take up any of 
the dyes are the live healthy cells and are grouped in the lower-left quadrant (Q1-
LL), as shown by the BD Accuri™ C6 software. Cells that take up the Annexin V 
dye are those undergoing early apoptosis and are grouped in the lower-right 
quadrant (Q1-LR). Cell populations that take up both dyes are undergoing late 
apoptosis, necrosis or are considered dead and fall in the upper-right quadrant 
(Q1-UR). Populations that only take up the PI dye are either dead cells or debris 
and fall in the upper-left quadrant (Q1-UL) (Wlodkowic et al., 2011). 
2.2.12. Cellular uptake by confocal studies  
HepG2 and U251 cells were cultured on glass coverslips (AmScope) at a 
density of 1x105 to 70-80% confluency in 6 well tissue culture plates. Then the 
cells were treated with drug-loaded nanoparticles with final Dox concentration at 
5mg/mL in the fresh medium. Free Dox.HCl and non-treated cells were used as 
a control. After incubating for either 0.5,1 or 6 hrs, the cells were washed three 
times with cold PBS and fixed for 10 mins with methanol on ice. The cells were 
rewashed with cold PBS and left to dry. The coverslips were detached from the 
tissue culture plate, and the side containing the fixed cells was placed onto 10µl 
of diluted DAPI (5:995 v/v) dropped on a microscopic slide. The edges of the 
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coverslips were sealed with clear nail polish. Slides were stored at 4 ̊C in the 
dark before viewing under a confocal laser scanning microscope (Zeiss LSM 
880 confocal microscope, equipped with 405nm and 561nm excitation lasers 
using 40X/1.30 oil immersion DIC M27 objective). 
2.2.13. Statistical tests  
All experiments were repeated in triplicate. Data were expressed as mean 
values + standard deviation. The statistical differences between treatment 
groups were determined using two-way analysis of variance followed by 
Tukey’s post-hoc test. All analyses were performed with SPSS 19.0 for 





CHAPTER 3. DESIGN AND SYNTHESIS OF ALKYNATED    
                           PEPTIDE DENDRONS 
 
3.1. Introduction  
Dendrons are hyperbranched molecules with a well-tailored architecture. They 
are becoming the most attractive and rapidly growing area of new chemistry as 
they form repetitive sequence increasing to a great extent of chemical structure 
(Boris and Rubinstein, 1996; Tomalia et al., 1985). Their structure is related to 
the one of polymers because of their repetitive structure made of monomers 
(Carvalho, Fernandes and Baptista, 2019) consisting of an initiator core, an 
interior layer (generations composed of repeating units that are attached to the 
initiator core) and the outer core (terminal functionality) (Tomalia et al., 1985; 
Nanjwade et al., 2009).  
                             
Figure 3-1. Schematic structure of the dendron synthesis method. A. Divergent 
method and B. Convergent method (Nanjwade et al., 2009).                                                                          
                                                                                                                                         
Dendrons are either prepared via the divergent or convergent method. The 
divergent way consists of assembling monomeric modules in a radical, branch 
upon branch whereas the convergent method consists of reacting several 
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dendrons with a multifunctional core to obtain a product (Tomalia, 1996; Hawker 
and Frechet, 1990; Nanjwade et al., 2009). The divergent route enables 
dendrons of high generation to be prepared; for example, this route has been 
used to produce PANAM dendrimers of up to generation 10 with nearly 4096 
terminal groups and molecular weight of 934720 (Noriega-Luna et al., 2014). 
However, purification of higher generation can be challenging, and higher 
generation of dendrimers increase with size (from 4 to 4096nm) resulting in 
more toxicity compared to smaller dendrimers of similar surface functionality 
(Noriega-Luna et al., 2014; Malik, 2000).  
Herein, we have designed the synthesis by the divergent growth method of an 
alkynated peptide dendritic molecule consisting of three generation.                                  
The synthesis of alkynated peptide dendrons includes the conjugation of two or 
three successive additions of L-lysine into an alkyne-containing compound 
followed by the addition of L-arginine bearing eight hydrophobic protective 
groups or another l-lysine molecule. On the periphery of these molecules reside 
the hydrophobic 4 BOC groups and 4 PBF groups which combine alkyl, 
aromatic, and peptide dendritic hydrophobic segments at the same time. 
Compared to the structure of aromatic amino acid, PBF and BOC chemical 
structures show much higher hydrophobicity. PBF contains a benzene group 
(log P of 2.13) in which three –CH3 are attached (CH3 aromatic Log P 0.52), 
and BOC also includes three –CH3 hydrophobic groups (CH3- aliphatic with a 
log P = 0.50), determining the overall hydrophobicity of both compounds. On 
the other hand, the removal of protected groups would result in cationic 
Dendron. Both types of dendrons can then be conjugated to polymers to form 
non-viral systems for hydrophobic drugs or gene delivery.  
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3.1.1. Schematic overview of the synthesis of arginine-based 
dendrons  
                                  
Figure 3-2. Schematic synthetic route of generation 1, 2 and 3 dendrons. Step 1: 
Propagylamine reaction with Boc-Lys(Boc)OH to yield Dendron of generation 1 
containing terminal Boc groups, followed by the deprotection of G1 Dendron;       
Step 2:  G1 dendron reaction with Boc-Lys(Boc)OH to yield Dendron of 
generation 2 containing terminal Boc groups, followed by the deprotection of G2 
Dendron; Step 3: G2 dendron reaction with Boc-Arg(Pbf)OH to yield Dendron of 
generation 3 containing terminal BOC and PBF groups.  
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3.1.2. The process of dendron synthesis by peptide bond 
formation via the condensation of acid and amine  
For each synthesis of dendrons, a peptide bond formation takes place between 
the amine groups of the core molecule (Propagylamine) and carboxyl groups of 
the molecule added (either L-Lysine or L-arginine).  
                                 
Figure 3-3. General chemical equations of peptide bond formation. 
                                                                                                                                          
An acid-base reaction takes place at high temperature (>200 C̊) in the presence 
of an amine and carboxylic acid to form a stable salt, but the high temperature 
conditions of condensation are usually incompatible. Activation of the carboxy 
moiety followed by the attachment of a leaving group to the acyl carbon of the 
acid allowing an attack by the amino group is a necessary process (Jursic and 
Zdravkovski, 1993; Montalbetti and Falque, 2005). Moreover, it is important that 
the reaction for amide formation gives a high yield of the product with ease of 
purification and prevented racemisation and degradation. Therefore, various 
coupling agents that activate the carboxy components to generate compounds 
such as acid chlorides, (mixed) anhydrides, carbonic anhydrides or active 
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esters have been developed. The first ever coupling agents to be synthesised 
were the carbodiimides which include dicyclohexyl-carbodiimide (DCC), 
diisopropyl carbodiimide (DIC), 1-ethyl-3-(3’-dimethylamino) carbodiimide HCl 
salt (EDC or WSC.HCl), each producing different urea product (Figure 3-4.). 
These react with the carboxylic acid to form the intermediate O-acylisourea 
mixed anhydride (figure 3-5a.) which contains a N=C group that provides 
powerful activation and, therefore, can directly react with the amine to yield the 
desired amide. However, the formation of an amide product can be 
accompanied with some side reactions leading to unwanted urea by-products 
such as dicyclohexylurea (DCU) and N-acylurea. This happens due to the 
nucleophilic centre on O-acylisourea, which competes with the amino 
component for the O-acyl residue, and this competition leads to the formation of 
unwanted by-product. Therefore, in addition to coupling agents, nucleophile 
agents (DMAP, HOBT, HOAt,..) that react faster than the competing acyl 
transfer are generally used in to reduce side reactions such as epimerisation 
and racemisation. HOBT invented in 1970 by Konig and Geiger, reacts with the 
intermediate O-acylisourea to give the OBt active ester (Figure 3-5d.) which 
enhances the reactivity of the activated ester by encouraging the approach of 
the amine via hydrogen bonding (Valeur and Bradley, 2009; Montalbetti and 
Falque, 2005). In contrast to activation by carbodiimides, the formation of the 
amide bond using these coupling agents also requires the presence of a base 
such as Diisopropylethylamine (DIPEA) and N-methylmorpholine (NMM) which 
are the most frequently used ones. This method was used for the synthesis of 
lysine based dendron of generation-1 because it is easily controllable, and the 
reaction is rapid. EDC.HCl was the carbodiimide type used because the by-
product obtained is easily eliminated by washing (Figure 3-6.).  
83 
 
Figure 3-4. Commonly used carbodiimides and their resulting urea product 
obtained depending on the coupling agents used (Montalbetti and Falque, 2005).  
 
In the case of the synthesis of the dendron of generation 2 and 3, because the 
number of amine groups to be conjugated increases, reactions can take longer 
to complete, and more undesired side reactions can occur. Therefore, higher 
coupling agent rates are needed to speed up the reactions and to reduce side 
reactions. In recent years, different types of reagents including phosphonium- 
and the aminium-salts (BOP, PyBOP, PyBrOP, TBTU, HBTU, HATU, COMU, 
and TFFH) have been developed. BOP coupling was established in 1975 by 
Castro et al. and was proved to be very effective compared to the carbodiimide 
because it is racemisation-free and exhibits superior kinetics. However, BOP is 
not accepted in peptide synthesis because it has some toxicity. Therefore, it’s 
analogue HBTU is more widely used as a coupling agent in combination with 
HOBT.  
The reaction mechanism of carboxylic acid activation by EDC.HCl, HBTU or 
HOBT and N-acylation are summarised in the Figures 3-5 & 6.  
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Figure 3-5. The synthesis of lysine-dendron of generation 1 by the coupling of 
propargylamine and Boc-Lys (BOC)-OH in the presence of EDC.HCl, HOBT and 
DIPEA. A. EDC.HCl and DIPEA act as the base to deprotonate the molecules. The 
lone pairs on the nitrogen of EDC.HCl takes the proton (H) from Boc-Lys (BOC)-
OH leaving an electron behind to the oxygen. The protonated nitrogen wanting 
electron will withdraw some electron density away from the carbon next to it; the 
carbon losing some electron density will become positive and react as an 
electrophile whereas the oxygen of the carboxylic acid will act as the nucleophile 
which then attacks the electrophile to form a new bond between EDC.HCl and 
Boc-Lys(BOC)-OH forming the by-product O-Acylurea.  The by-product can then 
react in 3 ways: B. React with another molecule of Boc-Lys (BOC)-OH to form an 
intermediate molecule Boc-Lys (BOC)-O-Boc-Lys (BOC) which then reacts with 
the amine group of propargylamine to give the desired amide. C. React directly 
with the nucleophile nitrogen of propargylamine to give the amide G1 dendron. 
D. React with the nucleophile HOBT to give the HOBT ester which permits the 
amine group of propargylamine to act as a nucleophile to form the amide bond. 
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Figure 3-6. The synthesis of lysine-dendron of generation 2 and arginine-
dendron of generation 3 by the coupling of the lysine-dendron of generation 1 or 
lysine of generation 2 and Boc-Lys (BOC)-OH or BOC(Arg)PBF in the presence of 
HBTU, HOBT and DIPEA. The base deprotonates the carboxylic acid to form the 
carboxylate anion which then attacks the electron deficient carbon atom of HBTU 
to form the HBTU ester and BtO-. The resulting HBTU ester reacts with the anion 
product to form the HOBT activated ester, tetramethyl urea, CO2, ketene and 





3.2. Aims and objective  
To be able to produce a successful delivery system we aim in this chapter to 
confirm the successful synthesis of the hydrophobic and cationic arginine 
dendrons of third generation by matching the characterisation of products 
obtained with the predicted structures of interest, also, we aim to confirm their 
purity and determine if the products are fit for purpose.  
3.3.  Methodology 
The alkynyl peptide dendrons of generation 1, 2 and 3 (G1, 2 and 3) were 
prepared using the previously reported methods (Li et al., 2013; Luo et al., 
2012) with a few modifications.  
3.3.1. Synthesis of the lysine- dendron of generation 1 (PL) 
                       
Figure 3-7.  Synthesis equation of G1 dendron (PL). 
                                                                                                                                          
First, equal molar of Boc-Lys (Boc)-OH (3.5g, 1.1mmol), HOBT (1.3g, 1.1mmol) 
and EDC.HCl (2.0g, 1.1mmol) were co-dissolved into 40.0mL of dried CH2Cl2 
(DCM) under N2 atmosphere. The flask was kept under an ice bath, and DIPEA 
(6.3ml, 4.0mmol) was injected into the mixture, followed by the addition of 
propargylamine (0.6ml, 1mmol). The mixture was first stirred at 0 ̊C for 30min 
and then brought to room temperature for 48 hrs. After the reaction, the mixture 
was concentrated by removing CH2Cl2 through rotary evaporation and then 
dissolved with 300mL of chloroform. The product was then washed three times 
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with saturated NaHCO3, HCl (1M) and NaCl to remove Impurities. MgSO4 was 
then added to the organic phase and left to stand overnight, and the organic 
phase was filtrated and concentrated by rotary evaporation. Further purification 
was carried by column chromatography using ethyl acetate/petroleum (1:1, V/V) 
as eluent. The final purified product obtained was dried by rotary evaporation 
and then by a low-pressure pump followed by vacuum drying to get a white 
solid.   
3.3.2. Synthesis of the lysine-dendron of Generation 2 (PLL) 
               
Figure-3.8. Synthesis equation of G2 dendron (PLL). 
3.3.2.1. Removal of BOC from G1 dendron  
For the preparation of G2 dendron, the Boc groups of G1 were first removed 
using TFA (20mmol). 2.60g (1mmol) of G1 was dissolved in CH2Cl2, followed by 
the addition of TFA (16ml of anhydrous TFA/CH2Cl2 mixture (V/V: 1.8/1) and left 
to stir for 5 hours at RT under N2 atmosphere. After the solvent was removed 
by rotary evaporation, absolute diethyl ether was added, and precipitates 
appeared after stirring overnight. The precipitates were collected by 
centrifugation and then dried under high vacuum. TLC was used to monitor 
whether all the boc groups were removed. 
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3.3.2.2. Synthesis reaction of PLL 
G2 dendron was prepared by co-dissolving equal molar of Boc-Lys (Boc)-OH 
(3.5g, 2.4mmol), HOBT (1.3g, 2.4mmol), HBTU (2g, 2.4mmol) and G1 (no Boc, 
1mmol) into 50ml of dried DMF under N2 atmosphere. The flask was kept under 
an ice bath, and DIPEA (6.ml, 5mmol) was injected into the mixture. The 
mixture was first stirred at 0 ̊C for 30min and then brought to RT for 48 hrs. The 
pure product was obtained by the same method used to purify the G1 dendrons. 
The obtained crude product was purified by column chromatography (silica gel: 
ethyl acetate/petroleum = 4:1, V/V to remove impurities and free lysine followed 
by ethyl acetate/petroleum = 4:1, V/V to collect the pure product).  
3.3.3. Synthesis of the dendron of generation 3 (PLLA and 
PLLL)  
3.3.3.1. Removal of BOC from G2 Dendron  
The BOC groups of G2 Dendron were removed by the same procedure as 
described for G1 Dendron. The obtained G2 (1mmol) was treated with 70ml of 
anhydrous TFA (40mmol)/CH2Cl2 mixture (V/V: 1.8/1) and stirred for 8 hours at 
RT under N2 atmosphere. A white product (6.3g) was obtained after 
precipitation overnight with absolute diethyl ether. TLC was used to monitor 
whether all the Boc groups were removed. 
3.3.3.2. Synthesis of arginine dendron of generation 3 (PLLA) 
PLLA synthesis was carried out by co-dissolving equal molar of Boc-Arg (Pbf)-
OH (12g, 6mmol), HOBT (3.3g, 6mmol), HBTU (8.79g, 6mmol) and deprotected 
G2 (1.7g, 1mmol) into 55ml of dried DMF under N2 atmosphere. The flask was 
kept under an ice bath, and DIPEA (7ml, 10mmol) was injected into the mixture. 
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The mixture was first stirred at 0 ̊C for 30min and then brought to RT for 48 hrs. 
Purification was achieved by applying the same method used for G1 and G2 
purification. The mixture was carefully washed three times with saturated 
NaHCO3, HCl (1M) to avoid any emulsion. Then the organic phase was dried, 
concentrated and purified by column chromatography using ethyl 
acetate/petroleum ether (1/1 to 40/1, V/V) and then using 
dichloromethane/methanol (50/1 to 10/1, V/V).  It is important to note that the 
TLC indication gave a large amount of traces that could make the separation 
process and the collection of the correct product more difficult.  
 
Figure 3-9. Synthesis equation of Dendron of Generation 3 (PLLA). 
3.3.3.3. Synthesis of Lysine Dendron of Generation 3 (PLLL) 
                                                         




The removal of Boc/Pbf from PLLA to result in PLLA+ was not successful (see 
appendix section 1), for this reason, PLLL synthesis and guanidinylation of 
PLLL was carried out to yield into PLLA+. However, guanidinylation could only 
be carried out after conjugation of PLLL into pullulan (refer to chapter 7). 
The PLLL synthesis was carried using the same method as PLLA. Equimolar 
equivalent of Boc-Lys (Boc)-OH (9.9g, 6mmol), HOBT (3.86g, 6mmol), HBTU 
(10.8g, 6mmol) and deprotected G2 (4g, 1mmol) were dissolved into 60ml of 
anhydrous DMF under N2 atmosphere. The flask was kept under an ice bath, 
and DIPEA (8.29ml, 10mmol) was injected into the mixture. The mixture was 
first stirred at 0 ̊C for 30min and then brought to RT for 48 hrs.  
The pure product was obtained by the same method used to purify the G1 and 
G2 dendrons by washing 3 times with saturated NaHCO3, HCl (1M) and brine. 
The concentrated crude product was then purified by column chromatography 
using ethyl acetate/petroleum ether (1/1 to 40/1, V/V) and then followed using 
dichloromethane/methanol (50/1 to 10/1, V/V). Yield: 12g, 75%. 
To yield PLLL+, the product PLLL was deprotected by removing the BOC in a 
similar way to G1 and G2. 
3.3.4. Characterisation of Dendrons  
Each generation of Dendrons synthesised was identified, and their chemical 
structures were confirmed by MS and H1NMR studies. Their purity was also 
confirmed by TLC. Moreover, details on each characterisation method and the 
purification of Dendron are given in chapter 2. 
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3.4. Results  
3.4.1. Characterisation of lysine generation 1 dendron (PL) 
The reaction of the propargylamine and Lysine led to the production of the white 
product PL Dendron of Generation 1 with a yield of 2.60 g (74.01%). Figure 3-
11. shows the mass spectra confirming the molecular weight of the PL Dendron 
(C19H33N3O5) with 2 terminal Boc groups. The most abundant peak 
(m/z=406.03) was assigned as a sodium adduct [M+Na]+ and corresponded to 
the calculated molecular mass of dendron PL being 383.24g/mol.   
Figure 3-11.  Mass spectra of the PL Dendron of generation 1. ESI-MS: m/z= 
406.03 (M+Na+) (calculated 383.49 for C19H33N3O5). 
 
Moreover, to further confirm the structure of the product obtained, the H1NMR 
spectrum was obtained (Figure 3.12.). The peaks in the spectrum have been 
labelled with numbers representing the carbon or nitrogen number in chemical 
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structure. The carbon or nitrogen contains 1, 2 or 3 hydrogen atoms which 
cause signals giving peaks in the spectrum. Therefore, the different peaks in the 
spectrum tell us about how many types of hydrogen bearing carbon or nitrogen 
there is in the chemical structure. The intensities of the signals are proportional 
to the number of hydrogen present.  
Figure 3-12. H1NMR spectrum of Dendron PL(400 MHz, CDCl3): d (ppm), 1.251–
1.915 (m, 24H, CH2 Lys and CH3-Boc), 2.252 (s, 1H, CHCCH2),  3.128 (m, 2H, 
CH2NHCO), 4.070(s, 2H, CHCCH2NH), 4.058 (m, 1H, COCH(R)NH), 4.664(s, 1H, 
CONH), 5.150 (s, 1H, CONH), 6.568(s, 1H, CONH). 
                                                                                                                                             
The high peak seen at 1.251-1.915 ppm corresponds to the 24 hydrogens 
present in the lysine-BOC structure. 6 hydrogens (CH2-Lys) are situated in the 
main bone of the lysine structure at carbon number 4, 5 and 6 whereas the 
other 18 hydrogens are from the 2 BOC groups protecting the amine at carbon 
number 8, 9,10,11,12 and 13 (CH3-Boc). The peak at 2.252 ppm, corresponds 
to the hydrogen situated at carbon number 1 (CHCCH2) of the alkyne group 
from propargylamine. The peak at 3.128 and 4.070 ppm have same height 
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peaks corresponding to the 2 hydrogens situated at carbon 2 of the 
propargylamine (CH2NHCO) and carbon 7 of the lysine (CHCCH2NH). The peak 
at 4.058 ppm represent the single hydrogen located in carbon number 13 
(COCH(R)NH) and the hydrogen present in the 3 amine molecules (14,15 and 
16) are observable by the peaks produced at 4.664 ppm (s, 1H, CONH), 5.150 
ppm (s, 1H, CONH), 6.568ppm (s, 1H, CONH).  
The purity of the PL product was also confirmed by TLC. After the reaction, a 
drop of the concentrated product was run into a TLC plate using the solvents 
ethyl acetate/Petroleum (1/1,V/V). Figure 3-13A. shows traces of impurities 
under the U-V light (Top spot of HOBT and EDC.HCl), the product (the stained 
middle spot) and spots of lysine (stained by ninhydrin at the bottom). The value 
Rf value of the product PL was determined to be 0.61. After purification by 
column chromatography, Figure 3-13B. shows a clear spot of the purified 
product PL. Separation was known to be completed when the TLC plate 
showed only one spot of lysine trace (Figure 3-13C.).  
To create a branched structure, another lysine group was further conjugated to 
the terminal amine groups of G1 dendrons to lead into dendrons of generation 2 





Figure 3-13. 3 TLC plates of A. product PL obtained after reaction; B. pure PL 
after separation and C. Lysine left after separation by column chromatography. 
Rf value determined to be 0.61 in the presence of PE: EA (V: V; 1:1) solvent. 





3.4.2. Characterisation of lysine generation 2 dendron (PLL) 
PLL was obtained in a yield of 12.5g (78.02%); Figure 3-15. shows the 
expected molecular weight of PLL being 840.23g. The higher peak shows the 
formation of sodium adduct [M+Na]+ with a mass of   862.26g. The PLL 
Dendron of generation 2 contains 4 terminal amine groups which are protected 
with BOC groups.  
  
Figure 3-15. Mass spectra of the PLL Dendron of generation 1ESI-MS: m/z = 
862.26(M + Na+) (calculated 840.07 for C41H73N7O11). 
                                                                                                                                                         
The H1NMR spectrum in Figure 3-16. shows the ppm values for protons in a 
different chemical environment which confirms the chemical structure of PLL. 
The high peak seen at 1.207-2.180 ppm corresponds to the 54 hydrogens of the 
CH2 situated on the lysine long chain and the CH3 of the protecting BOC 
groups. The peak at 2.263ppm corresponds to the hydrogen present in the 
alkyne group of propargylamine. The peak at 3.107 corresponds to the 6 
hydrogens from CH2 groups present at the end of the long chain (CH2NHCO). 
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The peak at 3.486 ppm is for the hydrogens from the CH2 group of the 
propargylamine. The peak at 4.038 ppm represent the single hydrogen located 
in carbon 3,12, and 36 carbon from the PLL structure (COCH(R)NH) and the 
hydrogens of amine groups from lysine (CONH) are at 4.819, 5.543 and 5.936 
ppm whereas the hydrogen of the amine of the propargylamine gave a peak at 
6.942.  
Figure 3-16.  H1NMR spectrum of Dendron PLL (400 MHz, CDCl3): d (ppm) , 
1.207– 2.180 (m, 54H, CH2-Lys and CH3-Boc), 2.263 (s, 1H, CHCCH2), 3.107(m, 
6H, CH2NHCO),  3.486(s, 2H,CHCCH2NH), 4.038 (m, 3H, COCH(R)NH, 4.819(s, 2H, 
CONH), 5.543 (s, 2H, CONH), 5.936(s, 2H, CONH),  6.942(s, 1H, CONH). 
 
TLC analysis in Figure 3-17 of the product after reaction shows some impurities 
visible in UV-light only, the brown stained product and traces of lysine. 
Impurities were first collected and discard in the presence of 1/1 volume of 
EA/PE and the product was obtained at 4/1 volume with a determined Rf value 
of 0.44, traces of lysine were easily washed off (see appendix section 9.4). 
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Figure 3-17.  8 TLC plates of PLL dendrons obtained at different stages of 
purification (PE/EA:1/1-8). The first TLC plate on the left shows different traces of 
impurities (top 2 clear circles), PLL dendrons (middle brown circles) and Lysine 
(bottom circles). The other TLC from left to right shows the products collected 
after separation by column chromatography over time. The impurities are first 
collected and discarded. Then pure product is collected separately, and the 
separation is stopped when traces of lysine appears on its own.  




Similarly, to PL, the protective BOC groups present in PLL were also removed 
for further reaction, and the molecular weight 440.07 g was confirmed by Mass 
spectrometry (Figure 3-18.). 
3.4.3. Characterisation of arginine dendron of generation 3 
(PLLA (BOC/PBF)) 
The chemical structure and purity of PLLA (BOC/PBF) were verified by H1NMR 
(Figure 3-19.). The structure has some repeating chemical chains, therefore, 
the main long chain which contains all the hydrogen groups was numbered. The 
peak at 1.139-2.285 ppm represent the 106 hydrogens of methyl groups in 
lysine, BOC and PBF groups (106H, CH2-Lys, CH3-BOC and CH3 PBF), at 
2.306ppm, the peak corresponds to the single hydrogen present in the alkyne 
group of propargylamine. 24 hydrogens from the CH2 protective PBF groups 
(position 13 and 14) are seen by the double peak at 2.410-2.806 ppm whereas 
the peak at 2.971 ppm represents the 8 hydrogens of the CH2  in PBF at 
position 16. The peak at 3.113-3.336 corresponds to the 14 hydrogens located 
in position 7 and 11. The other peaks at 3.969 ppm are for the 2 hydrogens of 
the carbon position 2; 4.115-4.516ppm for the singlet hydrogen of the carbon at 
position 3 and 8 whereas the 5.792-6.212 and 6.324-6.875 are for the hydrogen 
available in amine groups of the lysines chains.  
Purification of the product was monitored by TLC analysis. Figure 3-20 shows 
the TLC plate of the PLLA product before and after separation by column 
chromatography in different solvents mixture ratio (1/1, 1/40 (PE/EA) and 1/10 
and 1/50 ( DCM/MeOH)). In the presence of PE and EA, the product does not 
move from the mobile phase whereas the Rf value is determined to be 0.59 with 
ratio 1/50 (DCM / MeOH) and 0.50 for 1/10 ratio.  
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Figure 3-19. H1NMR spectrum of dendron PLLA (CDCl3), d (ppm), 1.139-2.285 
(106H,CH2-Lys ,CH3-Boc and CH3 PBF), 2.306 (1H,s, CHCCH2), 2.410- 2.806 (24 
H, d, CH2 PBF), 2.971 ( 8H, CH2 PBF) , 3.113-3.336 (14 H, m, CH2NHCO), 3.969 
(2H, CH^CCH2NH), 4.115-4.516 (7H, m, COCH(R)NH), 5.792-6.212(8 H, s,  NHCO), 
6.324-6.875(12 H, s, NHCO). 
                                          
Figure 3-20. 3 TLC plates of PLLA dendrons before and after purification under 
the presence of: A. 1/1 (V/V) PE/EA solvent; B. 1/40 (V/V) PE/EA solvent and C. 
1/10 (V/V) DCM/MetOH solvent. The Brown dots on top shows the traces of the 
product whereas the ones at the bottoms are traces of impurities. 
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PLLA dendron were also confirmed by  MS (Figure 3-21). The mass is shown 
as half the mass (2472.41g) with a sodium adduct. The yield of the product 
PLLA dendron was 7g (73.20%). 
              
Figure 3-21. ESI-MS of PLLA dendron, m/z= 1259.6187(M/2+Na)+ (calculated 
2472.41 for C121H201N23O23S4). 
 
3.4.4. Characterisation of the lysine generation 3 dendron 
(PLLL+)  
Figure 3-22 shows the successful synthesis of PLLL containing 8 protective 
BOC groups (MW=1752.13) due to the highest peak corresponding to half of 
the mass of PLLL with 2 sodium adducts ([M+2Na] at m/z= 899.5543). Similarly, 
to PLLA, the PLLL structure was confirmed by H1NMR (Figure 3-23). To 
produce positive bearing amine based Dendron, the protective 8 BOC were 
removed and the mass spectrum of [M + 3H]+++ at m/z = 318.24 (Figure 3-24) 
was corresponding to the signal of PLLL+ dendron, indicating the lysine 
dendron of generation 3 bearing eight free primary amines had been 
successfully synthesised.  
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Figure 3-22. ESI-MS of PLLL dendron, m/z= 899.5543 [M+2Na]+ (calculated 
1752.13 for C121H201N23O23S4). 
                 
Figure 3-23. H1NMR spectrum of dendron PLLL (CDCl3), d (ppm), 1.182-1.888 
(114H,CH2-Lys ,CH3-Boc), 2.201 (1H,s, CHCCH2), 3.250- 2.755 (8H, q, CH2NHCO), 
3.371 ( 2H, CH2NHCO) , 3.751 (4H, m, CH2NHCO), 4.023 (2H, CH^CCH2NH), 4.598-





Figure 3-24. The ESI-MS of the deprotected PLLL G3 dendron (calculated 952.13). 
 
3.5. Discussion  
Dendrimers show several advantages over linear polymers; they have been 
found to be easily modified, providing an ability to interact with several drugs 
and genes. In this chapter, we have been concentrating on the synthesis of 2 
different peptide-based dendrons. Both dendrons are of the third generation and 
consist of the same initiator core and interior layer but differ with their periphery. 
The initiator core consists of an alkyne group that can undergo click reactions 
with azidated polymers (see chapter 4, 5, 6 and 7). The interior layer is 
connected with the initiator core and is made up of a repetitive generation of 
lysine units and arginine. One dendron is characterised by 8 hydrophobic 
terminal groups (BOC/PBF) whereas the other consists of 8 terminals positively 
charged amine groups. Results show the successful synthesis of dendrons by 
the repetitive synthesis process to increase the generation. For each dendron 
generation, the yield of more than 70% was obtained (74.01% for G1, 78.02% 
for G2 and 73.20% for G3). This high yield could be due to the use of HOBt as it 
has been shown that the use of this additive yields to higher product and lower 
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epimerization (Valeur and Bradley, 2009). Moreover, the method used here 
seems to be very efficient yielding dendrons in high quantities and in gram scale 
which is advantageous for extensive biological testing compared to the solid 
phase method which produces lower generations dendrons in milligram scale 
(Janiszewska et al., 2016). During activation of carboxyl groups, it is known that 
the main side reaction known as racemisation can occur however the use of 
protected BOC amino acids helped to retain the optical purity upon activation of 
the lysine and arginine at each generation reaction (documents.bachem.com). 
Moreover, the use of peptides such as lysine and arginine easily helped to 
detect the violet colour products in TLC plates because of the presence of 
ninhydrin which interacted with the amino acids to form a Ruhemann’purple 
complex. The hydrogen bonding interactions in a chloroform solution of each 
Dendron products were investigated by 1HNMR which confirmed their structure, 
and their molecular weight was confirmed by mass spectrometry. As the 
generation increases from G1 to G3, the molecular weight was also observed to 
increase, which also suggest an increase in size. The process to obtain the 
dendrons via divergent synthesis required excess time due to all the process 
involved such as a reaction and long chromatographic separations, particularly 
with dendron of generation 3 (Svenson and Tomalia, 2012). However, the 
process was easily repeated, and higher yield was obtained. We also aimed to 
obtain the amine terminal bearing generation 3 Dendron by the removal of BOC 
and PBF from the surface. However, treatment by TFA did not allow the full 
deprotonation of the dendron. Instead, unexpected mass results were opened 
(appendix section 9.1&2). The mass of arginine Dendron of the third generation 
bearing eight amine group at the periphery was expected to be 1063.73. 
However, products obtained after deprotonation did not match to the mass 
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expected. Also, the poor solubility in water of the deprotected products 
confirmed the unsuccessful deprotonations. There is a possibility that the 
dendrons did undergo racemisation during deprotection reaction, therefore, 
resulting in different products. For this reason, a new way was designed, lysine 
dendron of third generation bearing 8 BOC groups was synthesised following 
the method of Ma et al., 2013 and Li et al., 2013. To then obtain a terminal 
arginine structure we proposed to conjugate the terminal amine groups of lysine 
from PLLL+ with guanidine groups (see chapter 7). The fact that Dendrons can 
be modified at any point to obtain desired terminal functional groups makes 
them very special and the ideal molecules for drug and gene delivery. The 
successfully synthesised dendrons PLLA and PLLL can be conjugated into 
polymers to form nanocarriers for drug and gene delivery. PLLA can be used to 
carry hydrophobic drugs and improve their solubility, whereas, PLLL bearing 
positively charged amine can easily interact with negatively charged DNA for 
gene delivery.  
In Conclusion, this chapter presents a deep understanding of the production of 
dendrons and various alternations choices to produce Dendron with different 











CHAPTER 4. MICELLAR DENDRONS FOR THE 
DELIVERY OF DOXORUBICIN IN VITRO CELL MODELS 
 
4.1.  Introduction  
Chemotherapy is one of the most effective therapies against many types of 
cancer. However, chemotherapeutic agents that are toxic to tumour cells are 
usually also toxic to healthy cells (Ahles and Saykin, 2007; Cheok, 2012; Huang 
et al., 2017), suffer from resistance or present low bioavailability due to their 
poor solubility in water (Kalepu and Nekkanti, 2015), therefore results in severe 
side effect or in reduced therapeutic efficiency. For this reason, many new 
carrier systems have been developed for targeted drug delivery to achieve 
desirable efficiency and to minimise side effects. It is, however, important to 
note that any carrier systemically administrated will also have to overcome 
many obstacles within the body. To reach the targeting site, it is essential that 
the carrier resists from plasma proteins, opsonisation (or evade uptake by 
macrophages), clearance by renal filtration and degradation by endogenous 
nucleases (Alexis et al., 2008). 
Moreover targeting tumours in large organs of the body is very challenging due 
to their very complex anatomical organisation characterised by various barriers 
that stop foreign materials. Examples include the Blood-brain barrier (BBB) in 
the brain and barriers preventing access of parenchymal cells by Sinusoidal 
endothelial cells and Kupffer cells clearance in the liver. 
The brain survives from a system consisting of neural cells (brain parenchyma, 
70-80%), the vascular system (3-5%) and the brain interstitial system (ISS, 15-
20%). The two main functional neural cell types are neurons and glial cells 
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(astrocytes, oligodendrocytes and microglia) (Lyon et al., 2017; Lei et al., 2017; 
Fumagalli, Ortolano and De Simoni, 2014). The capillaries in brain tissues 
contain some barriers that separate the circulating blood from the brain 
parenchyma, including the most selective barrier blood-brain barrier (BBB) 
(Abbott, 2005; Kipnis, 2016). In the case of a Brain tumour, the BBB is 
breached therefore can allow the passage of immune cells into brain 
parenchyma. It has been reported that higher grade brain tumours can lead to 
exacerbated irregular vascularisation, tumour necrosis, BBB disruption, antigen 
expulsion and elevated interstitial pressure of the fluid that can influence 
therapeutic infiltration (Charles et al., 2011; Dubois et al., 2014; Goel et al., 
2011). Although the BBB is known to be leaky in a brain tumour, there is still 
presence of intact BBB in some region that present barriers for drug delivery 
and immunotherapy (Van Tellingen et al., 2015), the BBB can prevent the 
passage of 98% of small molecular drugs and 100% of large molecular drugs 
within the bloodstream (Zhou et al., 2013).  
On the other hand, the liver is composed of 80% of parenchymal cells 
(hepatocytes cells) and 20% of non-parenchymal cells (sinusoidal cells). The 
sinusoidal cells comprise 70% of sinusoidal endothelial cells (SECs), 20% of 
Kupffer cells (KCs, the liver macrophages), 10% of hepatic stellate cells (HSCs, 
the fat-storing cells or Ito cells) and less than 1 % of pit cells (natural killer cells) 
(Do et al., 1999; Sasse, Spornitz and Piotr Maly, 1992; Blouin, 1977; Knook and 
Sleyster, 1980 ; Jacobs et al., 2012 ; Mohar et al., 2015). Moreover, like all the 
other endothelial cells within the body, the sinusoidal endothelial cells form 
highly specialised capillaries with endothelial lining that contains fenestrae 
which then provides an open pathway between the sinusoidal lumen and the 
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space of Disse in which numerous microvilli from parenchymal liver cells 
protrude (Braet et al., 2009; Jacobs et al., 2012). Although these fenestrations 
can provide direct access for delivery systems to hepatocytes cells, they can 
also restrict the entrance of large particle sizes since the fenestrae measure 
100 to 200 nm. Also, the efficiency of delivery systems can be limited by the 
uptake of sinusoidal endothelial cells and Kupffer cells before reaching to 
hepatocytes cells. The sinusoidal endothelial cells have been reported to be 
scavengers cells that can internalise particles of sizes up to 230nm whereas 
Kupffer cells present in sinusoid capillaries account for 80-90% of resident 
macrophage in the entire body, therefore, forming the major part of the RES 
system (Mishra et al., 2013; Shiratori et al., 1993; Xu et al., 2008; Jacobs et al., 
2012). 
 As we have described before in chapter 1, particle size, surface properties 
such as charge, solubility and targeting ligands to cells of interest are the key 
importance to overcome these challenges.  
4.2. Aims and objective  
The specific above obstacles faced by delivery systems in large organs have 
led us to develop a new delivery system that can deliver hydrophobic 
therapeutic agents successfully to their target. Nanoparticles systems can be 
the primary way of reducing drug elimination and also can be a way to 
overcome the BBB challenge (Von Maltzahn et al., 2011).  
Since we have already successfully synthesised hydrophobic arginine dendron 
bearing terminal PBF and BOC groups (PLLA-PBF/BOC) that can form a cavity 
for drugs. We propose the synthesis of a polymeric micellar dendrons based 
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system capable of delivering the drug Dox into liver or brain tumour cells.                        
To form targeting micelles, the hydrophilic polysaccharide pullulan is chosen 
because of its recognition of Asialoglycoprotein receptor (ASGPR) expressed 
uniquely and in large numbers on hepatocytes (Li et al., 2016). We, therefore, 
hypothesise that the amphiphilic system consisting of pullulan conjugated 
hydrophobic arginine dendron (P-PLLA) can self-assemble into nanocarriers in 
aqueous solution and therefore encapsulate hydrophobic drugs such as Dox for 
the treatment of hepatic cancer and brain tumours. Our primary objective is to 
form nanocarriers of small sizes so that the pullulan bearing conjugate could 
gain access to hepatocytes or glioblastoma cell by passing through the 
fenestrated endothelium of the sinusoid or efficiently bypass the BBB barriers. 
Once inside the cells of interest, the drug can be released at lower pH inside 
cancerous cells and reach their site of action to stop or reduce cell proliferation. 
Specifically, we aimed to develop and characterise the nanocarrier system P-
PLLA and investigate: 
1) the loading and encapsulation efficiency of doxorubicin;  
2) the stability of the blank and loaded nanoparticles;  
3) the drug release studies; 
4)  the toxicity against an experimental brain and liver cancer cell line in vitro 
and; 
5) the ability to uptake the doxorubicin-loaded nanoparticles into brain and liver 




4.3. Methodology  
4.3.1. Synthesis of the arginine dendron of generation 3 (PLLA)  
Refer to chapter 3 
4.3.2. Pullulan azidation (PN3) 
Figure 4-1.  Synthesis equation of the azidated pullulan PN3. 
 
Two reactions were carried out at the same time. First, 0.98g (1mmol, the 
equivalent of anhydrous glucoside units) of Pullulan and 3.15g (8mmol) NaN3 
were dissolved in 30mL of anhydrous DMF at 80ºC for 2 hours under N2 
atmosphere. After cooling to RT, an ice bath was added in one flask, and the 
other flask was left at RT. A freshly prepared solution of PH3P (2g in 5ml DMF, 
1.6mmol) was then added in each flask followed by the addition of a CBr4 
solution (3g in 5ml DMF, 1.6mmmol). The ice bath was removed after 30min of 
stirring, and both reactions were allowed to stir for 20hrs at RT. The solution 
was then exposed to air and methanol (5ml) was added and left to stir for 5 min 
to quench the reaction. Finally, the azidated pullulan was precipitated into 
300ml of ethanol. The precipitate was recovered by centrifugation and then 
washed with 100mL of a 7:3 ethanol/water solution followed by 100mL ethanol. 
The solid obtained was then allowed to dry at 60°C overnight in a vacuum. 
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4.3.3. Click reaction between azidated pullulan and PLLA 
dendron  
Figure 4-2. Synthesis equation of Pullulan clicked PLLA (PG3or P-PLLA). 
 
PLLA (2.35g, 2 mmol) and PN3 (0.1g, 1mmol) were added successively in 30 
ml of DMSO and stirred to dissolve under an N2 atmosphere at 50 ̊C for 1hr. 
The mixture was then brought to RT and passed into argon under stirring. Then 
5ml of a deoxygenised aqueous solution of sodium L-ascorbate (0.075g, 
0.4mmol) and 5ml of deoxygenised blue aqueous solution of copper (II) 
sulphate pentahydrate (0.048g, 0.2mmol) was injected successively into the 
reaction. The yellowish resultant reaction mixture was stirred under argon for 55 
hrs at 40 ̊C. After the reaction, the flask was left to stir in the presence of 
oxygen to allow de-activation of the agents. A small amount of EDTA was 
added and left to stir for 2-3 hrs until the solution turned blue. The resulting 
solution was dialysed against distilled water containing a lower amount of EDTA 
for 1 day and against distilled water for 2 days (MWCO=3500). The final 
yellowish solution was then lyophilised to yield the product PG3.  
4.3.4. Characterisation  
The characterisation was carried by FTIR, NMR and EA, the details of each 
method are given in chapter 2. In addition, Chapter 2 contain the method details 
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of micelle formation of P-PLLA, Dox loading and drug release, characterisation 
details by SEM, TEM and DLS, stability studies (CAC studies), cell culture, in 
vitro cytotoxicity in 3T3, Hek293, U251 and HepG2 cells, flow cytometry, FACS 
studies and apoptosis.  
4.4. Results  
4.4.1. Characterisation of the azidated pullulan  
Different conditions of azidation reactions were carried out to investigate the 
best parameter for giving more azidation. Table 4-1 lists the conditions 
employed as well as elemental analysis with the calculated DS (defined here as 
the degree of substitution per anhydroglucose unit). As seen, ten equivalent 
molars of sodium azide gave a higher conversion (232.16%) in a condition 
where equimolar quantities of Ph3P/CBr4 were added in the presence of ice 
bath compared to a lower conversion (155.04%) when added at room 
temperature. 
Table 4-1. Determination of the substitution degree of azidated pullulan by 







C (%) H (%) N (%) DS (% per    
unit) 
Pullulan – 40.33 6.66 – – 
PN3(1) 1: 10 (RT) 39.34 5.68 11.86 155.04% 
PN3(2) 1:10 (0ºC) 32.94 5.62 14.87 232.16% 
PN3(3) 1:9 (0ºC) 39.51 6.67 5.93 77.19% 
PN3(4) 1:8 (0ºC) 39.24 6.56 3.74 49.02% 
 
In addition to the Elemental analysis, the FTIR analysis also confirms the 
successful azidation to pullulan. Figure 4-3 shows the FTIR spectra for pullulan 
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and PN3. On both Spectra, broadband appeared at 3401 cm
−1 due to -OH 
stretching and a sharp band at 2918 cm−1 was characteristic of C-H stretching.  
                
Figure 4-3.  IR spectrum of Pullulan and Azido-Pullulan (4) PN3 containing a 
strong C-N3 stretching vibration at 2107 cm-1 which matches that of published 
data. 
 
The peaks at 1413, 1156, 1014 and 590 cm−1 were due to C-O-H bending, C-O-
C stretching, C-O stretching and alpha configuration, respectively. The band at 
1646 cm−1 corresponds to the vibrations of the C-O-C bond and glycosidic 
linkage (Sugumaran et al., 2013; Saber-Samandari et al., 2014). The FTIR 
spectra of the PN3 show an extra strong C-N3 stretching vibration at 2107 cm
-1 
which confirm the successful azidation. 
 
4.4.2. Characterisation of clicked PG3(BOC/PBF) product 
A classic copper-catalysed reaction was used to synthesise the pullulan 
conjugate PG3(BOC/PBF) by reacting the alkyne-functionalized PLLA dendron 
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with the azidated pullulan containing 77.19% of azide groups. In Figure 4-6, 
three spectra are given for comparison of peaks produced by azidated pullulan, 
dendron of generation 3 PLLA and their clicked product.  
                         
Figure 4-4.  FTIR spectrum of the azidated Pullulan, dendron of generation 3 
PLLA and clicked product PG3 BOC/PBF. 
 
All peaks present from PN3 and PLLA are also observable in the product 
PG3(BOC/PBF) spectrum suggesting the strong click reaction. The presence of 
pullulan is confirmed by the adsorption peak at 3000-3500 cm-1 due to O-H 
stretch and 2932 cm-1 due to C-H stretch. The N-H stretch at 3348 cm-1 of G3 
is overlapped with the O-H stretch of pullulan whereas the absorption peak at 
1532 cm-1 due to C=C and 1375 cm-1 due to S=O present in the PBF groups of 
G3 are also present in the clicked product. Furthermore, the disappearance of 
the azido group peak at 2107cm-1 in PN3 and the alkyne peak at 2347 cm-1 
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assigned to the dendrons G3 suggest the full clicked conjugation of G3 into 
pullulan.                               
Moreover, the 1HNMR spectra of the clicked product PG3(BOC/PBF) showed a 
signal at 7.90 ppm (He) indicating the triazole proton present in the 5-membered 
heteroatom ring formed from the click chemistry.  
Figure 4-5. 1HNMR (400 MHz, DMSO-d6) of clicked PG3. 
 
The characteristic peaks in 1HNMR corresponds to particular hydrogens in the 
structure: 0.734-1.154 (d, 12H, CH3-PBF, G3); 1.546 (s, 24H, CH3-BOC-PBF, 
G3); 1.964-2.103 (s, 12H, CH3-PBF, G3); 2.410- 2.806 (d, 24 H, CH3-PBF, 
G3); 4.8 (d, 66H per 100 glucose units, pullulan C1 H (1-4); 5.0 (s, 33H per 100 
glucose units, pullulan C1 H (1-6)); 7.90 (s, 1H, NCHCH, triazole ring). Also, the 
graft level of G3 dendrons onto the azidated pullulan was 20.32%, according to 





4.4.3. The self-assembly of P-PLLA(BOC/PBF) or PG3 
PG3(BOC/PBF) form an amphiphilic system that could self-assemble to form 
micelles in aqueous media due to the enhancement of the hydrophobic effect. 
The size distribution of PG3 based nanoparticles (1mg/ml) in distilled water was 
measured by dynamic light scattering (DLS); TEM; and SEM (Figure 4-6). PG3 
showed an average size of 87.07nm with a PDI of 0.241. Moreover, TEM and 
SEM images showed monodispersed spherical nanoparticles with an average 
size similar to the one obtained with DLS analysis. 
Figure 4-6. Size distribution and morphology studies of blank of PG3 by A. DLS, 
B. TEM and C. SEM. 
 
4.4.4. CAC and Stability studies of PG3(BOC/PBF) micelles 
  The CAC of the PG3 was determined by fluorescence technique, using pyrene 
as a hydrophobic probe. Figure 4-7 shows the plots of the fluorescence intensity 
116 
 
ratio I337 / I334 against the logarithm of the PG3 micelles concentration. For 
PG3, a value of 10.47ug/ml was obtained, which indicates high stability of 
mixed micelles and excellent stability upon dilution in body fluid.  
 
                                              
Figure 4-7. Critical association concentration of PG3 measured using the 
fluorescent dye pyrene. 
4.4.5. Drug loading into P-PLLA (P-PLLA-Dox) 
The drug doxorubicin was physically entrapped and stabilised in the 
hydrophobic dendron core of the micelles PG3 via hydrophobic-hydrophobic 
interaction.  
The loading and encapsulation efficiency were determined using the line of 
equation of the standard curve of doxorubicin being y=5.0939x-0.5728 (Figure 
4-8)     
Drug loading was carried out with a different weight ratio between the carrier 
and the drug Dox. As seen in table 4-2, the loading content of P-PLLA-Dox at 
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ratio 5:1, 2:1 and 1:1 micelle was 19.17%, 22.77% and 27.14%, respectively 
whereas the encapsulation efficiency was 64.15%, 53.20% and 40.64%, 
respectively.  
                                            
Figure 4-8. A standard curve of Doxorubicin determined at 480nm.  
 
PG3 loaded with Dox at ratio 5:1 showed the highest encapsulation efficiency 
with excellent distribution of PG3-Dox in aqueous media and was therefore 
used for further studies. 





DLS, TEM and SEM measurements showed an increase of the average size of 
the Dox-loaded P-PLLA nanoparticles with a mean of 138nm compared to blank 
y = 5.0939x - 0.5728 



















PG3:DOX (ratio) LC%± Std.dev EE% ±Std.dev 
5:1 (20%) 19.17±1.50 64.15±6.25 
2:1 (50%) 22.77±2.92 53.20±5.35 
1:1 (100%) 27.14±1.75 40.64±4.66 
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P-PLLA micelles (Figure 4-9). The successful loading of the drug is therefore 
evidenced by the increase in size because the Dox molecules loaded into the 
micelles increased the inner space of the micelles (Zhou et al., 2016; Fan et al., 
2018). 
Figure 4-9. Size distribution of DOX-loaded PG3 micelles in water determined by 
A. dynamic light scattering and B. TEM and C.SEM. 
4.4.6. In vitro drug Release studies of P-PLLA-Dox NPs 
 Since the pH change occurs at many specific or physiological sites in the body, 
the release of Dox from PG3 was investigated at different pH (5.0, 6.8 and 7.4).  
Throughout 60hours, the higher sustained release rate of up to 53% of the drug 
load was observed under pH 5 condition (intracellular environment pH) whereas 
only 23 % was released at pH 6.8 and 16% at pH 7.4 (blood pH). This 




with hydrophilicity enhancement at lower pH values (Quader et al., 2014 and 
Ma et al., 2015).  
                        
Figure 4-10. pH sensitive release of Dox from PG3 (BOC/PBF) micelles. 
4.4.7. Stability of blank and Dox-loaded PG3 micelles  
The micelles formulations were stored as a freeze-dried powder (Figure 4-11A) 
at -20 ºC, whereas blank and Dox-loaded micelle suspension in DI water 
(Figure 4-11B&C) was stored at 4ºC for 3months.  
From the stored sample, no sedimentation, no precipitation, no aggregations or 
phase separation were observed in 3 months stability test showing that the 


























pH5.0       pH6.8       pH7.4 
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Figure 4-11. Images and size distribution of blank PG3 and loaded Dox-PG3 
micelles stored for 3 months: A. lyophilised PG3 micelles in powder form; B. 
Blank PG3 micelle suspension in DI water; C. Dox-loaded PG3 micelle 
suspension in DI water; D. Size distribution of blank freeze dried PG3 powder by 
dynamic light scattering; E. Size distribution of blank PG3 suspension in DI by 
dynamic light scattering; F. Size distribution of Dox-Loaded PG3 suspension in 
DI by dynamic light scatter. Note: Size distribution of the samples were 
determined in triplicate (peak colours blue, red and green in D, E and F).  
 
Furthermore, changes in size were also monitored; there were no significant 
changes in sizes for the micelles in suspensions showing the high storage 
stability. Although micelles in dried form showed a higher particle size of 
106nm, they showed good stability profile. Also, in 3 months, there was a slight 
decrease in the drug content from 19.17% to 16.75% this is maybe due to the 
slow release of Doxorubicin from micelles.  
4.4.8. Cytotoxicity of Dox.HCl, blank and loaded Dox-P-PLLA 
The in vitro cytotoxicity study of the blank P-PLLA micelles was carried out 
against normal cell lines (Hek293 and NIH3T3) and cancerous cell lines 
(HepG2 and U251) for 72hours. Figure 4-12 shows that all cell types exposed to 
the blank PG3 micelles stayed more than 80% confluence in the period of 
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72hours. The blank micelles, therefore, had no cytotoxicity in the concentration 
of 0-100µg/mL. In comparison between cell lines, normal cells Hek293 and 
NIH3T3 were almost 95% confluent, which indicates the safe use of blank 
micelles PG3 as a nanocarrier for cancer therapy. The cytotoxicity of Dox 
loaded P-PLLA and their in vitro antitumour effect was also investigated against 
HepG2, U251, Hek293 and NIH3T3 cells. As seen in Figure 4-13, the toxicity of 
P-PLLA-Dox exhibited concentration and time dependence against each cell 
lines. As the concentration of Dox.HCl and P-PLLA-Dox concentration 
increased from 0 to 200µg/mL, cytotoxicity to cells also increased.  
                 
Figure 4-12. A.  Biocompatibility assay of HepG2, U251, Hek293 and NIH3T3 cells 
against blank PG3 nanoparticles for 72h B. Image of the PG3 micelles 
suspension in DMEM containing 10% (V/V) FBS.  
 
Table 4-3 shows the calculated IC50 values of free Dox.HCl and PG3-Dox in 
each cell lines at a varying time. As seen the IC50 of loaded Dox in PG3 was 
always higher than that of free Dox.HCl in each cell and at all-time intervals. 
These observations might be because of hydrophilic Dox.HCl could be easily 
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transported into the cells and accumulated rapidly in nuclei, whereas 
hydrophobic Dox-loaded P-PLLA NPs may be internalised by endocytosis 
followed by the disassembly of the nanoparticles, releasing Dox from cytosolic 
compartments in a sustained manner and continuously producing a toxic effect 
after incubation (Eliaz et al., 2004).  
Table 4-3. Calculated IC50 values of free Dox.HCl and PG3-Dox in HepG2, U251, 
Hek293 and NIH3T3 cell lines at a varying time 
 
 
It is also observable that the toxicity of P-PLLA-Dox in cancerous cells HepG2 
and U251 is higher compared to normal cells Hek293 and NIH3T3 and that the 
cell viability of HepG2 decreased the most. These results suggest that P-PLLA-
Dox had a higher affinity toward the HepG2 cells and could kill both tumour cells 
but were less toxic to normal cells.  
Figure 4-13. Image of the 
PG3-Dox micelles 
suspension In DMEM 
containing 10% (V/V) FBS  
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Figure 4-14. The in vitro cytotoxicity of Dox.HCl and PG3-Dox after 24, 48, 72 and 





4.4.9. Cellular internalisation by Flow cytometry and confocal 
studies 
Doxorubicin is fluorescent with a maximum excitation and emission wavelength 
of 470 and 560 nm, respectively (Kauffman et al., 2016).  Laser flow cytometry 
has been widely used for monitoring the accumulation in cells of fluorescent 
anticancer drugs (e.g. Doxorubicin), other fluorochromes and antibodies 
(Krishan and Hamelik, 2005). Therefore, flow cytometry has been used here for 
the quantitative determination of Dox uptake in HepG2 and U251 cells.  
                   
Figure 4-15. Flow cytometry plots. A. Dot plot of HepG2 control gated as P1, B. 
histogram plot of the control HepG2 cells and C. Dot plot showing the Dox 
fluorescence intensity of hepG2 cells treated with 5µg/mL of Dox.HCl at various 
time.  
 
Cells without any Dox treatment were used as a negative control. The 
internalisation of Dox.HCl was investigated for the duration of 0.5,1 and 6hours 
incubation. Figure 4-15 shows a shift of fluorescence intensity to the right as the 
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time increases, which is directly proportional to the amount of Dox internalised 
in cells. 
Figure 4-16. The cellular uptake by Flow Cytometry of Dox.HCl and PG3-Dox 
nanoparticles at 0.5, 1 and 6 hours in HepG2 cells. The flow cytometry 
histograms are represented in 2 ways: first top 2 histogram plots represent 
separate plots of the changes in fluorescence intensity of Dox.HCl treated HepG2 
cells (peaks in purple), and PG3-Dox-treated HepG2 (peaks in Blue) over time 
whereas the three bottom plots compare the fluorescence intensity of Dox.HCl 
and PG3-Dox-treated HepG2 cells at each time intervals. Untreated HepG2 cells 
were also used as control (peaks in Red). 
 
Treatment to both tumour cells showed that the internalisation of Dox-PG3 was 
also time dependent and lower fluorescence intensity compared to Dox.HCl 
treated cells at 0.5 and 1hour incubation was observed indicating the slower 
uptake of PG3-Dox compared to Dox.HCl (Figure 4-16 and 4-17). In addition to 
flow cytometry plots, confocal studies (Figure 4-18 and Figure 4-19) also 
showed the increase with time of strong red signals inside cells, which indicates 
the successful uptake off Dox.HCl and PG3-Dox inside cells.  
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Figure 4-17. The cellular uptake by Flow Cytometry of Dox.HCl and PG3-Dox 
nanoparticles at 0.5, 1 and 6 hours in U251cells. The flow cytometry histogram 
represented in 2 ways: first top 2 histogram plots represent separate plots of the 
changes in fluorescence intensity of Dox.HCl treated U251 cells (peaks in 
purple), and PG3-Dox-treated U251 cells (peaks in Blue) over time whereas the 
three bottom plots compare the fluorescence intensity of Dox.HCl and PG3-Dox-
treated U251 cells at each time intervals. Untreated U251 cells were also used as 
control (peaks in Red). 
For both cells, the pathway of internalisation of Dox.HCl and the PG3-Dox 
nanoparticles were different because the distribution of the red signals 
representing Dox in cells treated with Dox.HCl was different from that of cells 
treated with PG3-Dox nanoparticles. In Figure 4-18 and 4-19, at 0.5h, HepG2 
and U251 treated cells with Dox.HCl showed strong red fluorescence in the 












As the hours of incubation increased to 1 and 6h, stronger red fluorescence was 
observed in both cells nuclei in addition to a very weak fluorescence in the 
cytoplasm. This observation indicates the rapid intercalation of intracellular 
Dox.HCl by passive diffusion into the HepG2 and U251 cells. On the other 
hand, throughout all 6hrs of incubation, HepG2 and U251 cells treated with 
PG3-Dox showed strong red fluorescence throughout the cytoplasm, revealing 
that PG3-Dox Nps were initially trapped within endosomal compartments after 
cellular uptake. At 6hours, both HepG2 and U251 treated cells with PG3-Dox 
showed some red fluorescence in the nuclei as well, indicating that Dox was 
successfully released from the PG3 carriers and successfully delivered to the 
nuclei where its mechanism of action takes place.  
4.4.10. Apoptosis studies  
Flow cytometry was also used to quantitatively investigate the apoptosis of 
HepG2 and U251 cells after 12h treatment with Dox.HCl and PG3-Dox. The 
cells were stained with FITC-labeled Annexin V and propidium iodide (PI) and 
then analysed with triplicate determinations.  
From the Figure 4-20, after the incubation for 12h, the control sample containing 
non-treated HepG2 cells showed an apoptotic rate of 4.0% including the early 
and late apoptosis rate of 0.9% and 3.1%, respectively. The early and late 
apoptosis rate of the Dox.HCl treated HepG2 cells were 21.2 % and 4.2%, 
respectively, whereas those treated with PG3-Dox were 20.3% and 3.4%, 
respectively. This indicates that the apoptosis rate induced by PG3-Dox was not 
much different from that of Dox. Similar results were obtained with treated U251 
cells, the early and late apoptosis rate of the Dox.HCl treated U251cells were 
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9.1 % and 0.9%, respectively, whereas those treated with PG3-Dox were 7.6% 
and 1.2%, respectively.  
Figure 4-20. The effect of free Dox.HCl and Dox-loaded PG3 on the induction of 
apoptosis in HepG2 and U251 cells. Tumour cells were quantified by flow 
cytometric analysis of Annexin V FITC staining in tumour cells following 12h 
treatment with 5µg/mL equivalent Dox concentration. The lower left (LL) quadrant 
represents live/healthy cells, the lower right (LR) quadrant represents early 
apoptosis, and the upper right (UL) represents cells in late apoptosis, while the 
top left (UR) represents the percentage of Dox uptake/dead cells. The percentage 
of cells undergoing early or, late apoptosis is indicated in the respective 
quadrate.  
 
4.5. Discussion  
Amphiphilic Dendronised Polymer-based NPs that self-assemble to form 
micellar structure are the new systems extensively been studied for the 
solubilisation and the safe delivery of hydrophobic drugs in cancer therapy. One 
of the most common hydrophobic drugs used to test such a carrier system is 
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the anthracycline antibiotic doxorubicin (Dox) which is presently used in the 
treatment of a wide variety of cancers. We have developed an amphiphilic 
dendronised polymer based nanocarrier for the delivery of the hydrophobic drug 
Dox in liver and Brain cancer cells. Polysaccharides including Hyaluronic acid, 
Dextran, Chitosan, Heparin, cyclodextran, pullulan,… have shown to be the 
most important group of polymers used in delivery systems (Goodarzi et al., 
2013). Pullulan was chosen here as the ideal backbone of the nanocarrier since 
its neutral, non-toxic, non-immunogenic, noncarcinogenic and non-mutagenic, 
can target liver cells and most important can readily undergo chemical 
modification (Kumar et al., 2012). Here, we have successfully conjugated the 
hydrophobic arginine dendron of the third generation into pullulan through an 
approach known as Huisgen azide-alkyne 1, 3-dipolar cycloaddition or “click” 
reaction. Pullulan consists of maltotriose units connected by α (1→4) glycosidic 
bond, whereas consecutive maltotriose units are connected by α (1→6) 
glycosidic bond. There are nine OH groups per repeating unit available for 
substitution in the pullulan structure. Azidation of various polysaccharide such 
dextran (Mai et al., 2015), starch (Shey et al., 2006) and amylose (Cimecioglu 
et al., 1997; Pang et al., 2015) have been achieved before. Since the click 
chemistry consists of the cycloaddition of azides and terminal alkynes to form 
1,2,3-triazoles, we have successfully converted up to 232.16% of OH into 
azides groups per unit of pullulan in a condition where equimolar quantities of 
Ph3P/CBr4 were added in the presence of an ice bath with a ratio of pullulan: 
NaN3 being 1:10. The characteristic strong absorption peak at 2107 cm-1 was 
observed in the FTIR of PN3, which matches that of published data and 
confirmed the vibration of azido groups present in pullulan. Compared to the 
azidation of starch by cimeciogluin 1997 and Pang in 2015, which was carried in 
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the same conditions as our experiment, only 40-75% of conversion was 
achieved. The authors reported that the conversion could easily be affected by 
moisture content; therefore, during the azidation of pullulan, any source of 
moisture was avoided. Moreover, the experimental conditions we used for 
pullulan azidation was much more straightforward, efficient and quicker 
compared to the method used by Mai et al., in 2015 who first carried the 
oxidation of dextran to then achieve the azidation of dextran.  
The successful azidated pullulan was then clicked with alkyne containing 
dendron PLLA G3 (BOC/PBF) which was confirmed by FTIR and H1NMR. The 
click reaction was very reliable and easy to perform, not very elevated 
temperature was needed, and the reaction was taken place in deoxygenated 
water. High yield was also obtained, and purification of the product was simple. 
These convenient factors have been reported previously by Hein, Liu and Wang 
in 2008 who describes the wide application of click chemistry in biomedical and 
especially in pharmaceutical sciences and its emerging applications in drug 
delivery and nanomedicine. The authors also report that click chemistry is a 
powerful linking reaction catalysed by CuI, which makes the reaction 107 times 
faster than the uncatalyzed version.  
The final clicked product PG3 (PLLA) was therefore composed of a hydrophilic 
backbone in which 20.32% of hydrophobic dendron was introduced. The 
amphiphilic structure was also confirmed by the fact that PG3 was able to self-
assemble in aqueous solution to form spherical nanomicelles of 87.07nm with a 
PDI of 1.87. The particle size distribution and polydispersity index (PDI) of 
nanocarriers are highly critical physical characteristics to be considered. The 
size of particles gives us an overview of how efficiently the carriers can reach 
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their target without being eliminated in the bloodstream, whereas the PDI 
represents the distribution of the size population within the sample. A PDI value 
lower than 0.05 is mainly seen with highly monodisperse standards whereas a 
PDI value bigger than 0.7 indicates that the sample has an extensive particle 
size distribution and is probably not suitable to be analysed by the dynamic light 
scattering (DLS) technique (Danaei et al., 2018). 
For this reason, PG3 has shown excellent physical characteristics in term of 
size and PDI as their sizes are within 30-200nm with a PDI lower than 0.7. 
Moreover, stability studies showed that PG3 stayed stable even after 3 months 
with no change in size. However, following intravenous administration, the 
polymer concentration may fall below the critical association (CAC), in this case, 
PG3 also showed a low value of CAC 10.47µg/mL which shows high assembly 
stability in aqueous solution (Allen, Maysinger and Eisenberg, 1999).         
 In addition to enormous size and stability properties, PG3 nanocarriers showed 
to be a safe carrier as no toxicity of the carrier was observed in Hek293, 
NIH3T3, U251 and HepG2 cells. These results suggest that the neutral 
amphiphilic PG3 nanocarrier would be an ideal carrier to improve the solubility 
of hydrophobic drugs and deliver hydrophobic drugs safely into cancerous cells 
since their sizes would permit their escape from RES clearance and bypass 
barriers in the liver and brain.  
To investigate the ability of PG3 to deliver hydrophobic drugs into liver and brain 
cancer cells, the hydrophobic drug Dox was incorporated inside PG3 via 
physical entrapment. 19.17% of drug Dox was successfully loaded into PG3, 
and the loaded carrier size was increased to 138nm which is still convenient as 
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a carrier size for the delivery of doxorubicin in liver and brain cancer cells. As 
expected, the rate of drug release was affected by pH of the environment, 
where acidic pH resulted in Dox release into the surrounding media while the 
conjugate retained its stability at neutral pH and even when stored for 3 months. 
PG3 also displayed effective cellular toxicity towards all cell lines. However, 
higher toxicity was observed in cancer HepG2 and U251 cells compared to 
normal Hek293 and NIH3T3 cells lines, which suggested that PG3 enhanced 
the delivery of doxorubicin into cancerous cell lines. Moreover, in vitro cellular 
uptake of the drug-loaded PG3 was also confirmed by flow cytometry, confocal 
studies and even apoptosis assays. It was noted that by the time of 6 hours, a 
similar amount to free Dox could be taken inside both U251 and HepG2 cells by 
PG3 however free Dox would almost be internalised inside the nucleus whereas 
most of Dox-loaded PG3 was still localised in cells cytoplasm. In addition, in 
12hours incubation, PG3-Dox-induced the apoptosis of 23.7% of HepG2 cells, 
whereas only 8.8% of U251 cells did undergo apoptosis. These results could 
confirm that pullulan was able to target HepG2 cells and influence the uptake of 
the carrier which also affected the higher toxicity of HepG2 cells more than 
U251 cells since the determined IC50 in HepG2 treated with PG3Dox at 
different interval of time was much lower than those in U251 cells.  
4.6. Conclusions  
In this study, we have described the feasibility of using the amphiphilic pullulan 
grafted Dendron bearing hydrophobic PBF and BOC groups as a carrier for the 
delivery of anticancer hydrophobic drugs such as Doxorubicin. The loaded PG3-
Dox micelles presented well enough physical characteristic to be able to deliver 
Dox in liver or Brain tumours. The carrier system could rapidly organise into 
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remarkably stable, nanosized micelles that possess some unique physical 
properties, including extremely low CMC and cytotoxicity, excellent pH-
responsive behaviour and micellar stability. Moreover, CLSM and flow 
cytometric analyses further confirmed the efficient uptake via endocytosis of the 
loaded PPLLA-Dox in HepG2 and U251 cells. These results strongly suggest 
that PG3 could be employed to dramatically improve the effectiveness of 
chemotherapy in the low pH tumour microenvironment, while its sustained drug 
release profile would reduce the toxicity effects in healthy cells under normal 





CHAPTER 5. MODIFIED MICELLAR DENDRON FOR 
TARGETED DOX DELIVERY IN VITRO 
 
5.1.  Introduction 
Until today, Hepatocellular carcinoma (HCC) remains the leading cause of 
death among cirrhotic patients, with 782,451 cases diagnosed and 745,533 
deaths in 2012, it is the third cause of cancer-related mortality worldwide (El-
Serag, 2004, Parkin et al., 2005, Gorad, Mandlik and Gujar, 2013, Wong et al., 
2017). Nanoparticle-based drug delivery systems have been developed to treat 
and improve the existing therapies for HCC. Previously in chapter 4, we have 
described the physiological barriers that nanocarriers may face during delivery 
of therapeutic agent into liver tumour cells. Fortunately, there are ways to 
improve nanocarriers safety and to overcome these challenges through the 
passive accumulation of nanocarrier therapeutics and active targeting by 
surface modifications of nanoparticles with specific ligands such as 
carbohydrates, peptides, proteins and antibodies. Nanocarriers can easily reach 
the liver, but it is essential that they target the cell of interest at the same time. 
Thus, the challenge is to obtain a selective accumulation of drugs in one 
specific cell type and to sustain intracellular levels for a more extended period 
(Mishra et al., 2013). Since, hepatocytes consist of 80% of the cells in the liver 
and are the primary cells that play the major functions in term of metabolic and 
secretory activities of the liver, any mutation or malfunction related with these 
cells can result to severe damage of the liver and other diseases (including 
hepatocellular carcinoma). Targeting the hepatocytes cells in the liver would, 
therefore, be an essential strategy for liver cancer therapy and other conditions 
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related to hepatocytes malfunction. It has been reported that improved delivery 
(enhanced localisation) to the parenchyma is achieved with small size delivery 
system that is ≤50 nm which can also diffuse deeper in the space of Disse. 
Moreover, the delivery system of sizes 150nm can avoid Kupffer cells and 
diffuse the sinusoids through the fenestrations and reach hepatocytes plates 
(Ogawara et al., 1999; Allen et al., 1991; Mishra et al., 2013). The size of the 
delivery system therefore always comes into consideration. Furthermore, 
specifically targeting the hepatocytes can be achieved by grafting targeting 
moieties into the delivery systems that can target receptors overexpressed in 
hepatocytes. Receptors that can be targeted in hepatocytes for treatment and 
that constitute a possible pathway of entry mechanisms in these cells are 
asialoglycoprotein receptor (ASGP-R), HDL-R, LDL-R, IgA-R, scavenger R 
(Class BI), transferrin R and insulin R (Harashima, 1994; Mishra et al., 2013).  
The asialoglycoprotein receptors also known as hepatic lectin are the most 
commonly exploited target expressed on the sinusoidal surface of the 
hepatocytes cells and recognises carbohydrates (mainly galactose and N-
acetylgalactosamine) in high affinity. Once the carbohydrate residues bind to 
the carbohydrate recognition domain in the extracellular space of hepatocytes, 
the cells then take up the carbohydrate residues containing molecules via 
receptor-mediated endocytosis and the ligands are then released into 
endosomes-lysosomes by their segregation from the receptor due to the low pH 
in endosomes-lysosomes (Wragg and Drickamer, 1999; Wu, 2002; Mishra et 
al., 2013). Various ligands have been used to target ASGP-receptors including 
galactose moieties (Yan et al., 2017), lactose moieties (Thao et al., 2017), 
Asialofetuin (Detampel et al., 2013), Lactoferrin (Xu et al., 2015), soybean-
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derived sterylglucoside (SG) and polymers such as  poly-(N-ρ-vinylbenzyl-O-b-
D-galactopyranosyl-[1-4]-D-gluconamide(PVLA)) (Watanabe et al., 2000) and 
pullulan (Li et al., 2016).  
5.2.  Aim and objective  
In chapter-4, we demonstrated that the targeting pullulan-based arginine 
dendron nanocarrier could successfully load the hydrophobic DOX and 
efficiently be internalised into liver cancer cells. However, we could not confirm 
that the carrier was internalised via receptor-mediated endocytosis by the 
targeting of pullulan into ASGP-receptor. Similarly, the work of Guhagarkar et 
al. in 2011 evaluating the in vitro ASGPR-mediated uptake of pullulan-
functionalized Dox nanoparticles in HepG2 cell lines showed that in vitro studies 
does not assess thoroughly the ASGPR-mediated uptake of polysaccharide-
based ligands. For this reason, since no one has done this type of work, we 
proposed to modify our PG3 system by adding the ligand lactose to enhance 
the targeting of pullulan for ASGP receptors and therefore increase the overall 
efficiency of the carrier in HepG2 cells by increasing high cellular uptake. 
Lactose is not only used here to improve the targeting of pullulan but also is 
used as the addition of polar groups to yield a higher solubilisation of the 
modified pullulan and therefore increase the micellation process of the 
amphiphile structure. Pullulan is still used here because of its reported tropism 
in liver (Farris, 2014; Yamaoka, Tabata, and Ikada, 1993; Kaneo, 2001), its 
excellent biological and physiochemical features (Ambattu and Rekha, 2015; 
Belbekhouche, 2011). We, therefore, aim in this work: 
- To successfully conjugate lactose into PG3 
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- Improve the active targeting of ASGP receptors in HepG2 cells by the 
lactosilated carrier 
- Improve the passive targeting by reducing the size of the nanocarrier 
- increase the micellation process of the amphiphile structure 
5.3. Methodology 
5.3.1. Dendron synthesis and pullulan azidation  
G3 Dendrons PLLA (BOC/PBF) synthesised and Pullulan azidated containing 
49.02% azide groups were used. Their synthesis details are described in details 
in chapter 3 and 4.  
5.3.2. Conjugation of lactose to azidated Pullulan (P(lactose)N3) 
             
Figure 5-1. The synthesis equation of the azidated pullulan modified lactose. 
 
Firstly, Pullulan bearing the azide groups (0.77g, 1mmol equivalent of 
anhydrous glucoside units) was completely dissolved for 2-3h in 20 mL of 
anhydrous DMSO at 60°C. Lactobionic acid (10.5g, 8mmol), EDC.HCl (3.8g, 
5.4mmol) and DMAP (2.24g, 5mmol) was dissolved in 40mL of anhydrous 
DMSO and stirred at 50–60ºC for 30min under N2 atmosphere to activate the 
140 
 
carboxyl group. To this solution, the PN3 solution was then added dropwise, 
and the dark brown mixture was left to stir for 48hrs at 60°C. Purification of the 
product was achieved by dropping the mixture into 90% of ethanol (300.00 mL) 
under vigorously stirring and then the precipitated product was dialysed against 
DI water (MWCO 3500 Da) for one day. The brown solids appeared in the 
dialysis bag were then collected by lyophilisation. 
5.3.3. Click reaction between pullulan bearing lactose and PLLA 
Figure 5-2. The synthesis equation of pullulan bearing G3 clicked PLLA 
(P(Lac)G3. 
 
The click reaction was carried out with the same method used in chapter 4. 
Briefly, PLLA Dendron G3(2.35 g, 2 mmol) and P(Lac)N3 (0.10 g, 1 mmol) were 
dissolved in 30 mL DMSO under N2 atmosphere at 50 ºC for 1 h. The mixture 
was then brought at RT and passed into argon, then 5. mL of a deoxygenated 
aqueous solution of sodium L-ascorbate (0.08 g, 0.40 mmol) and 5.00 mL of 
copper (II) sulfate pentahydrate (0.05 g, 0.20 mmol) were added successively 
into the reaction. The resultant yellowish mixture was stirred for 55h. After the 
reaction, a little amount of EDTA_2Na was added and left to stir for 2-3h. The 
resulting solution was finally dialysed against DI water for 2 days (MWCO 3500 
Da) and then lyophilised to yield the product Pullulan (Lac) PLLA. 
141 
 
5.3.4. Characterisation  
The characterisation was carried by FTIR and NMR, the details of each method 
are given in chapter 2, and the other experiments were similarly carried as in 
chapter 4.  
5.4. Results 
5.4.1. Characterisation of the lactose conjugated pullulan 
(P(LAC)N3) 
To achieve a liver-targeted system, pullulan modification was further conducted 
by directly conjugating lactobionic acid onto the surface of PN3 via EDC 
chemistry to gain azido-lactosylated pullulan (P(Lac)N3) which was confirmed 
by FTIR and 1HNMR analysis.  
                                              
Figure 5-3. IR spectrum of Pullulan, lactobionic acid and lactose conjugated 
azidated pullulan (P(Lac)N3) showing the ester peak at 1746cm-1. 
 
Figure 5-3 shows 3 spectra of FTIR showing the azidated Pullulan (2), pure 
lactobionic acid and conjugated lactobionic acid into pullulan. The appearance 
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of a sharper peak at 1746 cm1 in the spectra of the P(lac)N3 FTIR was the 
stretching vibration absorbance of C=O in ester bonds which confirmed the 
conjugation between carbonyl groups of the lactobionic acid and hydroxyl 
groups of the pullulan. 
Moreover, the 1HNMR spectrum (Figure 5-4) show the peaks at 4.2 and 4.6 
ppm in (P(Lac)N3 related to the Ha and Hb signals of lactobionic acid moiety, 
respectively. The peaks at 4.8 and 5.0 ppm correspond to the 33 H per 100 
glucose units of pullulan C1 H (1-6) and 66H per glucose units of pullulan C1 H 
(1-4) (Sasaki et al., 2011).  
                                        
Figure 5-4. 1H-NMR (DMSO), d (ppm) of pullulan and P-(lac) N3. 
 
The chemical composition of lactobionic acid in PN3 at C-6 per anhydroglucose 
unit was determined to be 34.45% by assigning the protons of Hd in pullulan and 
the proton of Hb in lactobionic acid. It should be noted that the PN3 used at this 
step contained 49.02% azide groups to allow more chances of lactobionic acid 




5.4.2. Characterisation of the clicked product P(Lac)G3 
The chemical structures of graft copolymers were verified by FTIR (Figure 5-5). 
The click conjugation was confirmed by the disappearance of the azido group 
peak at 2108 cm1 in P(Lac)N3 and all the characteristic peaks of pullulan 
conjugated lactose and of dendron G3 are present in the FTIR of P(Lac)G3.  
                                                                                         
Figure 5-5. FTIR spectrum of azidated lactose bearing pullulan, Dendron of 
generation 3 PLLA and clicked product P(Lac)G3. 
 
Moreover, the 1HNMR spectra of P(Lac)G3 in Figure 5-6 showed a signal at 
7.90 ppm (He) indicating the triazole proton present in the 5-membered 
heteroatom ring formed from the click chemistry. The peaks details are as 
follow: 1HNMR (400 MHz, DMSO-d6):d(ppm), 0.734-1.154 (d, 12H, CH3-PBF, 
G3); 1.546 (s, 24Hh, CH3-BOC-PBF, G3); 1.964-2.103 (s, 12Hg, CH3-PBF, 
G3); 2.410- 2.806 (d, 24 Hf, CH3-PBF, G3); 4.2 (s, 1Hc, OHCHCO, lactobionic 
acid); 4.6 (s, 1Hd, CHCHCO, lactobionic acid); 4.8 (d, 66Hb per 100 glucose 
units, pullulan C1 Hb (1-4); 5.0 (s, 33Ha per 100 glucose units, pullulan C1 Ha 
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(1-6)); 7.90 (s, 1He, NCHCH, triazole ring). Also, the graft level of G3 dendrons 
onto the lactosylated pullulan was 18.51%, according to the integral intensities 
of Hh in G3 dendron and Ha in pullulan.  
Figure 5-6. (A) Chemical structure of P(Lac)G3, and (B) 1HNMR (400 MHz, DMSO-
d6) of pullulan, P(lac)N3 and P(Lac)G3. 
 
5.4.3. The self-assembly of P(Lac)G3 
Similarly to PG3 in chapter-4, bearing the same chemical components like PG3, 
the clicked P(Lac)G3 also consist of an amphiphilic structure that could self-
assemble to form micelles structure in aqueous solution. The size and size 
distribution of P(lac)G3 nanoparticles in DI water presented a lower average 
size (54±8 nm with PDI 0.131) (Figure 5-7). Moreover, the morphology of the 
micelles was determined by TEM and SEM images which shows spherical 
shaped nanoparticles of sizes around 50nm.  
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Figure 5-7. Size distribution and morphology studies of blank of P(Lac)G3 by A. 
DLS, B. TEM and C.  SEM. 
5.4.4. CAC and Stability studies of P(Lac)G3 micelles  
The micellisation behaviour was investigated in aqueous media by fluorescence 
spectroscopy in the presence of pyrene. Figure 5-8 shows an increase in the 
value I337/334 ratio with the increase of the log concentration of micelles and the 
determined CAC value being 8.87µg/mL.  
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Figure 5-8. Critical association concentration of P(Lac)G3 measured using the 
fluorescent dye pyrene. 
 
5.4.5. Drug loading in P(Lac)G3  
P(lac)G3 could be used as a novel nanocarriers for the application in anticancer 
therapy. These nanocarriers were used as drug delivery systems for the 
anticancer drug doxorubicin to try and minimise the drug harmful side effects 
and increase its therapeutic efficacy in liver cancer cells. Dox was successively 
entrapped physically into the hydrophobic core of P(lac)G3 and the amount of 
entrapped doxorubicin and encapsulation efficiency at ratio 5:1, 2:1 and 1:1 was 
calculated using the standard curve of Doxorubicin presented in chapter-4.  








P:DOX (ratio) LC%± Std.dev EE%± Std.dev 
5:1(20%) 16.89±2.41 56.34±4.66 
2:1(50%) 18.99±3.53 46.13±8.70 
1:1(100%) 23.07±1.26 33.04±7.44 
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The loading content was 16.89%, 18.99% and 23.07% whereas the 
encapsulation efficiency was 56.34%, 46.13% and 33.04%, respectively. 
Furthermore, DLS, TEM measurements (Figure 5-9) showed the excellent 
distribution of drug loaded Dox-P(Lac)G3 nanoparticles in aqueous media. An 
increase of the average size of the Dox-loaded P(Lac)G3 nanoparticles was 
observed with a mean of 68 ±9 nm. TEM images showed spherical shaped Dox-
P(Lac)G3 micelles, and self-aggregated micelles observable by SEM were also 
roughly spherical.  
Figure 5-9. Size distribution of Dox-loaded P(Lac)G3 micelles in water 
determined by A. dynamic light scattering; B. TEM and C.SEM.  
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5.4.6. In vitro drug release studies of Dox-P(lac)G3 
nanoparticles 
In vitro drug release of Dox from Dox-P(Lac)G3 nanoparticle was investigated 
at different pH (5.0, 6.8 and 7.4) conditions. As illustrated in Figure 5-10, the 
Dox-P(Lac)G3 nanoparticles had brought about approximately 6 wt% of Dox 
released at pH 7.4 after 62 h.  
      Figure 5-10. The pH-sensitive release of Dox from P(Lac)G3 micelles. 
 
 
The Dox release rate was increased along with the decrease of pH value. The 
cumulative release of Dox showed only a slight increase and reached 10 wt% at 
pH 6.8 at the same timescale. In an acidic pH condition (pH 5.0, mimicking 
endo/lysosomal state), the Dox drug release was much faster than in a 
physiological pH as it showed a quicker release to reach over 25 wt% within 10 
h, continued a sustained release to reach almost 40 wt% after 62 h. 
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5.4.7. Stability of blank and Dox-loaded P(Lac)G3 micelles  
To explore the long-term stability of the Dox-P(Lac)G3, the NPs were 
suspended in DI water, 10% (V/V) FBS diluted with DI water, and DMEM 
containing 10% (V/V) FBS up to 120 h.  
Figure 5-11. (A) DLS results of Dox-P(Lac)G3 nanoparticles after 3 months 
storage in DI water, (B) Image of Dox-P(Lac)G3 nanoparticles in DMEM 
containing 10% (V/V) FBS, (C) Image of Dox-P(Lac)G3 nanoparticles in DMEM 
containing 10% (V/V) FBS, (D) image of lyophilised P(Lac)G3 micelles in powder 
form, (E) DLS results of Dox-P(Lac)G3 nanoparticles after long time incubation in 
DI water, 10% (V/V) FBS and DMEM containing 10% (V/V) FBS, respectively. (F) 
Particle size changes of Dox/LP-g-G3P nanoparticles after dilution of different 
times with DI water, 10% (V/V) FBS and DMEM containing 10% (V/V) FBS, 
respectively. 
 
DLS measurement showed there were few size distribution changes in three 
different media as the time increased even to 120 h (Figure 5-11E), which 
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signified that these three different media did not affect the size distribution and 
PDI of the Dox-P(Lac)G3 nanoparticles. The stability of Dox-P(Lac)G3 
throughout 3months was also investigated. Images in Figure 5-11B, C and D 
are images of the micelles suspension of Dox-P(Lac)G3, P(Lac)G3 in DMEM 
containing 10% (V/V) FBS and lyophilised micelles which were stored at 4ºC for 
3months. The samples showed well-dispersed micelles with no precipitation 
and the size of Dox-P(Lac)G3 was slightly increased to 72.06nm from 68nm 
(Figure 5-11A).  
5.4.8. Cytotoxicity of Dox.HCl, blank and loaded Dox-P(Lac)G3 
Toxicity of the Blank P(Lac)G3 NPs were investigated in both HepG2, and 
NIH3T3 cell by CCK8 assay (Figure 5-12B) whereas measurement by SRB 
assay was done for HepG2, Hek293 and NIH3T3 cell lines (Figure 5-12A).  
Figure 5-12. Biocompatibility assay of (A) HepG2, Hek293 and NIH3T3 cells 
against blank P(Lac)G3 nanoparticles for 24h by the SRB assay and (B) HepG2 





Results show that both assays produce similar cell viability percentage values 
which demonstrate that SRB assay can be used as an alternative to CCK8 
assay. Also, both assays showed no significant cytotoxicity (viabilities remained 
above 80%) of blank P(Lac)G3 observed in HepG2, Hek293 and NIH3T3 cell 
lines even at a higher concentration up to 100-200 µg/mL.  
       
Figure 5-13. Dose-dependent cytotoxicity of (A) HepG2 and (B) NIH3T3 cells 
against Dox-P(Lac)G3 nanoparticles and free Dox.HCl solutions for 24 h. (C) 
Enhanced cytotoxicity of the Dox-P(Lac)G3 nanoparticles in HepG2 cells for 
varying time periods. (D) Cell viability against HepG2 and NIH3T3 cells incubated 
with the Dox-P(Lac)G3 nanoparticles at the Dox equivalent 0.5 µg/mL for different 
time intervals (n = 6, **p < 0.05 by two-way ANOVA, followed by Tukey’s post-hoc 
test). 
 
Moreover, Viability of cells treated with Dox.HCl was also investigated using 
CCK8 and SRB assay for 24hours. HepG2 and NIH3T3 cells were ASGPRs 
and RCA120 positive and negative cells, respectively.  
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Figure 5-14. The in vitro cytotoxicity by SRB assay of Dox.HCl and Dox-P(Lac)G3 
after 24, 48, 72 and 96 hours of incubation against A. NIH3T3 cells; B. Hek293 




In both assays (Figure 5-13A&B and Figure 5-14A&C), cytotoxicity was 
concentration dependent and increased with increasing Dox concentration for 
both free Dox.HCl solution and Dox-P(Lac)G3 nanoparticles treated HepG2 and 
NIH3T3 cells.       
Table 5-2. Calculated IC50 values of free Dox.HCl and Dox-P(Lac)G3 in HepG2, 













CCK8 SRB CCK8 SRB SRB 
 
24h  
Dox.HCl 0.046 0.084 0.129 0.258 5.754 
Dox-
P(Lac)G3 
0.675 0.847 1.701 2.153 9.763 
 
48h  
DOX.HCl - 0.058 - 0.234 4.267 
Dox -
P(Lac)G3 
0.507 0.475 - 0.976 7.489 
 
72h 
Dox.HCl - 0.049 - 0.165 3.588 
Dox -
P(Lac)G3 
0.242 0.317 - 0.856 6.358 
 
96h  
Dox.HCl - 0.041 - 0.069 0.943 
Dox -
P(Lac)G3 
0.162 0.195 - 0.469 5.699 
*Important note: The CCk8 assay was only carried out in HepG2 and NIH3T3 cell 
lines and at an only particular time for publication purpose.  
 
Similarly, the IC50 (the concentration that caused 50% cell death) value was 
also obtained with Dox concentration varied from 0.001 to 200 µg/mL. The IC50 
of the free Dox.HCl solution and Dox-P(Lac)G3 nanoparticles determined by 
CCK8 were calculated to be 0.046 µg/mL and 0.675 µg/mL, respectively in 
HepG2 cells, while 0.129 µg/mL and 1.701 µg/mL, respectively, were calculated 
for NIH3T3 cells. In comparison, the IC50 determined by SRB were calculated 
to be 0.084 µg/mL and 0.847 µg/mL, respectively, in HepG2 cells whereas 
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0.258 µg/mL and 2.153 µg/mL, respectively, were obtained in NIH3T3 cells 
(table 5-2). Cell viability analysis by both SRB and CCK8 showed that the 
cytotoxicity of the Dox-P(Lac)G3 nanoparticles in HepG2 cells was time-
dependent as well. The IC50 values by CCK8 (SRB) assays after 1, 2, 3 and 4 
days were 0.675 (0.847), 0.507(0.475), 0.242 (0.337) and 0.160(0.307) µg/mL, 
respectively. Meanwhile, cytotoxicity of Dox.HCl and Dox-P(Lac)G3 by SRB 
assay were determined in Hek293 and NIH3T3 cells lines after 1,2,3 and 4 days 
(Figure 5-14A&B). The IC50 values given in table 5-2 were very high for 
Hek293 cells and NIH3T3 cells compared to HepG2 cells which implied that the 
Dox-P(Lac)G3 nanoparticles had a better affinity toward the HepG2 cells and 
could kill the tumour cells. 
5.4.9. Cellular internalisation by Flow cytometry and confocal 
studies 
It is likely that lactosylated pullulan serving as the hydrophilic shell of P(Lac)G3 
nanoparticles could facilitate liver-targeted delivery. To preliminarily investigate 
the cellular internalisation efficiency of the Dox-P(Lac)G3 nanoparticles, 
confocal laser scanning microscopy and flow cytometry were performed. Free 
hydrophilic Dox.HCl solution and Dox-P(Lac)G3 nanoparticles with an 
equivalent amount of Dox (5 mg/mL) were added to exponentially growing cells 
for 0.5, 1 or 6 h. As presented in Figure 5-15, after 0.5h, both Dox. HCl and 
Dox-P(Lac)G3 treated cells exhibited some weak red signals in the cytoplasm, 
whereas for the time increased to 1 and 6h, the cells treated by Dox.HCl 
already presented very strong signals inside the nucleus in addition to a very 
weak fluorescence in the cytoplasm. The Dox-P(Lac)G3 treated cells instead 
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showed speckled red dots throughout the cytoplasm for all 6 hours incubation 






Figure 5-16. The cellular uptake by Flow Cytometry of Dox.HCl and PG3(lac)-Dox 
nanoparticles at 0.5, 1 and 6 hours in HepG2 cells. The Flow cytometry 
histograms are represented in 2 ways: first top 2 histogram plots represent 
separate plots of the changes in fluorescence intensity of Dox.HCl treated HepG2 
cells (peaks in purple) and Dox-P(Lac)G3 treated HepG2 (peaks in yellow) over 
time whereas the 3 bottom plots compare the fluorescence intensity of Dox.HCl 
and Dox-P(Lac)G3 treated HepG2 cells at each time intervals. Untreated HepG2 
cells were also used as control (peaks in red). 
 
The flow cytometry (Figure 5-16) also indicated that the hydrophobic Dox was 
successfully transported into cells by being loaded in Dox-P(Lac)G3 
nanoparticles as the fluorescence intensity was increased with time. 
5.4.10. Apoptosis studies 
To further demonstrate that Dox was effectively released from P(Lac)G3 
nanocarriers, the carriers containing Dox were treated with HepG2 cells to 
investigate if they could induce apoptosis. 
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Figure 5-17. The effect of free Dox.HCl and Dox-P(Lac)G3 on the induction of 
apoptosis in HepG2 cells.  Tumour cells were quantified by flow cytometric 
analysis of Annexin V FITC staining in tumour cells following 12h treatment with 
5µg/mL equivalent Dox concentration. The lower left (LL) quadrant represents 
live/healthy cells, the lower right (LR) quadrant represents early apoptosis, and 
the upper right (UL) represents cells in late apoptosis, while the upper left (UR) 
represents the percentage of Dox uptake/dead cells. The percentage of cells 
undergoing early or, late apoptosis is indicated in the respective quadrate.  
 
The total apoptotic ratio of Dox.HCl was 29.7% obtained by summation of the 
early apoptotic ratio of 23.3% and the late apoptotic ratio of 6.4%, which was 
higher than that obtained with Dox-P(Lac)G3 being 23.7%. 
5.5. Discussion  
Herein, we have successfully synthesised the amphiphilic lactobionic acid 
modified pullulan bearing hydrophobic arginine dendrons P(Lac)G3 which was 
prepared similarly to PG3 (chapter-4) using azide-alkyne click chemistry 
between hydrophilic lactosylated pullulan and PLLA. The azidated pullulan 
containing 49.02% of N3 per unit was first modified by the addition of lactobionic 
acid through an esterification reaction between the non-azidated OH group of 
pullulan and carboxyl COOH group of lactobionic acid to form the ester 
P(Lac)N3.  Esterification of pullulan has previously been achieved by few 
methods available in literature using acetyl chloride with pyridine, acetic 
anhydride, pyridine and 4-dimethylaminopyridine, carboxylic acids in situ 
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activated with tosyl chloride, N, N-Dicyclohexylcarbodiimide and 4-
dimethylaminopyridine, iminium chloride and 1,1-carbonyldiimidazole and acetic 
anhydride activated with strong acids or metallic catalysts (Teramoto and 
Shibata, 2006, Kumareswaran, Gupta and Vankar, 1997, Hussain et al., 2010, 
Zhang et al., 2009). We have demonstrated the simple esterification process of 
lactiobionic acid into pullulan using EDC.HCl and DMAP which resulted in high 
yield and conjugation of 34.45% per unit. 18.51%/unit of arginine dendrons 
were then successfully clicked to the azidated lactose bearing to form an 
amphiphilic nanocarrier. The amphiphilic system could self-assemble to form 
well polydisperse micelles with great stability profile (54nm in size and CAC 
value of 8. 87µg/mL). Compared to PG3, P(LAC)G3 was made of 1.81% less 
hydrophobic moieties and higher hydrophilic backbone (due to the lactosylated 
pullulan) resulting in much lower particle size (PG3 of 87.07nm whereas 
P(Lac)G3 is of 54nm). The self-assembly of these amphiphilic systems is driven 
by the weak non-covalent intermolecular forces including the hydrophobic 
interactions (within BOC/PBF groups) and π-π interaction (within phenyl 
groups) which attract each dendron molecules to aggregate together minimising 
their contact to water molecules while optimizing the repulsion between the 
hydrophilic pullulan or lactosylated pullulan. The repulsive interaction is due to 
electrostatic or steric repulsion between the hydrophilic molecule which stays in 
contact with water. Unexpectedly, the extreme lower particle size reduction of 
P(Lac)G3 compared to PG3 could possibly due because of a higher hydrophilic 
periphery of the micelle enhancing a tighter hydrophobic core since it is known 
that the self-assembly of amphiphilic structures can be varied by controlling the 
ratio of hydrophilic and hydrophobic segments (Xia et al., 2017). Moreover, Ree 
et al. in 2017 also report the stabilisation of micelles by altering the ratio of 
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hydrophilic and hydrophobic blocks; the authors report that in contrast to a 
simple hydrophilic linear polymer backbone, hydrophilic bristles possess the 
ability to stabilise the micelle corona structurally. Therefore, we deduce that the 
addition of lactobionic acid into pullulan has extensively increased its overall 
hydrophilicity. It has also been reported that an increase in the length of the 
hydrophilic block is associated with an increase in the CMC (Rosen et al., 1982, 
Kulthe et al., 2012). However, P(Lac)G3 had a CAC value of 8.87µg/mL which 
was lower than that of PG3, this shows that the increased hydrophilicity did not 
affect the stability of micelles maybe because the targeting moieties are added 
on the surface of few units of the polymer and is not related with the polymer 
lengthening. To investigate if P(Lac)G3 could improve the targeting of HepG2 
cells, the hydrophobic drug Dox was incorporated into P(Lac)G3. PG3 contain a 
larger number of Hydrophobic segments, therefore, has a larger core size 
resulting in a greater ability to entrap hydrophobic drugs (Kulthe et al., 2012). 
The size of loaded P(Lac)G3 is only 68nm which shows that these nanocarriers 
have the most desirable size to deliver therapeutic agents into cancerous liver 
cells. It is known that in general, micelles with sizes between 20 and 50 nm can 
efficiently enter cancerous tissues through the openings of loosely packed 
cancer cells via the EPR effect (Danhier, Feron and Préat, 2010, Ree et al., 
2017). Therefore, P(Lac)G3-Dox of sizes 68nm would not only reach a tumour 
passively but would easily avoid Kupffer cells uptake, diffuse deeper in the 
space of Disse and diffuse the sinusoids through the fenestrations and reach 
hepatocytes plates to target them actively. In vitro release studies of Dox from 
Dox-P(Lac)G3 nanoparticles also showed a sustained release behaviour which 
could be the advantageous feature in therapy: the primary high drug release (25 
wt% within 10h) provides an initial dose, followed by a sustained release.                       
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Furthermore, owing to the dilution that can be caused by the bloodstream when 
the Dox-P(Lac)G3 nanoparticles are injected into the body, the nanoparticles 
would suffer from the dissociation of self-assemblies leading to the premature 
release of the loaded drug. Therefore, we explored the stability of the Dox-
P(Lac)G3 nanoparticles against dilution with three different media. As shown in 
Figure 5-11F, there were no obvious changes in three media even after 500-fold 
dilution, which implied the Dox-P(Lac)G3 nanoparticles had good stability 
against dilution. To preliminarily investigate the tumour cellular effect of the 
Dox-P(Lac)G3 nanoparticles, cell viability by CCK8 and SRB assays, confocal 
laser scanning microscopy, flow cytometry and apoptosis assays were 
performed. The toxicity of Dox-P(Lac)G3 in HepG2 cells carried by SRB assay 
was much higher than that of PG3-Dox at 24h and 48h (IC50 for Dox-PG3 and 
Dox-P(Lac)G3 was 1.765 and 0.847 µg/mL, respectively at 24h and 1.246 and 
0.475 µg/mL, respectively at 48h). Whereas at 72 and 96h, the IC50 were 
nearly identical (0.276 and 0.317 µg/mL, respectively at 72h and 0.174 and 
0.195 µg/mL, respectively at 96h). Since the high rate of release of Dox from 
the carriers more likely takes place inside the endosome-lysosome (low pH 
environment) compartment after internalisation of the loaded carriers, the 
toxicity results indicate that the HepG2 cells internalise quicker the Dox-
P(Lac)G3 nanoparticles which then have a quicker toxic effect compared to 
Dox-PG3 nanoparticles. Ghagada et al. in 2005 carried out a study were the 
factors influencing the uptake of folate-based liposomal in FR-expressing cells 
was observed. These factors were reported to be the ligand number, exposure 
time and carrier concentration. Increasing the incubation time increased the 
uptake for liposomes containing a low number of ligands whereas liposomes 
with a high number of ligands reached saturation rapidly decreasing the uptake 
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rate. The authors further reported that the internalisation process in cells is 
slower than the binding process of liposomes to the cell surfaces. However, in 
our study, we observed that the increase of ligands by the addition of 
lactobionic acid in pullulan increased the toxicity in HepG2 cells which may be 
related to increased uptake rate of P(Lac)Dox, therefore, resulting in higher 
toxicity. But the analysis of internalisation by confocal and flow cytometry does 
not correspond to these observations since the distribution of Dox after 0.5, 1 
and 6h in treated Dox-PG3 and Dox-P(Lac)G3 HepG2 cells does not differ and 
treated cells by both loaded systems exhibited same amount of fluorescence 
intensity after incubation at 0.5, 1 and 6h (refer to chapter 8).  
5.6. Conclusion  
In summary, we have successfully developed an original amphiphilic 
glycopolypeptide analogue, lactosylated pullulan-graft-arginine dendrons 
(P(Lac)G3) that could form core-shell nanoassemblies with an average 
diameter of about 54 nm by the fine-tuning of intra- and intermolecular 
interactions which could also provide a safe and spacious harbour for the 
hydrophobic drugs. Blank P(Lac)G3 nanoparticles exhibited excellent 
biocompatibility both in the normal and tumour cells, whereas Dox-loaded 
P(Lac)G3 NPs could be effectively internalised into the hepatoma carcinoma 
cells and dramatically inhibited cell proliferation. Thus, this study produced a 
liver targeting nanocarrier of excellent size distribution with higher toxicity effect 
to HepG2 cells in comparison to PG3 loaded Dox nanocarriers. Also, we 
demonstrated that varying the ratio between hydrophilic segment to 
hydrophobic segments within micelles could improve their size which is the 
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primary physical characteristic of a nanocarrier system for the delivery of 




CHAPTER 6. CO-DELIVERY OF DOXORUBICIN AND 
CURCUMIN USING REDOX-BASED MICELLAR 
DENDRONS 
 
6.1. Introduction  
Within the last decade, persistent efforts have been made in the development of 
stimuli-responsive drug delivery systems that can, when exposed to intracellular 
stimuli, produce physicochemical changes that favour drug release at the target 
site. We have introduced in chapter 1 the different types of biological stimuli that 
have been exploited for triggered drug release including temperature (Zhan et 
al., 2015), pH (Ma et al., 2015), magnetic field (Qin et al., 2009), redox potential 
(Li et al., 2009), enzymes (Li et al., 2014) or two parameters at the same time 
(Chen et al., 2013). Among these, redox stimuli-responsive nanocarriers 
characterised by disulphide bonds in the main chain, at the side chain or in the 
crosslinker for enhanced intracellular drug release has attracted more and more 
attention (Wang et al., 2014). This attention is driven by the great difference in 
the redox potential between the mildly oxidising extracellular milieu and the 
intracellular reducing milieu which are even higher in cancerous cells (Jhaveri, 
Deshpande and Torchilin, 2014, Wang et al., 2014). The reducing environment 
in the intracellular compartment is due to the presence of higher levels of the 
glutathione tripeptide (γ-glutamyl-cysteinyl-glycine) (GSH) in the cytosol and 
subcellular compartments (approximately 2–10 mM), which are about 100–1000 
times higher than in the extracellular compartment (approximately 2–
20 μM) (Schafer and Buettner, 2001, Li et al., 2012, Jhaveri, Deshpande and 
Torchilin, 2014). GSH can reduce disulphide bonds and is reported to be at 
several times higher concentrations in tumour tissues compared with normal 
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tissues (Wang et al., 2014, Li et al., 2012). Moreover, there are other types of 
source of redox reduction besides GSH in the intracellular compartments. 
These include thioredoxin reductase and cysteines present in lysosomes. The 
cysteines keeps  low mass iron in the reduced state (Fe2+) in the acidic 
compartment and therefore increases the lysosomal redox potential, also, 
cysteines assist the disulfide cleavage in endosomes (Söderberg, Sahaf  and 
Rosén, 2000; Kurz, Eaton and Brunk, 2010; Cheng et al., 2011; Li et al., 2012; 
Jhaveri, Deshpande and Torchilin, 2014). Many carriers have been developed 
using redox-responsive materials for the delivery of chemotherapeutic agents 
and have also been used in combination therapy as well, more specifically for 
the co-delivery of therapeutic agents (Jhaveri, Deshpande and Torchilin, 2014). 
Co-delivery systems are new methods developed that are capable of 
simultaneously transporting and releasing multiple therapeutics at a disease 
site. When a single therapeutic fail, treatment with 2 or more therapeutics at the 
same time can succeed. A main example of co-delivery involves targeting multi-
drug resistance (MDR) pathways (details in chapter 1) either through 
transporter inhibitors or targeting of MDR genes, while also delivering a 
chemotherapeutic. Many researchers have focused on the enhancement of 
Doxorubicin delivery by the co-delivery of Dox with Combrestatin, verapamil, 
cyclophosphamide, paclitaxel, P-gp siRNA, survivin mutant gene and p53 
antitumor gene to overcome drug resistance, increase its accumulation in 
tumour cells and the permeability in tumour microvessels (Dai et al., 2012; Wu 
et al., 2007; Ishida,  Shiraga, and Kiwada, 2009;  Wang et al., 2011; Meng et al., 
2010; Xiao et al., 2010; Zhao et al., 2012; Godsey, Suryaprakash, and Leong, 
2013). Furthermore, inhibition of p-gp-dependent drug efflux activity has shown 
to be achievable using the natural compound curcumin (CHANG et al., 2013; 
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Bar-Zeev, Livney and Assaraf, 2017). Curcumin, isolated from turmeric is a poor 
water-soluble compound that possesses anticancer and anti-inflammatory 
activity which are both critical for the suppression, formation and progression of 
cancer (Bar-Zeev, Livney and Assaraf, 2017; Basniwal, Khosla and Jain, 2014). 
Rivera-Espinoza and Muriel in 2009 have reported the possible ability of 
curcumin to cure and ameliorate hepatic disorders since curcumin has the 
ability to inhibit factors such as nuclear factor-kB, has anti-oxidant properties, 
can attenuate liver injury induced by ethanol, thioacetamide, iron overdose, 
cholestasis and acute, subchronic and chronic carbon tetrachloride (CCl4) 
intoxication; moreover, it reverses CCl4 cirrhosis to some extent. 
Structural Characteristics of Curcumin 
Curcumin also known as diferuloylmethane ((1E,6E)-1,7-bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione) has a chemical formula of C21H20O6, 
and molecular weight of 368.38.  
                                  
Figure 6-1. Chemical structure of curcumin (Priyadarsini, 2014). 
 
The structure of curcumin consists of two aromatic ring systems containing o-
methoxy phenolic groups, connected by a seven carbon linker consisting of an 
α,β-unsaturated β-diketone moiety. Curcumin can be in different isoforms 
depending on the environment. Mostly it is in crystal form either as cis-enol and 
keto form. It is a hydrophobic molecule with a log P value of ~3.0 which is 
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soluble in DMSO, methanol, ethanol, acetonitrile, chloroform, ethyl acetate, etc., 
and therefore curcumin has shown to have a low bioavailability when 
administrated orally or intravenously (Priyadarsini, 2014; Yallapu, Jaggi and 
Chauhan, 2012). For this reason, researchers have been working on solving the 
limiting factors of curcumin by improving its bioavailability, protecting its 
degradation and metabolism and by increasing its targeting capacity into tumour 
cells via its incorporation into a different type of nanoparticles (Yallapu, Jaggi 
and Chauhan, 2012).  
6.2.  Aims and objective 
In this work, we aim to improve the release rate of pullulan modified arginine 
dendron PLLA by adding a reductive disulphide linkage between pullulan and 
the hydrophobic dendron to form PSSG3. As we previously could not identify 
any difference between the internalisation of PG3 and P(Lac)G3 into HepG2 
cells. We choose here to keep it simple and produce pullulan modified G3 
nanocarriers via a disulphide linkage which can stay stable at oxidising 
extracellular conditions but undergoes rapid breakdown or thiol-disulfide 
exchange in the presence of reducing agents like GSH in the intracellular 
compartment of liver cancer cells. Moreover, previous studies have shown that 
hepatocellular carcinoma cells exhibit increased resistance against re-treatment 
of Doxorubicin (Buschauer et al., 2018), therefore to improve the anti-cancer 
toxicity effect of loaded Dox nanocarriers compared to free Dox.HCl, the two 
hydrophobic drugs curcumin and Doxorubicin were chosen here to be loaded at 
the same time into PSSG3 to form overall a co-delivery system. Curcumin not 
only is a cheap natural anticancer drug but also could enhance the antitumor 
efficiency of Doxorubicin in HepG2 cells.  We, therefore, aim in this study to: 
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- successfully synthesise and characterise the pullulan modified G3  
bearing a disulphide leakage (PSSG3),  
-  investigate the self-assembly, morphology and stability of PSSG3, 
- investigate the loading and encapsulation efficiency of doxorubicin 
(PSSG3-Dox), curcumin (PSSG3-cur) and both doxorubicin and 
curcumin in PSSG3 (PSSG3-Dox/Cur),  
- investigate the in vitro toxicity of PSSG3, PSSG3-Dox, PSSG3-cur and 
PSSG3-Dox/Cur against HepG2, NIH3T3 and Hek293 cells,  
- Investigate the ability to uptake the doxorubicin and curcumin loaded 
nanoparticles into HepG2 cancer cells.  
6.3. Methodology  
6.3.1. Dendron synthesis 
Hydrophobic G3 Dendrons PLLA (PBF/BOC) synthesised was used in this 
study. Their synthesis details are described in chapter 3.  
6.3.2. Addition of disulphide bond to Pullulan (P-SS-COOH) 
Figure 6-2. Synthesis equation of disulfide-linked pullulan PSS-COOH. 
 
Briefly, pullulan (1mmol) dissolved in 25ml of DMSO was added to a 50mL 
solution of a mixture of DTDPA (8mmol), EDC.HCl (5.4mmol) and DMAP 
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(5mmol) in DMSO. The reaction was left to stir for 2 days at 50-60 ̊C under N2 
atmosphere. The solution turned to dark brown within a day.  
The solution was then dropped (dropwise) into 90% of ethanol (300ml) under 
vigorous stirring, and the precipitated product was dialysed against distilled 
water (MWCO 35000) for a day. The brown solids appearing in the dialysis bag 
were then collected by lyophilisation. 
6.3.3. Azidation of disulphide modified pullulan (PSS-N3) 
To yield PSS-N3, the carboxyl groups of the product PSS-COOH were reacted 
with the amine group of 3-azido propargylamine by a condensation reaction.  
   
Figure 6-3. Synthesis equation of azidated disulfide linked Pullulan (PSSN3). 
 
First, P-SS-COOH (0.35g, 1mmol) was first dissolved in 50ml MES buffer and  
25ml of DMSO (0.1M, PH6). Then EDC (0.13g, 0.668mmol) and NHS (0.08g, 
0.668mmol) were added, and the mixture was left to stir at 4°C for 4hrs in the 
absence of O2 to activate the carboxyl groups. 3-azidopropylamine (0.1g, 
1mmol) was lastly added, and the reaction mixture was left to stir for 36h at RT.  
The resulting yellowish solution was dialysed against water to remove 
unreacted agents (MWCO 3500) for 2 days. Finally, the PSSN3 solution was 
lyophilised and stored at 4 ̊C until further use.  
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6.3.4. Click reaction between PSSN3 and PLLAG3 dendron 
 
Figure 6-4. Synthesis equation of disulphide pullulan modified G3 bearing a 
disulphide leakage (PSSG3). 
 
The PSSG3 was obtained by click reaction in a similar way as PG3 and 
P(Lac)G3 formation (details in chapter 4 and 5).  
6.3.5. Characterisation  
The characterisation was carried by FTIR and NMR, details of each method is 
given in chapter 2 and the other experiments were similarly carried as in 
chapter 4 and 5.  
6.4. Results  
6.4.1. Characterisation of the PSS-COOH and P-SS-N3 
conjugates 
Addition of the disulphide bond into Pullulan was synthesised by condensing the 
carboxyl acid group of 3, 3`-dithiodipropionic acid and the hydroxyl group of 
Pullulan. After the addition of DTDPA into pullulan, the terminal COOH group 
from DTDPA were then reacted with the amine group of 3-azidopropylamine to 
form an amide bond-containing product with a terminal azide group. Figure 6-5 
shows the FTIR spectrum of the successful conjugation of DTDPA which is 
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confirmed by the characteristic absorption band at 1732 cm1 indicating the 
carbonyl group (C=O) stretching vibration of the ester group (Li et al., 2014).  
Moreover, the azido group added to the disulphide linkage was also confirmed 
by the appearance of the strong absorption peak at 2111 cm1 which 
corresponds at the N3 group of the 3-azidopropylamine.  
                       
Figure 6-5. FTIR spectrum of pure pullulan, pullulan-SS-COOH and Pullulan-SS-
N3 conjugates.  
 
The successful conjugation of DTDPA in pullulan was also confirmed by 
1HNMR. Figure 6-6. shows the 1H-NMR spectrum in which the characteristic 
peak of pullulan and DTPA are identified and matches with that of published 
data (Akiyoshi et al., 1993; Yang et al., 2014; Sivakumar and Panduranga Rao, 
2003). The proton identified are 2.66 ppm (4H, m, a-H2,DTPA), 2.71 (4H, m, b-
H2,DTPA), 2.99-3.94 ppm (4H, glucose C2, C3, C4, and C5,Pullulan), 4.42-
5.75ppm (glucose,–OH, Pullulan), 4.66 ppm (1H, s, 1-glucose α-1,6, Pullulan), 
5.00 ppm (1H, s, 2-glucose α-1,4, Pullulan). The degree of substitution of 
DTDPA in pullulan (DS; number of DTPA residues per 100 glucose units in 
172 
 
pullulan) was determined to be 16% by calculating the ratio of methylene group 
protons of DTDPA (2.66 ppm) to sugar protons of pullulan (C1 position of a-1,6 
and a-1,4 glycosidic bonds, 4.66 and 5.00 ppm).  
Figure 6-6.  1H-NMR spectrum of pullulan and Pullulan-SS-COOH conjugate. 
 
6.4.2. The self-assembly of PSSG3 and their stability studies  
The successful conjugation of dendrons G3 (PBF/BOC) linked via disulphide 
bond in pullulan (PSSG3) was confirmed by the fact that PSSG3 could self-
assemble into spheroidal nanoparticles of size 68.1nm as figure 6-7A&B shows. 
Moreover, the PSSG3 exhibited great stability throughout 3-month storage. In 3 
months, no significant change in size was observed showing that the NPs 
retained their micellar structure. Moreover, in the presence of 10mM DTT, the 
nanoparticles exposed in DTT for 24hours showed that the disulphide linkage 
breaks resulting in various increased size distribution with a mean of 615nm.  
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Figure 6-7. Size distribution and morphology studies of the blank PSSG3. DLS 
images at 0h (in red), after 3 months storage (in purple) and in the presence of 
10mM DTT for 24hrs (in Blue) (A), SEM images at 0h (B) and TEM images at 0h 
(C). 
High stability of the micelles PSSG3 was further confirmed by their low critical 




Figure 6-8. Critical association concentration of PG3 measured using the 
fluorescent dye pyrene. 
 
 
6.4.3. Drug loading into PSSG3 nanocarriers  
Since PSSG3 showed good stability profile, the carrier capability of loading 
hydrophobic drugs was investigated. Doxorubicin and Curcumin were loaded 
individually and in combination into the PSSG3 carrier. The loading and 
encapsulation efficiency were determined using the line of equation of the 
standard curve of doxorubicin being y=5.0939x-0.5728 (chapter 4) and the line 
of  equation of the standard curve of doxorubicin being y=0.1252x-0.0541. 
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Figure 6-9. A standard curve of curcumin determined at 425nm. 
 
Drug loading was carried out at a ratio of 5:1 (PSSG3: Dox or Cur or Dox/Cur). 
Table 6-1 shows that the drug loading and encapsulation efficiency of Dox into 
PSSG3-Dox is 18.14% and 59.74 %, respectively which is higher than that from 
PSSG3-Dox /cur being 15.59% and 57.80%, respectively. Similarly, the drug 
loading and encapsulation of curcumin from PSSG3-Cur is 19.21% and 
91.44%, respectively, which was also higher than that from PSSG3-Dox/cur 







Table 6-1. Drug loading content (LC) and encapsulation efficiency (EE) of Dox 
and Cur in PSSG3 nanocarriers  
 
   P:Dox:Cur                              
      Ratio 
Doxorubicin Curcumin 
5:1:1 (20%)         LC%±std 
dev 
EE%±std dev LC%±std 
dev 
EE%±std dev 
PSSG3-Dox 18.14±3.50 59.74±7.44 N/A 
PSSG3-cur N/A 19.21±3.01 91.44±1.11 
PSSG3-Dox/cur 15.59±5.30 57.80±4.73 17.01±2.13 88.72±2.00 
 
The size and morphology of the various drug-carrier conjugates were also 
investigated. The sizes of PSSG3-Dox was 91.28nm with similar size seen by 
SEM images (Figure 6-10B), and red spherical small particles are visible in 
fluorescence microscopy. However, a slightly increased to 118.46nm in size 
was observed after 3 months, which is maybe due to the slow release of the 
drug in normal PBS conditions. In the presence of 10mM DTT, broad size 
distribution is observed indicating the distribution of the free drug and 
disassembled carrier sizes.  
The morphology and size distribution of the loaded curcumin into PSSG3 
(Figure 6-11) are similar to that of PSSG3-Dox. The mean size is 78.82nm at 
0h, which increases to 164.18nm after 3 months, and in the presence of DTT, 
the size distributions increase from 274.92nm to over 955.64nm. The greenish 
fluorescence inside the nanocarrier is also visible under fluorescence 
microscope showing the spherical morphology of the loaded PDDG3-Cur. 
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Figure 6-10. Size distribution and morphology studies of PSSG3-Dox. DLS 
images of at 0h (pink), after 3 months storage (Blue) and in the presence of 
10mM DTT for 24hrs (green) (A), SEM images at 0h (B) and fluorescence 




Figure 6-11. Size distribution and morphology studies of PSSG3-Cur. DLS 
images of at 0h, after 3 months storage and in the presence of 10mM DTT for 
24hrs (A), SEM images at 0h (B) and microscopic fluorescence images at 0h(C). 
 
Furthermore, Figure 6-12 shows that the PSSG3-Cur/Dox has a mean size 
distribution of 112.9nm, which also disassemble in the presence of 10mM DTT 
to particles of sizes bigger than 624.92nm. The SEM images further confirm the 
disassembly of the carrier as the PSSG3-Cur/Dox at 0h exhibited spherical 
morphology (Figure 6-12B) whereas after being exposed to DTT, irregular 
shapes (Figure 6-12C) corresponding to the disintegrated particles.  
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Figure 6-12. Size distribution and morphology studies of PSSG3-Dox/Cur. DLS 
images at 0h, after 3 months storage and in the presence of 10mM DTT for 24hrs 
(A), SEM images at 0h (B) and SEM images in the presence of 10mM DTT for 
24hrs(C). 
6.4.4. In vitro drug Release studies of PSSG3-Dox (or cur or 
cur/Dox) nanoparticles 
The reduction triggered drug release from PSSG3-Dox, PSSG3-Cur and 
PSSG3-Dox /Cur micelles were evaluated under 10mM DTT condition at pH 7.4 
and pH 5.0. Figure 6-13 shows the release curve of Dox from PSSG3-Dox and 
PSSG3-Dox /Cur in the presence and absence of 10mM DTT. The release of 
Dox from both carriers shows a significant accelerated release by the addition 
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of DTT to the release media. Both micelles loaded drugs released nearly 70% 
of drug Dox in the first 12h under 10mM DTT followed by a sustained release in 
the subsequent time until 60.5h. Compared to the release at pH 7.4 conditions 
without DTT, only 13% was released from both carrier formulations. 
Furthermore, since Dox can protonate under acidic conditions, investigation of 
Dox release from both formulations was investigated under pH 5.0. A fast 
release of Dox reached 46% within the first 12 hours also followed by a 
sustained release reaching 57% of Dox release for a period of 60.5h.  
Figure 6-13. Cumulative release profiles of Dox from PSSG3-Dox and PSSG3-
Dox/Cur at pH 7.4 (with and without 10mM DTT) and pH 5.0 in a period of 
65hours.  
 
The release of Curcumin from PSSG3-Cur and PSSG3-Dox/Cur was also 
investigated. The curcumin present in PSSG3-Dox/Cur nanoparticles displayed 
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68% of curcumin was released at 12h followed by a sustained release reaching 
87% of released curcumin. Also, in acidic conditions, 42% of curcumin from 
PSSG3-Dox/cur was released at 12h compared to the release of curcumin at 
pH7.4 where only 25% of curcumin is released for a period of 60.5h.  
Figure 6-14. Cumulative release profiles of curcumin from PSSG3-Cur and 
PSSG3-Dox/Cur at pH 7.4 (with and without 10mM DTT) and pH 5.0 in a period of 
60.5hour. 
 
In comparison, to the release of curcumin from PSSG3-Dox/Cur, curcumin 
release from PSSG3-Cur was slower releasing 50% of curcumin at 12h under 
DTT conditions. Similarly, in acidic conditions (pH 5.0), at 2.5h, the released 
curcumin from PSSG3Dox/Cur is almost double (23%) than the release in 




































PSSG3-Dox/Cur, 10mM DTT, pH 7.4
PSSG3-Dox/Cur, pH 7.4
PSSG3-Dox/Cur,  pH 5.0





significant difference between the curcumin percentage released from PSSG3-
Dox/Cur (25%) and PSSG3-cur (23%).  
6.4.5. Cytotoxicity                                                                                                                   
The anticancer effect of PSSG3-Dox, PSSG3-Cur and PSSG3-Dox/Cur was 
tested against HepG2, NIH3T3 and Hek293 cells. Free Dox, free curcumin and 
blank PSSG3 micelles were used as controls. As seen in Figure 6-15. the blank 
PSSG3 did not exert any toxicity towards any of the cells tested. On the other 
hand, all the loaded micelles and free drugs exhibited a strong dose-dependent 
pattern after 72h of treatment. 
Table 6-2. IC50 determined by SRB assay in the HepG2, NIH3T3 and Hek293 cells 






HepG2 NIH3T3 Hek293 
Dox.HCl 0.049 0.165 3.588 
PSSG3-Dox 0.085 2.654 5.764 
Curcumin 2.645 6.235 7.355 
PSSG3-cur 1.345 10.03 58.641 
PSSG3-Dox/Cur 0.013 0.276 0.743 
 
 By analysing the IC50 values in table 6-2, The loaded Dox in PSSG3 showed a 
lower toxic effect on each cell lines compared to free Dox whereas PSSG3-Cur 
exhibited higher toxicity on HepG2 cells compared to free curcumin. However, 
in NIH3T3 and Hek293 cells, the toxicity of PSSG3-cur was much lower than 
free curcumin.  
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Figure 6-15. Cytotoxicity of blank PSSG3, PSSG3-Dox, PSSG3-Cur and PSSG3-
Dox/Cur against A. HepG2 cells, B. NIH3T3 cells and C. Hek293 cells after the 72h 
incubation period. The concentrations of PSSG3-Dox/Cur corresponds to the 




Moreover, PSSG3-Dox /Cur showed a significant enhancement on the toxicity 
in HepG2 cells with a very low IC50 value of 0.013 µg/mL compared to PSSG3-
Cur, PSSG3-Dox and free Dox and cur.  
6.4.6. Cellular uptake by confocal studies 
The effect of PSSG3-Dox/Cur, PSSG3-Dox and PSSG3-Cur on the cellular 
uptake of either or both Dox.HCl and Cur were also evaluated in the HepG2 
cells based on the intrinsic red fluorescence of Dox and green fluorescence of 
Cur. The cells were treated with free Dox.HCl, Curcumin, PSSG3-Dox, PSSG3-
Cur and PSSG3- Dox/Cur NPs at Dox concentration of 5.1µg/ML and Cur 
concentration of 5.1µg/ML for 6hours. As seen in Figure 6-16, free curcumin 
displayed high green fluorescence in cytoplasm and very little fluorescence in 
the nucleus compared to free Dox, which was already distributed in the cell 
nucleus at 6h. This indicates the slow uptake of free curcumin compared to free 
Dox by the HepG2 cells which are because Dox can easily permeate the 
nuclear envelope and intercalates DNA (Capranico, Kohn and Pommier, 1990; 
Gu et al., 2012). All three PSSG3-Dox, PSSG3-Cur and PSSG3-Dox/Cur 
nanoparticles could be efficiently taken up by hepG2 cells. There was no 
significant difference in the uptake of single loaded drug nanoparticles PSSG3-
Dox and PSSG3-Cur or 2 drugs loaded nanoparticles PSSG3-Dox/Cur. The 
loaded Dox and curcumin from each nanoparticle were predominately 
distributed in the cytoplasm after 6 h of incubation. On the other hand, at 
elevated incubation time, the HepG2 cells treated with PSSG3-Dox/Cur 
nanoparticles for 10h exhibited higher red and green fluorescence intensity in 
the nucleus showing that both drugs had been released from PSSG3-Dox/Cur. 
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Figure 6-16. Confocal scanning electron micrographs of HepG2 cells after 6h 
incubation with Dox.HCl, Curcumin, PSSG3-Dox, PSSG3-Cur and after 6 and 10h 
incubation with PSSG3-Dox/Cur. Cell nuclei were stained with blue (DAPI), cell-





Pullulan has been widely explored in targeted gene, and drug delivery systems, 
especially, researchers have focussed on redox-sensitive pullulan-based 
amphiphilic copolymers for Doxorubicin delivery (Wang et al., 2014; Li et al., 
2014). Taking advantage of factors such as low pH and high elevated level of 
GSH in intracellular compartments of the tumour cells, we proposed to modify 
the previous nanocarrier synthesised PG3 (Chapter 4) by adding a disulphide 
linkage to improve the drug release rate of hydrophobic drugs. A disulphide 
linkage has been added in many different amphiphilic systems via esterification 
or amide formation by either first modifying the polysaccharides acting as 
backbone then reacting with the hydrophobic group or by either modifying the 
hydrophobic group first with disulfide linkage and then substitute in the 
polysaccharide backbone.  The disulfide-containing fragments that have been 
mostly used are cystamine and DTDPA. Cystamine has been conjugated into 
hydrophobic MSNs via amide formation using EDC/NHS and then linked into 
deacetylated heparin by Dai et al., 2014, also, Cystamine has been conjugated 
to carboxylated pullulan to form the amide product Pullulan-SS-NH2 and then 
linked with hydrophobic stearic acid using EDC/NHS by Wang et al., 2014. 
Furthermore, DTDPA has been conjugated into Dextran containing hydrophobic 
segments PBLG via ester formation using EDC/DMAP and then crosslinked to 
another molecule of Dextran containing hydrophobic segments PBLG by Zhang 
et al., 2013. DTDPA has also been conjugated to hydrophobic cholesterol via 
esterification using DCC/DMAP and then linked into Pullulan via esterification 
by EDC/DMAP by Li et al., 2014. Based on the published work, we proposed to 
link our hydrophobic Dendron PLLA into pullulan by adding the disulphide 
187 
 
containing segments DTDPA. Although these published papers showed that the 
esterification reaction could be done in the presence of DCC/DMAP, successful 
esterification between DTDPA and Pullulan were only achieved in the presence 
of EDC/DMAP using DMSO (see appendix section 9-6). Also, to conjugate the 
hydrophobic Dendron into disulfide modified pullulan via click reaction, azide 
groups were first successfully added by conjugating PSS-COOH with amine 
group from 3-azidopropylamine using EDC/NHS. The Dendron of generation 3 
PLLA(BOC/PBF) was added in excess, expecting all the azide group to be 
reacted, therefore reaching 16% of Dendron conjugated via disulphide linkage 
into pullulan. The amphiphilic PSSG3 system could self-assemble into uniform 
spherical nanoparticles of 68.1nm with good stability characteristics. PG3 and 
P(Lac)G3 nanocarriers have been able to load enough Dox, but the loaded 
carriers have not been able to reach the therapeutic effect that free Dox.HCl 
can achieve on HepG2 cells. This is maybe due to the slow cumulative release 
of Dox from the carrier which affects the efficiency of the drug Dox since 
insufficient intracellular drug release can limit the amount of antitumour drugs 
that reaches cancer cells which then hinders the efficiency of cancer therapy 
and induces side effects. We hypothesised here that the disulfide linkage of 
PSSG3 could improve the drug release of Dox from the carrier and the co-
delivery of Cur with Dox would enhance the anticancer effect of Dox since 
delivering 2 anticancer drugs at the same time would have a higher effect on 
the cancer cell. Cur and Dox could successfully be encapsulated into the carrier 
and formed nanoparticles of size ranging 112nm with the loading content of Cur 
and Dox being 15.59% and 17.01% respectively. It was noted that the 
encapsulation efficiency of Cur (88.72%±2.00) was higher than that of Dox 
(15.59%±5.30) and the size of PSSG3-Cur(78.82nm±8.08) was smaller than 
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PSSG3- Dox (91nm%±5.75). This is explained by the fact that Dox has a lower 
logP value 1.3 (Gallois et al., 1996) compared to that of Cur being 3.0, which 
implicates that molecules of Cur had stronger hydrophobic interaction with 
hydrophobic groups BOC and PBF from the Dendron G3-PLLA compared to 
Dox and therefore resulting in smaller core size. Moreover, the release rate of 
loaded drugs into PSSG3 was enhanced by the breakage of disulphide bonds in 
the presence of 10mM DTT. Surprisingly, Cur had a higher release rate at pH 5 
from PSSG3- Dox/Cur compared to its release from PSSG3-Cur, this suggested 
that the release of DOX influenced the release of Cur since, in acidic conditions, 
the Dox protonation triggers its release which also weakens Cur interactions 
with dendrons. Cur is then released depending on the diffusion of the 
environmental hydrophilic solutions inside the core of nanoparticles which 
solubilise the Cur in acidic conditions and therefore releases from the 
nanoparticles (Shah et al., 2008). Furthermore, it was confirmed that Cur 
enhanced the toxicity of Dox in HepG2 cells as PSSG3-Dox/cur had higher 
toxicity effect compared to PSSG3-Dox and free Dox.HCl (Figure 6-18A). 
Moreover, Cur has shown to have much lower toxicity effect compared to Dox a 
specially in normal cells suggesting its safety. The fact that disulfide containing 
Cur was more toxic to HepG2 cells compared to free Cur proves that the 
nanoparticle influenced the internalisation of Cur and the high content of GSH 
within the cancerous cells triggered the fast release of Cur, therefore, resulting 
in higher toxicity. Very interestingly, the loaded carriers were not seen as highly 
toxic compared to the free drugs toxicity in normal cells NIH3T3 and Hek293 as 
seen in HepG2 cells. This could be because cancerous cells have higher GSH 
level than normal cells lines (Jhaveri, Deshpande and Torchilin, 2014) but also it 
has been reported that NIH3T3 and Hek293 cells can largely be resistant to Cur 
189 
 
treatment and therefore displaying minimal toxicity for which Cur was suggested 
to have different sensitivity in different cell types (Manson, 2005; Kloesch et al., 
2014). Moreover, confocal studies showed the ability of the carrier to be able to 
deliver Dox and Cur at the same time into HepG2 cells. At 10hours treatment 
with PSSG3-Dox/Cur, loaded Dox and Cur could already be released in 
response to the high redox potential in endosome/lysosome and reach the 
nucleus but also increased fluorescence was still observed in the cytoplasm. 
Curcumin being in the cytoplasm increases the levels of topoisomerase II-
mediated DNA cleavage in the cytoplasm through its natural antioxidant activity 
(Ketron et al., 2012) but also generate ROS species which can then cause cell 
death (Woo et al., 2003; Traverso et al., 2013). Therefore, PSSG3-Curcumin 
not only can be used for cancer treatment but also in the treatment of other 
various liver diseases.   
Overall, the prodrug PSSG3-Dox/Cur nanoparticles provide a promising 
approach for combination therapy in cancer therapy.  
In summary, the co-delivery system PSSG3-Dox/Cur developed in this study 
targets HepG2 cells via ASPGR receptors and get internalised inside cells via 
endocytosis where the loaded Dox protonates at lower pH, weakening the 
intermolecular hydrophobic interaction of Cur with dendron, therefore, 
enhancing release rates. In addition to the acidic environment, high level of 
GSH within endosome and lysosome also improve the release of Dox and Cur 
by the breakage of disulphide linkage within the PSSG3 carrier. High GSH level 
decreases the level of ROS within cells, therefore, Cur released would use its 
antioxidant activity and would not only influence ROS production and increase 
the levels of topoisomerase II-mediated DNA cleavage (López-Lázaro et al., 
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2007) but also would inhibit MDR against Dox resulting in enhanced Dox 



















CHAPTER 7. GUANIDINYLATED DENDRON GRAFTED 
PULLULAN TOWARD GENE DELIVERY  
 
7.1. Introduction  
Gene therapy has become an immense interest worldwide over the last few 
decades for the treatment of chronic diseases and tumours. The cationic 
polymeric vector is one of the most important carriers for the delivery of 
negative genes among various non-viral gene vectors. Numerous cationic 
polymers, such as polyethyleneimine (PEI), polyamidoamine (PAMAM), and 
poly(L-lysine), are known to be efficient non-viral gene carriers (Choi et al., 
2004; He et al., 2013; Janiszewska et al., 2016). They form complexes with the 
negatively charged DNA and still possess a net positive surface charge. 
Nevertheless, cationic surface charge mediated toxicity, non-compatibility, and 
non-specific interactions with blood components limit the use of cationic 
polymers. Neutralisation of the cationic surface charge is an important strategy 
to overcome these problems associated with the cationic polymers. For 
example, shielding of the peripheral cationic groups by PEGylation is 
demonstrated to reduce the toxicity. However, it may have a negative effect on 
transfection efficiency (Suk et al., 2016). Therefore, designing a gene vector 
with a balance of low toxicity and high transfection efficiency is of crucial 
importance. Previously high transfection efficiency has been achieved using 
Cellular penetrating peptides (CPPs), which are well-known peptides that can 
penetrate the plasma membrane of mammalian cells. Among them, human 
immunodeficiency virus transactivator of transcription (HIV-1 TAT) protein 
(Vives, Brodin and Lebleu, 1997; Nakase et al., 2008), oligoarginine (Rothbard 
et al., 2000), penetratin (Dupont, Prochiantz and Joliot, 2011) and virion protein 
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22 (VP22) (Langel, 2019) are the best-known ones. The most obvious common 
feature of these CPP structures is undoubtedly the high content of basic amino 
acid, especially the number of arginine guanidinium residue (Nakase et al., 
2008). The guanidinium residues seem to be the essential ingredients of the CPPs 
to cross the plasma membrane, which has allowed for the design of a range of 
guanidinium-bearing analogues. Although the exact mechanism of guanidinium-rich 
polymers improved gene delivery remains unclear, it is suggested that 
incorporating guanidinium groups to the cationic polymers is a feasible approach to 
improve transfection efficiency (view chapter 1).  
7.2. Aim and Objective 
Considering the inherent properties of pullulan and the synthesised lysine 
dendron of generation 3 (PLLL) (chapter3), we proposed to develop a cationic 
guanidinylated-based dendronized pullulan for gene delivery. PLLL G3 dendron 
can be covalently attached into the neutral pullulan through Huisgen azide-
alkyne 1,3-dipolar cycloaddition or “click” reaction leading to G3P.  The primary 
amines of the generation 3 lysine dendron periphery could then be converted 
into guanidine groups resulting in an Octa-guanidine functionalized generation 3 
lysine dendrons-graft-pullulan (OGG3P=PLLA+). Herein, we aimed to: 
- Synthesise and characterise the conjugation of PLLL into pullulan (G3P), 
- Synthesise and characterise the conversion of lysine group into 
guanidine(OGG3P), 
- Investigate the DNA complexation by agarose gel retardation assay of 
G3P and OGG3P 
- Investigate the size, charge and morphology of the DNA complexes 
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It is important to note that this work was carried out with our colleagues in 
China, where we aimed to demonstrate that dendrimers structure can be easily 
manipulated to achieve different purposes. My work presented in this chapter 
was to demonstrate the ability of Octa-guanidine functionalized generation 3 
lysine dendrons-graft-pullulan (OGG3P) to encapsulate a gene, whereas my 
colleagues in China further carried more studies by investigating the toxicity, 
gene transfection, and uptake mechanism of OGG3P. Also, the therapeutic 
plasmid, pKillerRed-mem into the OGG3P carrier was studied. Our colleagues 
work is not presented here but can be viewed in our published paper (Zhou et 
al., 2018).  
7.3.  Methodology  
7.3.1. Synthesis of Lysine dendron of generation 3 (PLLL+) and 
Pullulan azidation  
 
Refer to chapter 3 and 4.  
7.3.2. Click reaction between PLLL+ dendron and azidated 
pullulan  
                          
Figure 7-1. Synthesis equation of clicked PLLL dendron into pullulan. 
 
Azidated pullulan (0.17g, 0.17 mmol) was dissolved in DMSO under argon 
atmosphere. PLLL (0.33g, 0.34 mmol) and sodium ascorbate (0.05g, 0.23 
mmol) were dissolved in the deionised water respectively and added into the 
194 
 
above solution. Then the CuSO4∙5H2O (0.03g, 0.12 mmol) was also dissolved in 
deionised water and added under a constant flow of argon. Then the reaction 
mixture was stirred at 45°C for 48 hours in the dark. EDTA·2Na powder (0.04g) 
was added into the above reaction mixture to chelate the excess copper ion. 
Finally, the solution was dialysed (MWCO = 3500 Da) with deionised water for 2 
days, followed by lyophilisation to get the product pullulan-PLLL(G3P). 
7.3.3. Guanidinylation of generation 3 (PLLL) dendrons  
Figure 7-2. Synthesis equation of guanidinylated pullulan-PLLL. 
 
Guanidinylation was carried out using 1H-pyrazole-1-carboxamidine 
hydrochloride as the guanidylating reagent. Briefly, the amino groups of 
Pullulan-PLLL (0.05g, 1mmol) were guanidinylated with 5 equivalent moles of 
1HPC (0.04g) and DIPEA (1.5ml) in 2ml water/DMF (1/1: V/V) under N2 
atmosphere for 3days at RT to convert the amine groups of lysine to guanidine 
groups.  
The synthesised pullulan-PLLLG was then dialysed (MWCO = 3500 Da) against 




7.3.4. Characterisation  
The structure of the clicked product Pullulan-PLLL(Boc) and the Octa-guanidine 
functionalized generation 3 lysine dendrons-graft-pullulan (OGG3P) 
Characterisation was carried by 1HNMR and EA, the details of each method is 
given in chapter 2. 
7.3.5. DNA Complexes Assembly 
The complexes were prepared by mixing DNA with cationic Pullulan-PLLL(G3P) or 
OGG3P solution gently at varying weight ratios from 0.2 to 200 (cationic G3P or 
OGG3P to DNA) in HBG buffer (HEPES 20 mM, pH 7.4, 5% glucose), and 
incubated at room temperature for 30 min before use. 
7.3.6. Agarose Gel Retardation Assay 
To study the DNA compaction ability of G3P or OGG3P polymers, gel 
retardation assay was introduced. The commercially available non-therapeutic 
pEGFP plasmid-encoded enhanced green fluorescent protein (4731base pair) 
was used, transformed in Escherichia coli DH5α and extracted using PureLink® 
HiPure Plasmid Filter Maxiprep Kit. Various G3P/DNA complexes and 
OGG3P/DNA complexes with different weight ratios (from 0.2 to 200) were 
mixed and incubated at 37°C for 30 min. 25 kDa PEI/DNA complexes at weight 
ratio 1.33 and naked DNA were used as positive and negative controls, 
respectively. The final amount of DNA was adjusted to 200 ng per well. Ten 
microliters of each different complexes solution were analysed by 1% agarose 
gel electrophoresis (80 V, 45 min) in standard TAE buffer. After electrophoresis, 
the gel was stained with ethidium bromide, and the resultant DNA migration 
behaviours were visualised through the Molecular Imager ChemiDoc XRS+ 
(Bio-Rad, USA).  
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7.3.7. Particle Size characterisation  
Complexes at varying weight ratios were prepared at a final DNA concentration 
of 3 μg/mL. Measurements of the particle size distribution and zeta potential 
were carried out by Malvern Instruments (Zetasizer Nano ZS, Malvern, UK) in 
physiological conditions (pH 7.4) in deionised water. The morphologies of G3P 
complexes and OGG3P complexes at the weight ratio of 8 were also observed 
by transmission electron microscopy (TEM).  
7.4. Results  
7.4.1. Synthesis and characterisation of clicked Pullulan- 
PLLL(Boc) (G3P) and OGG3P 
The click reaction between pullulan and PLLL(BOC) dendron was confirmed by  
1HNMR. Figure 7-3. shows the 1HNMR spectra of pure pullulan, pullulan-
PLLL(G3P) and OGG3P, as seen, in comparison to pullulan spectra, there were 
new peaks appeared at 1.0-2.0 ppm and 7.0-8.0 ppm in the G3P and OGG3P 
spectra which are the designated to the peaks of G3 dendrons.  
Additionally, the peak at 7.90 ppm was speculated to be the peak of triazole 
proton (proton c), which confirmed the successful click reaction.  Moreover, the 
1HNMR spectra of G3P showed the heavily diminished intensity of protons’ 
peaks next to primary amines (proton a, δ= 3.02) compared to that of OGG3P 
spectra were the protons shifted to downfield (proton b, δ = 3.18, protons next 
to guanidine groups). Therefore, the data from 1H-NMR spectra proved that we 
have successfully synthesised both G3P and OGG3P. At the same time, the 
comparison of integration values between the two proton peaks (a and b) also 
revealed that about 95.90% of primary amines in the G3P polymer were 
converted to guanidines. 
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Figure 7-3. The 1H-NMR spectra of pullulan, pullulan-PLLL(G3P) and the pullulan-
octa-guanidine functionalized generation 3 lysine dendrons (OGG3P) in D2O. 
 
Table 7-1 presented the accurate mass measurements of pure pullulan, azido-
pullulan, G3P and OGG3P. The azido content of azidated pullulan was 
calculated to be 49.02 per 100 anhydrous glucoside units and the PLLL 
dendrons contents conjugated onto pullulan was determined as 12.62 per 100 
anhydrous glucoside units, whereas the contents of guanidines modified PLLL 
dendrons in OGG3P were 12.52 per 100 anhydrous glucoside units. The 
elemental analysis further confirmed that the substitution degree of 
198 
 
guanidinylated G3P was established to be 99.21%, which was consistent with 
the guanidinylation degree result determined from 1H-NMR.  
Table 7-1 Determination of the substitution degree by elemental analysis 
 C (%) N (%)  H (%) DS (%)  
Pullulan  40.33  6.66  /  /  
PN3  37.11  6.56  3.74  49.02  
G3P  39.24  6.59  11.56  12.62  
OGG3P  39.04  6.74  14.77  12.52  
 
7.4.2. Characterisation of DNA Complexes 
 As the Figure 7-4 shown, OGG3P was able to completely retard the migration 
of DNA on the gel at the weight ratio less than or equal to 2 and form stable 
complexes with DNA, whereas G3P could not retard the DNA migration until the 
weight ratio greater than or equal to 15. These phenomena strongly suggested 
that the guanidinylated OGG3P cationic polymer had a better DNA compaction 
ability than natural G3P cationic polymer, which may be the result of specific 
guanidinium-phosphate interactions.  
We also investigated the surface charges of OGG3P complexes as a function of 
OGG3P cationic polymer to DNA weight ratios by measuring the zeta potential 
of a suspension using a Malvern Nano ZS equipment. As shown in Figure 7-4B, 
the zeta potential of OGG3P complexes was 11.73 mV at a weight ratio of 1. 
Then the zeta potential would increase with the increase of the OGG3P to DNA 
weight ratios. A zeta potential plateau (~ +23 mV) occurred when the weight 
ratio reached to 6 despite increasing with the weight ratio up to 40, indicating 
the OGG3P cationic polymers were able to condense DNA completely and form 
positively charged nanoparticles. 
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Figure 7-4. A. 2 Gel retardation assays for OGG3P and G3P complexes prepared 
at varying weight ratios. The different bands present in both gels show the 
different forms of DNA: nicked, linear, supercoiled, circular or single-stranded 
form (B) Zeta potential of OGG3P complexes prepared at different OGG3P to 
DNA weight ratios (Note: DNA made of 4731bp).          
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Figure 7-5. Size distribution and TEM images of A. OGG3P complexes; B. G3P 
complexes at the weight ratio of 8 and C. Zeta potential measurements of OGG3P 
complexes and G3P complexes at the weight ratio of 8.                                                                                                                                          
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The sizes, size distributions and morphologies of OGG3P and G3P complexes 
were also measured by transmission electron microscopy (TEM) and dynamic light 
scattering (DLS). As Figure 7-5A&B shown, results from TEM confirmed that both 
OGG3P and G3P cationic polymers could condense DNA at the weight ratio of 
8 and form uniform, compact, and spherical nanoparticles. Samples of OGG3P 
complexes gave smaller size and narrower size distribution than that of G3P 
complexes. Additional DLS analyses and zeta-potential measurements also 
revealed that the resulting OGG3P complexes were well dispersed in the 
aqueous solution with a size average of 86.1 ± 6.8 nm (polydispersity index 
(PDI): 0.178) and present a strong zeta potential of 23.6 ± 1.5 mV while G3P 
complexes were 115.2 ± 10.7 nm with a broad particle size distribution (PDI: 
0.301) and showed a zeta potential of 14.1 ± 1.3 mV (Figure 7-5C).  
7.5. Discussion  
Gene therapy has become a promising strategy for the treatment of cancer. 
There have been various developed gene carriers including cationic liposomes 
to linear cationic polymers, and now to topological (branched, dendritic and 
hyperbranched) cationic polymers. For gene delivery, it is essential that the 
gene carrier can bind and condense the plasmid DNA into nanoscale 
complexes and exhibit appropriate positive surface charges. The positively 
charged nanoscale complexes tend to interact with the negatively charged cell 
membrane, presumably facilitating their cellular uptake (Albuquerque et al., 
2017). With this in mind, we investigated the DNA compaction ability of the 
cationic polymers (G3P and OGG3P) using gel retardation assay. PEI and 
naked DNA were used as positive and negative controls, respectively. OGG3P 
has a high number of amine groups giving a higher positive value of zeta 
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potential, therefore, can interact more strongly at a lower ratio with the gene via 
electrostatic attraction resulting in smaller particle sizes compared to G3P. As 
expected, the general trends in sizes and size distributions found from the TEM 
observation correlated well with those measured by DLS. The above 
observations indicated the resulting OGG3P complexes possessed the proper 
size and narrow size distribution, appropriate positive surface charges and 
excellent dispersion stability in an aqueous solution, presumably arising from 
guanidinylated OGG3P had a better DNA compaction ability than natural G3P 
cationic polymer. 
Moreover, the zeta potential of the nanoparticles is most often used as an 
indicator of dispersion stability. Zeta potential of about ±25 mV is usually 
required to achieve a reasonably stable dispersion. Therefore, OGG3P 
complexes solution could disperse stably when the weight ratio was greater than 
or equal to 6. Also, the uniform nonionic hydrophilic hydroxyl groups in pullulan 
probably benefited shielding the excessive harmful cationic charges of the 
OGG3P cationic carriers. The better DNA compaction ability of OGG3P cationic 
polymer could protect the enclosed nucleic acids from nucleases and hence 
maintain their stability and integrity until cellular uptake of complexes taking 
place.  
7.6. Conclusion  
In summary, we have successfully developed a tailor-made guanidine-decorated 
dendronized pullulan, Octa-guanidine functionalized generation 3 lysine dendrons-
graft-pullulan (OGG3P) which can act as a vector for gene therapy. The obtained 
OGG3P could efficiently condense DNA into spherical nanosized complexes with 
appropriate positive surface charges to enable entry into cells and to assure 
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successful gene delivery. In conclusion, the guanidine-decorated dendronized 
pullulan could, therefore, serve as a reliable gene delivery nanoplatform to enable 




CHAPTER 8. GENERAL DISCUSSION AND FUTURE 
STUDIES 
 
8.1. General Discussion  
In the past few decades, there have been various anticancer drugs developed 
most notably taxanes (paclitaxel and docetaxel) and the platinum-based drugs, 
however, most of these drugs lack aqueous solubility and therefore undergo 
unwanted interaction within the bloodstream that cause their quick clearance 
and higher toxicity resulting in lower antitumor efficacity (Narvekar et al., 2014). 
The use of polymeric-based nanomaterials such amphiphilic micellar system 
has therefore extensively been studied for the enhancement of anticancer drug 
solubility, bioavailability and delivery into the tumour site. Nishiyama and 
Kataoka in 2006 reported the advantages of micelles as delivery systems, 
including their simple preparation, increased drug solubility, reduced toxicity, 
increased circulation time, enhanced tissue penetration and targetability.  
8.1.1. General chemical structure of the micellar carriers 
synthesised 
 
Amphiphilic block copolymers consist of hydrophobic segments conjugated with 
hydrophilic polymers which self-assembles to form regular micelles and have 
shown to be more promising as micellar carriers especially to minimise micelle 
disintegration after dilution and to potentially prolong drug delivery (Nishiyama 
and Kataoka, 2006). In this work, we proposed to develop a new targeting 
carrier system for the delivery of hydrophobic drugs in a liver tumour. Pullulan 
was the perfect choice as a polymer because it has a safe history of use in 
Japan as a food ingredient and as a pharmaceutical bulking agent. Most 
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importantly, pullulan can target with high affinity to the asialoglycoprotein 
receptors present in the sinusoidal surface of the hepatocytes of the liver and 
also can accumulate the liver in higher amounts than other soluble polymers 
(Rekha and Sharma, 2007). In this work, we have investigated the best 
experimental parameters to achieve the pullulan azidation (chapter 4) and 
esterification (section 9.4) in addition to other chemical modification previously 
achieved by other authors including carboxymethylation, sulfation, etherification, 
chlorination and oxidation (Prajapati, Jani and Khanda, 2013) which therefore 
demonstrated that pullulan can easily undergo chemical modification. The 
chemical modification of pullulan into various derivatives is simplified by its 
natural chemical structure containing repeating maltotriosyl unit which contains 
nine hydroxyl groups in a geometrically unique environment, and therefore the 
introduction of different functional groups into the pullulan extends its potential 
applications in various fields (Bataille et al., 2011). Furthermore, to develop an 
amphiphilic micellar system, we proposed to conjugate a hydrophobic segment 
into the modified pullulan. Recently, a new class of molecules known as 
dendronized polymers which are linear polymers that bear dendrons at each 
repeat unit have been developed for drug or gene delivery systems. These 
systems provide better-enhanced circulation time compared to the linear 
polymers (Singh and Lillard, 2009) and the dendritic macromolecules form the 
inner core cavity with a high density of surface functionalities, well-defined 
structures and molecular weight which is a new model of potential amphiphilic 
polymer for micelles preparation. We, therefore, developed dendron based on 
lysine and arginine peptides of third generation (chapter 3). The dendron 
consisting of amino acids were synthesised to form various peptide bonds in-
between generation. Since the amino acids are generally protected by 
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hydrophobic BOC groups or BOC/PBF groups, we hypothesised that the 
protecting groups at the terminal surfaces of dendrons could be useful for 
hydrophobic drug delivery whereas deprotection of the terminal groups would 
result into cationic amine terminal group for gene delivery. The synthesis was 
simple and easily repeated until the third generation. However, the purification 
and deprotection of third generation arginine dendron were difficult (section 
9.1). It was therefore decided to stop the synthesis at the third generation. 
Although the higher generation of dendrons (up to G10 PAMAM dendrimers) 
have been achieved, it has also been reported that higher generation synthesis 
and purification is difficult, also, their size increases and become more toxic as 
the generation increases (Luo et al., 2011). The arginine peptide dendron 
synthesised consist of appropriately functionalised various terminal functional 
hydrophobic group (high hydrophobicity of BOC and PBF) at a low generation 
which should be a great advantage compared to other hydrophobic dendron 
synthesised previously such as the polylysine dendrons. Firstly, peptide-based 
dendrons are designed to be biodegradable and have also been reported to be 
promising as vaccines, antiviral, antibacterial candidates and as new contrast 
agents for biomedical magnetic resonance imaging (MRI) (Gillies and Frechet, 
2005). Secondly, compared to the two types of dendritic polymers 
commercialised (polyamidoamine (PAMAM) and poly (propylene imine) (PPI)), 
the synthesised peptide arginine dendron shows higher stability structure 
because of the peptide bonds, the alkyne core and the terminal protective group 
of amino acids. Moreover, we have demonstrated that the structure of the 
dendron could easily be modified, although the removal of BOC/PBF was 
difficult in the arginine PLLA dendron to achieve cationic dendrons. Another way 
was therefore developed by synthesising the polylysine PLLL dendron of the 
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third generation and then converting the guanidine group to achieve terminal 
arginine containing amine structure OGG3P. The two types of dendrons could, 
therefore, be conjugated to pullulan to form the block copolymer pullulan based 
hydrophobic dendron for drug delivery or the pullulan based cationic amine 
dendron for gene delivery. The azide group in pullulan and alkyne group in 
dendron makes both molecules extremely stable at standard conditions. Both 
groups can tolerate oxygen, water, common organic synthesis conditions, 
biological molecules, a large range of solvents and pH’s, and the reaction 
conditions of living systems (reducing environment, hydrolysis, etc.) and 
therefore provide the azidated pullulan and alkynated dendron a long period of 
storage before any further use (Kolb and Sharpless, 2003; Hein, Liu and Wang, 
2008). The conjugation of dendron into pullulan is achieved by a simple linking 
reaction consisting of the cycloaddition between the azide and alkyne group to 
form a triazole compound, unlike amides and benzenoids, the triazole linkage 
cannot be cleaved hydrolytically and are almost impossible to oxidise or reduce 
(Kolb and Sharpless, 2003). The click reaction was carried out many times 
between dendrons and different pullulan derivatives; the process was simple, 
fast and high yield was achieved.  
8.1.2. The general effect of the hydrophobic/hydrophilic 
segment in the micellar self-assembly process  
 
The amphiphilic pullulan based hydrophobic dendron could self-assemble into 
the micellar structure; it is reported that the use of hydrophobic branched 
segments into a micellar structure induces stability and a tight packing 
behaviour within the micelle core compared to a simple hydrophobic linear 
segment (Ree et al., 2017). Moreover, the dendron based pullulan would 
maintain strongly the micellar structure rather than conventional polymeric 
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micelles because the hydrophobic dendron is connected via triazole linkage into 
pullulan derivative (Gillies and Frechet, 2005). It is known that the micellar size, 
shape, loading efficiency, stability and release rate all depends on the 
characteristics of the hydrophilic and hydrophobic segments within the system. 
In this work, three amphiphilic carriers (PG3, P(Lac)G3 and PSSG3) with 
different chemical characteristics were developed were the hydrophobic 
dendron was clicked into pullulan, pullulan bearing lactose and to disulphide 
modified pullulan. The table 8-1 represent all the different chemical and physical 
characteristics that each carrier possesses. PG3 carrier consists of a simple 
hydrophilic segment with the highest conjugated hydrophobic segments 
(20.32%), P(Lac)G3 has a higher hydrophilic segment with 18.51 % of 
hydrophobic dendrons whereas PSSG3 have a simple hydrophilic segment with 
the least hydrophobic molecules but elongated. Herein, all carrier system 
developed in the presence of water showed to be able to self-assemble into a 
spherical micellar structure which shows that enough hydrophobic dendron was 
conjugated into pullulan derivatives and that the hydrophilic segment is longer 
than the core block, therefore, resulting in spherical micelles (Gaucher et al., 
2005). The driving force of micelle formation in water usually depends on the 
hydrophobic effect. By increasing the number of hydrophobic dendron in 
pullulan, we expect to improve the hydrophobic interaction within the micellar 
core and therefore reduce their size and CAC value, which would indicate 
greater stability. For example, Kang and Leroux in 2004 demonstrated by a 
steady-state pyrene fluorescence technique that increases the PDLLA 
proportion in PVP-b-PDLLA-b-PVP triblock copolymers from 27 to 55 mol% led 
to a decrease in CAC values from 19.9 to 5.1 mg/L. Conversely, PG3 containing 
the higher number of hydrophobic dendron exhibited the highest particle size 
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(87.07nm) and CAC value (10.47 µg/mL) compared to P(Lac)G3 and PSSG3. 
P(Lac)G3 presented the smallest particle size of 54nm and CAC value of 8.87 
µg/mL, whereas PSSG3 formed micelles of sizes 68.1nm with a CAC value of 
9.93 µg/mL. From these observations, we can deduce that the higher number of 
hydrophobic dendron did not have any significant effect on the size and CAC 
value compared to when an increase of the hydrophilic segment or the length of 
the hydrophobic segment was done. For the P(Lac)G3 system, the addition of 
lactose into pullulan increased the hydrophilicity of the outer layer which imparts 
steric stability by minimizing the interfacial free energy of the micellar core and 
by impeding hydrophobic intermicellar attractions (Gaucher et al., 2005), the 
high hydrophilicity is vital in preventing opsonin when administrated 
intravenously and for improved circulation. Similarly, to the addition of PEG, the 
high hydrophilic surface of pullulan and lactose may act as a protective layer 
around the micelles that can repel the absorption of opsonin proteins via steric 
repulsion forces, thereby prolonging their blood circulation (OWENSIII and 
PEPPAS, 2006). For the PSSG3 carrier, the increase in the length of the 
hydrophobic segment by addition of disulphide linkage influences the micellar 
stability (Gaucher et al., 2005) but may also influence the size reduction. This is 
explained by the fact that the hydrophobic segments are far from the hydrophilic 
segment, making their interaction hard with an aqueous solution and therefore 
increasing their hydrophobic interaction within the core. Overall, it is known that 
compared to low molecular weight surfactants, polymeric micelles exhibit 
significantly lower CAC values, indicating greater thermodynamic stability 
(Gaucher et al., 2005). It has been reported that the usual size of a 
pharmaceutical micelle is less than 80 nm, its CMC value is expected to be in a 
low millimolar region or even lower, and the loading efficacy toward a 
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hydrophobic drug should be between 5 and 25 wt.% (Rana et al., 2017). Our 
developed carriers PG3, P(Lac)G3 and PSSG3 all exhibited good spherical 
particle sizes (50-90nm range), well uniformity and dispersity (relatively low PDI 
less than 0.25), low CAC values showing great stability of the micelles and no 
toxicity towards HepG2, U251, Hek293 and NIH3T3 cell lines (Chapter4,5 and 
6). All these characteristics show that the micellar systems developed could be 
beneficial for the delivery of hydrophobic drugs. Therefore, the ability of the 
carriers to load, release and deliver the hydrophobic drug doxorubicin into 
cancer cells was investigated, and results are summarised in table 8-1.  
8.1.3. The general loading efficiency of hydrophobic drugs into 
the carriers and their effect on their sizes 
 
Loading content of doxorubicin into the carrier is seen to be enhanced by the 
number of hydrophobic dendron inside the micellar core and the size, the higher 
number of dendron and higher particle size showed a higher encapsulation and 
loading efficiency of doxorubicin in PG3 compared to P(Lac)G3 and PSSG3. 
The loading efficiency of each carrier was within the (5 and 25 wt.%) 
pharmaceutical range (Rana et al., 2017). It is also noticeable that the loading 
of drug exerted some effects on the particle size, all loaded carriers exhibited an 
increase in sizes which is because of the enlargement of core bulk due to the 
doxorubicin drug content. However, the contrary effect was seen when loading 
curcumin into the carrier PSSG3, the loading efficiency was much higher than 
Doxorubicin, and the size was not increased much like that of loaded 
Doxorubicin-PSSG3. This show that curcumin being more hydrophobic than 
doxorubicin had a different effect by improving the compact arrangement 
among the hydrophobic dendron interactions, therefore, resulting in smaller 
sizes. These observations agree with the theory reported by Qiu and Bae in 
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2007 were the author reports that drug encapsulation can exert two contrary 
effects on particle size, one effect is that the drug may improve the compact 
arrangement among chains through hydrophobic interactions and the other 
effect is the enlargement of core bulk due to the drug content. 
Moreover, although the sizes of loaded carriers increased, their sizes were not 
increased to more than 140nm, this indicates that the loaded carriers had right 
sizes to be able to deliver drugs to their target with prolonged circulation by 
avoiding recognition via RES and will be able to accumulate in tumours 
because of the enhanced permeability and retention effect (EPR effect). 
8.1.4. The general effect on the release rate of encapsulated 
drugs 
 
A general drawback on the use of hydrophobic dendrimer core in the micellar 
system is the difficulty to control the release of molecules (Gillies and Frechet, 
2005). The release depends on the strong hydrophobic interactions between 
drugs and the micellar cores and can be improved by adding cleavable linkage 
in specific physiological conditions such as pH and redox. The use of 
Doxorubicin as an example of the hydrophobic drug was an advantage since 
the drug can protonate in acidic conditions and reduce its interaction with the 
hydrophobic dendron, therefore, enhancing its release. 
This phenomenon was observed in the released studies of Doxorubicin from all 
carriers where the release at pH 5 showed the highest release rate compared to 
the release at pH 7.4 and 6.8. Moreover, the release of doxorubicin at pH 5 
from each carrier showed a typical biphasic pattern characterised by a fast-
initial release during the first 12h followed by a slow sustained release over the 
next 60 hours. 
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Table 8-1. Overall physical and chemical characteristics of the PG3, P(Lac)G3 




The initial fast release of Dox from each nanoparticle could be reasonably 
explained by the fact that a certain amount of Dox-loaded in the centre of the 
hydrophobic core may quickly respond to the change of pH value and 
preferentially diffuse through the pullulan derivative shell, whereas some Dox 
highly interacting with the hydrophobic dendrons would protonate slowly, 
causing a sustained release. It is essential to note the higher release rate of 
doxorubicin from PG3-Dox compared to P(Lac)Dox and PSSG3-Dox, which 
correlates with the size and loading effect of PG3. PG3 having the higher Dox 
content enlarges the micellar core and therefore present a higher number of 
Dox having weak hydrophobic interaction with the hydrophobic dendron which 
then quickly respond to the pH change and releases from the core. The ability 
of these carriers releasing the drug in a sustained way makes them beneficial 
for the treatment of chronic diseases, some infectious diseases and cancers 
(Trivedi and Kompella, 2010). Although we have demonstrated the excellent 
stability of the micelles synthesised after 3 months storage, in addition to great 
CAC values, micelles can still present instability over a long period. A very 
prolonged sustained release would therefore not be the best option for the use 
of micelles as not enough drug may be released on the target resulting in 
limited therapeutic effect. From the PG3 and P(Lac)G3 Dox-loaded carriers, no 
more than 55% of doxorubicin could be released for a period of 60hours. The 
presence of the redox stimuli-sensitive disulphide linkage in PSSG3-dox 
showed some improvement on the release of the drug doxorubicin up to a 
release rate of 85wt% at a 60h time. Furthermore, the low premature drug 
release in physiological pH condition (mimicking the blood circulation) confirmed 
the stability of the drug-loaded PG3-Dox, P(Lac)Dox and PSSDox/Cur/Dox-Cur. 
This show that the hydrophobic dendrons within micellar core have highly 
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strong interactions with Dox or Cur, including π -π interactions, hydrogen 
bonding and hydrophobic interactions. 
8.1.5. Effect on the addition of lactose to enhance pullulan 
targeting on HepG2 cells  
 
In this work, we aimed to actively and passively target the liver cancer cells. All 
the carriers PG3, P(Lac)G3 and PSSG3 exhibited small enough sizes to be able 
to target the tumour environment via EPR effect passively. Pullulan chosen as 
the backbone is reported to be able to target the overexpressed 
asialoglycoprotein receptor (ASGPR) in hepatoma cells of the liver actively. 
ASGPR is the most common target site of HCC for targeting drug delivery 
system because of their high expression on hepatocytes and hepatoma cells 
(HepG2 expresses 76,000 ASGPRs/cell with a high density on the membrane) 
but their minimal expression on extrahepatic cells (D'Souza and Devarajan, 
2015).  
We have investigated the uptake of the carriers into HepG2 cells using confocal 
laser scanning microscopy; it is important to note the practical advantage of 
using Doxorubicin and Curcumin as examples of hydrophobic anticancer agents 
because of their fluorescence properties. Curcumin, for example, has previously 
been used as a fluorescent probe for directly monitoring in vitro uptake of 
curcumin combined paclitaxel loaded PLA-TPGS nanoparticles (Nguyen et al., 
2016). Therefore, with the use of curcumin and Doxorubicin once treated with 
cells, was beneficial in indicating their localisation within cells. 
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Figure 8-1. The cellular uptake of PG3-Dox and P(Lac)Dox nanoparticles by 
HepG2 cells after 1h treatment with confocal laser. The left images are DIC 
images where the fluorescence is overlaid on a bright field image of the cells, 
whereas the right images are just red fluorescence.  
Although we could not demonstrate the targeting effect of pullulan from PG3 
into HepG2, there was a difference between the internalisation of Dox.HCl and 
PG3-Dox or PSSG3-Dox or Cur/Dox in which we deducted that the carriers 
were internalised via endocytosis into HepG2 cells. We then hypothesised that 
conjugating the lactobionic acid (a common ligand for hepatoma cells 
comprising a gluconic acid and Galactose moiety) would enhance the targeting 
of pullulan into HepG2 cells since pullulan segments in the micellar structure 
may not expose its chemicals fully on the surface for the receptor-ligand 
recognition to take place. The ASGPRs can recognise and bind D-galactose 
(Gal) and N-acetylgalactosamine residues with high specificity and efficiency; 
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their centre consists of six amino acids in which the H1 subunit forms an active 
ligand-binding site (D'Souza and Devarajan, 2015). Figure 8-1 and 8-2 show the 
confocal images and flow cytometry indicating the fluorescence intensity of Dox 
inside PG3 and P(Lac)G3.  
Figure 8-2. The Cellular uptake by Flow Cytometry of Dox.HCl, PG3-Dox and 
P(Lac)Dox nanoparticles at 0.5,1 and 6h in HepG2 cells. The flow cytometry 
histograms are represented in 2 ways: The three top plots show the changes in 
fluorescence intensity over different time for A. Dox.HCl treated HepG2 cells; B. 
PG3Dox-treated HepG2 and C. P(Lac)Dox-treated HepG2. The three bottom plots 
compare the fluorescence intensity of Dox.HCl, PG3-Dox and P(Lac)Dox-treated 
HepG2 cells at different times: D. 0.5h; E. 1h and F. 6h. Untreated HepG2 cells 
were also used as control (peaks in Red). 
 
Unfortunately, there were no significant changes observed in the uptake of 
PG3-Dox and P(Lac)G3-Dox by confocal microscopy, and the flow cytometry 
results indicate that same amount of Dox were internalised at 0.5, 1 and 6h by 
PG3-Dox and P(Lac)G3-Dox which indicate no difference in the uptake of both 
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carriers. However, the size and stability of P(LAC)G3 was more convenient for 
targeted delivery in liver cells. 
It is known that the uptake of nanoparticles by cells depends on their size, 
shape and surface properties. Micrometre-sized rigid spheroids are cleared 
immediately in the first pass through the microvasculature of various bodily 
organs and do not enter most cells whereas spherical and short filaments 
nanoparticles exhibit prolonged circulation and can be taken easily by cells 
(Geng et al., 2007). Herein, all three micellar formulations were all spherical 
with a particle size less than 150nm, therefore, facilitated their uptake in cells.  
Moreover, each formulated micelle was internalised in HepG2 cells via 
endocytosis followed by their localisation in endosome/lysosome where the 
drug was then released by the influence of low pH and redox effect. However, 
the rate of endocytosis was size-independent as seen there was no difference 
in uptake between all formulated carriers although they exhibited different sizes 
(Wang et al., 2015).  Furthermore, all carriers being internalised by endocytosis 
could have easily faced hardship in escaping endosomes/lysosomes 
compartments, but with increased time, confocal and toxicities studies 
demonstrated the successful release of the drug and their achievement in 
therapeutic effect towards the cancer cells, especially for PSSG3-Dox. The 
increased therapeutic effect of PSSG3-Dox emphases the importance of the 
addition of disulphide linkage to enhance endosome/lysosome escape of the 
nanocarriers as in addition to the cytosolic reducing conditions, the endosome 
and the lysosome also have a redox potential that can be used to promote 
endosomal and subsequent lysosomal escape (Jhaveri, Deshpande and 
Torchilin, 2014). In contrast to Dox, Cur is a hydrophobic drug which does not 
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have similar protonation effect at lower pH. For this reason, the use of 
disulphide leakage shows it’s importance to influence the release of curcumin. 
Moreover, the co-delivery system represents here as another essential future 
research direction; this is based on the concept of delivering 2 or more 
therapeutic agents at the same time for combination cancer therapy. In this 
work, we have demonstrated the ability of PSSG3 to deliver both Dox and Cur 
at the same time into HepG2 cells with increased therapeutic effect compared 
to the single drug delivery.  
8.2. Conclusions and future studies  
In summary, this work not only provides a potential route towards the 
development of multifunctional pH or redox-sensitive micelles but may also help 
to enhance the safety of hydrophobic anticancer drugs, increase 
chemotherapeutic efficacy, overcome chemotherapy resistance and potentially 
offers an exciting route to inhibit the accumulation of tumours in tissues. Future 
studies will be to investigate further precisely how the particles get internalised 
and transported in the cells and how the drugs get unloaded and permeate the 
intracellular membranous structures. Moreover, Modifying the formulated 
micelles by conjugating at the same time the amine and BOC/PBF containing 
dendrons into disulfide-linked pullulan could be used as a potential co-delivery 
system for drug and gene delivery into tumour cells.  
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CHAPTER 9. APPENDIX 
9.1. The Standard method of Removal of BOC and PBF from 
PLLA to yield PLLA+ 
Figure 9.1. Synthesis equation of dendron of generation 3 (PLLA) deprotonation 
into PLLA+ 
 
Like the process used for G1 and G2, the hydrophobic groups of the generation 
3 dendrons were removed by treating 3g (1mmol) of PLLA with 5ml of 
anhydrous CH2Cl2 and 8ml of TFA for 24hr at RT under N2 atmosphere. Then 
the solvents were removed under vacuum, and the product was precipitated 
under stirring with anhydrous diethyl ether overnight. The precipitates where 
collected by centrifugation and then dried under high vacuum. This method was 
repeated at least 4 times to achieve complete deprotonation. The reaction was 
carried out for a longer time (36 hours to 48 hours), but an unexpected colour 
change was observed. In every repeat, the colour change was different; most of 
the time, the solution would change to a green solution, but sometimes it would 




9.2. Characterisation of deprotected PLLA products (ESI-MS: 
(calculated 1063.73) 
After each deprotection reaction, the products were analysed by MS to verify if 
the reaction was successful. The Figures 9.2,3,4, and 5 show the MS results of 
the 4 repeated reaction were no resulted mass values corresponded to the 













   
Figure 9.3. ESI-MS of second deprotected PLLA dendron product 
 


























































  Figure 9.5. ESI-MS of second deprotected PLLA  dendron product 
 
Moreover, deprotection of PLLA was expected to present some cationic amine 
group on the surface that could interact with DNA. Therefore, we investigate if 
the PLLA deprotection could be achieved after being conjugated to pullulan. 
PLLA(BOC/PBF) was therefore first conjugated into pullulan and then 
deprotected. Agarose gel was then carried out to see if the deprotection was 
successful. However, Figure 9-6 shows that the product was not able to 
complex with the DNA suggesting the unsuccessful deprotection of PLLA. 
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Figure 9.6. Agarose gel electrophoresis retardation assay of PG3/pDNA and 
PEI/DNA complexes at various N/P ratios. 
 
Finally, we proposed a better way of synthesising the PLLA+ product by 
synthesising PLLL and then converting the terminal amine groups into 
guanidine groups. Since G2 was already synthesised, the guanidinylation of G2 
dendron was first investigated. 
 9.3. Guanidinylation of G2 Dendron for gene compaction  
Firstly, PLL dendron of generation 2 was clicked into pullulan via the same 
method as P-PLLA, and the method for the conversion of an amine into 
guanidine is given in chapter-7. 
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Figure 9.7. Synthesis equation of Pullulan-PLL. 
Figure 9.8. Synthesis equation of Pullulan-PLLG. 
 
The FTIR in Figure 9.9 confirms the production of P-PLL. 
                                            




                          
Figure 9.10. Agarose gel electrophoresis retardation assay of PG2/pDNA, 
PG2G/pDNA and PEI/pDNA complexes at various N/P ratios.  
 
Furthermore, Figure 9.10 shows the Agarose gel electrophoresis retardation 
assay of PG2/pDNA, PEI/pDNA and PG2G complexes at various N/P ratios 
showing that the guanidinylation was successful and can improve gene 
compaction. For this reason, Guanidilation of G3PLLL was then carried out 
(Chapter-7) 
9.4. Method for the Removal of Lysine or arginine from lysine-
dendron of generation 2 and Arginine-dendron of generation 3 
After purification by column chromatography to remove any traces of lysine or 
arginine observed by TLC, the dried product was dissolved in chloroform and 
then washed 3 times with NaHCO3 (stirred for 3 hours). The product was 
collected using a separatory funnel and then dehydrated overnight with 
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Mg2SO4. The dried powder was obtained by rotary evaporation and vacuum 
pump.  
9.5. Growth curve of HepG2 and U251 cells 
Tumour growth is known to be directly related to cell proliferation. When treating 
a tumor, the intention is to reverse the growth by killing or removing cancer 
cells. Determining the growth curve of cells in the subject describes the 
increases and decreases in the number of cells over time (Dang et al., 2003). 
Figure 9-11 shows the growth curve of HepG2 and U251 cells, which was 
cultivated for 237 hours under the same conditions (at 37ºC under CO2).  
Figure 9-11. A. HepG2 and U251 growth curve (conditions: cells were seeded at 
100000 cells B. HepG2 cells visualised and photographed under a light 
microscope C. U251 cells. 
 
The growth of both cell lines is presented as a semi-logarithmic plot of the cell 
density versus the time spent in culture. During the lag phase (from 0h to ˂48h), 
the cells are seeded, and prolonged growth is observed because the cells are 
still adapting to the culture environment. Both cells start proliferating 
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exponentially (doubling time) around 48h and consume the nutrients in the 
growth medium; this phase is known as the log phase. Treatment of these cells 
after a period of 48hour growth would, therefore, be more accurate for in vitro 
cells studies. When all growth medium is spent or when the cells occupy all of 
the available substrates, the cells enter a phase known as a stationary phase 
where the proliferation is significantly reduced or ceases entirely (Falgreen et 
al., 2014). HepG2 cells enter stationary phase around 180 hours, whereas 
U251 still proliferate until around 213hours.  
9.6. Investigation for the best parameters to carry out 
esterification reaction  
Pullulan was reacted with 3,3`-dithiodipropionic acid in the presence of a 
catalytic amount of DMAP, a best ester-activator intermediate was chosen 
between DCC and EDC.HCl with a suitable solvent (DMSO or DMF) 
Figure 9-12. Synthesis equation of disulfide-linked pullulan PSS-COOH. 
 
The conversion of pullulan OH into azide group linked by a disulphide bond was 
first achieved by esterification between OH in pullulan and COOH in DTDPA. 
Different experimental conditions were set up for successful esterification, 
suitable temperature (30-60ºC), catalysts (DCC or EDC.HCl) and solvents 
(DMSO or DMF) were investigated. 
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DTDPA (2mmol) and DMAP (0.15mmol) were first dissolved in 50ml of DMSO 
(or DMF) at 45 ̊C under N2 atmosphere. Pullulan (0.5g,1mmol equivalent of 
anhydrous glucoside units) and DCC (3mmol) were separately dissolved in 10 
ml of DMSO (or DMF or DMSO/DMF: V/V: 1/1) for 30 min at RT. The mixture of 
pullulan was then added dropwise to the DTDPA mixture solution and stirred for 
2 days at 45 ̊C. Pullulan solids appeared as precipitates into the solution. 
 Figure 9-13 shows the proton NMR of each product obtained after the reaction 
with different conditions.  
Figure 9-13. 1HNMR (400 MHz, DMSO-d6) of each pullulan derivatives obtained 
after different experimental condition.  
 
 As seen, the products 2,3 and 4 obtained after reaction using DCC as the 
coupling agents did not give any characteristic peaks in 1HNMR of the pullulan 
whereas product obtained when using EDC.HCl gave both pullulan and DTPA 
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peaks characteristics. It was therefore deduced that the best parameters for 
successful esterification are using EDC.HCl and DMAP which are all dissolved 
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